	<rdf:RDF xmlns:admin="http://webns.net/mvcb/" xmlns="http://purl.org/rss/1.0/" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:prism="http://purl.org/rss/1.0/modules/prism/" xmlns:taxo="http://purl.org/rss/1.0/modules/taxonomy/" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:syn="http://purl.org/rss/1.0/modules/syndication/">
	<channel rdf:about="https://biorxiv.org">
	<admin:errorReportsTo rdf:resource="mailto:biorxiv@cshlpress.edu"/>
	<title>Collection : <? echo $this_gname; ?></title>
	<link>https://biorxiv.org</link>
	<description>
	This feed contains articles for Collection "<? echo $this_gname; ?>"
	</description>

		<items>
	<rdf:Seq>
		</rdf:Seq>
	</items>
	<prism:eIssn/>
	<prism:publicationName>bioRxiv</prism:publicationName>
	<prism:issn/>

	<image rdf:resource=""/>
	</channel>
	<image rdf:about="">
	<title>bioRxiv/medRxiv</title>
	<url/>
	<link>https://biorxiv.org</link>
	</image>
	<item rdf:about="https://www.biorxiv.org/content/10.64898/2026.04.02.716254v1?rss=1">
<title>
<![CDATA[
Frustration Landscapes of Broadly Neutralizing SARS-CoV-2 Spike Antibodies Targeting Conserved Epitopes Reveal Energetic Logic of Escape-Proof and Escape-Prone Mechanisms 
]]>
</title>
<link>
https://www.biorxiv.org/content/10.64898/2026.04.02.716254v1?rss=1"
</link>
<dc:creator>Alshahrani, M.</dc:creator>
<dc:creator>Gatlin, W.</dc:creator>
<dc:creator>Ludwick, M.</dc:creator>
<dc:creator>Turano, L.</dc:creator>
<dc:creator>Foley, B.</dc:creator>
<dc:creator>Verkhivker, G.</dc:creator>
<dc:date>2026-04-03</dc:date>
<dc:identifier>doi:10.64898/2026.04.02.716254</dc:identifier>
<dc:title><![CDATA[Frustration Landscapes of Broadly Neutralizing SARS-CoV-2 Spike Antibodies Targeting Conserved Epitopes Reveal Energetic Logic of Escape-Proof and Escape-Prone Mechanisms]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory Press</dc:publisher>
<prism:publicationDate>2026-04-03</prism:publicationDate>
<prism:section></prism:section>
<description><![CDATA[
The continued evolution of SARS-CoV-2 has enabled escape from most monoclonal antibodies, yet a subset of broadly neutralizing antibodies targeting three newly identified super-conserved RBD epitopes SCORE-A, SCORE-B, and SCORE-C retains remarkable activity against even the most recent JN.1-derived sublineages. Here we employed an integrated computational framework combining conformational dynamics, mutational scanning, MM-GBSA binding energetics, and frustration profiling to dissect the molecular mechanisms by which XGI antibodies achieve broad neutralization and resistance to immune escape. Structural analysis revealed that all three SCORE epitopes share a common architecture: a highly conserved, minimally frustrated core that provides stable anchoring, flanked by peripheral regions that accommodate antibody-specific variations. Conformational dynamics showed that SCORE-A antibodies (XGI-183) rigidify the lateral epitope while leaving the RBM partially mobile; SCORE-B antibodies (XGI-198, XGI-203) clamp the RBM apex, directly blocking ACE2; and SCORE-C antibodies (XGI-171) allosterically loosen the RBM loop, impairing receptor engagement indirectly. Mutational scanning identified a hierarchical hotspot organization where primary hotspots (e.g., K356, T500, Y380, T385) are evolutionarily constrained and minimally frustrated, while secondary hotspots (e.g., V503, Y508, S383) are neutrally frustrated and represent the principal sites of immune-driven mutations. MM-GBSA decomposition revealed that van der Waals-driven hydrophobic packing dominates binding, with electrostatic interactions providing auxiliary stabilization. Critically, frustration analysis demonstrated that immune escape hotspots reside precisely in zones of neutral frustration "energetic playgrounds" that permit mutational exploration without destabilizing the RBD while minimally frustrated cores are evolutionarily locked. The comparative analysis of conformational versus mutational frustration distributions revealed a unifying principle: aligned neutral frustration yields permissive, escape-prone interfaces; decoupling enables targeting of constrained cores; and convergence of minimal frustration in both distributions creates invulnerable interfaces. These findings establish that broad neutralization arises not from ultra-high-affinity anchors but from strategic energy distribution across rigid, evolutionarily informed interfaces, providing a roadmap for designing next-generation therapeutics that target the invulnerable cores of viral surface proteins.
]]></description>
</item>
<item rdf:about="https://www.biorxiv.org/content/10.64898/2026.04.03.716256v1?rss=1">
<title>
<![CDATA[
The transmembrane domain regulates the kinetics of the SARS-CoV-2 spike conformational transition 
]]>
</title>
<link>
https://www.biorxiv.org/content/10.64898/2026.04.03.716256v1?rss=1"
</link>
<dc:creator>Kulshrestha, A.</dc:creator>
<dc:creator>Banerjee, A.</dc:creator>
<dc:creator>Lall, S.</dc:creator>
<dc:creator>Gosavi, S.</dc:creator>
<dc:date>2026-04-03</dc:date>
<dc:identifier>doi:10.64898/2026.04.03.716256</dc:identifier>
<dc:title><![CDATA[The transmembrane domain regulates the kinetics of the SARS-CoV-2 spike conformational transition]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory Press</dc:publisher>
<prism:publicationDate>2026-04-03</prism:publicationDate>
<prism:section></prism:section>
<description><![CDATA[
The homotrimeric SARS-CoV-2 spike glycoprotein comprises two subunits: S1, which recognizes host-receptors through its receptor-binding domains (RBDs), and S2, anchored to the viral membrane through its transmembrane domain (TMD), which facilitates the fusion of the viral envelope with the host cell membrane. Upon host-receptor engagement and proteolytic activation, S1 dissociates and triggers a large conformational transition in S2, involving structural rearrangements in the S2 ectomembrane-domains and the TMD. While studies have focused on the ectomembrane-domain dynamics, the TMD has typically been modeled as being in a trimeric state. Here, we use molecular dynamics simulations of a coarse-grained structure-based model (SBM) with an implicit membrane to investigate the role of TMD dynamics in modulating S2 conformational conversion. We first recapitulate previous results from an all-atom SBM with a trimeric TMD and re-emphasize that the extended pre-hairpin intermediate state of S2, which brings the two membranes into apposition, is a byproduct of the prefusion-to-postfusion transition. Next, by introducing dynamics into the TMD, we find a late fusion intermediate structurally similar to a recent cryo-EM structure. A dynamic TMD also makes the conformational transition faster. Simulations including the S1/S2 complex reveal coupled RBD-TMD dynamics: when all three RBDs are in the closed state, they can stabilize the TMD in a trimeric configuration, whereas the opening of a single RBD can trigger a transition to a dynamic TMD. So, the dynamics and the conformational preferences of the TMD can be tuned by the presence and conformation of S1. There is some evidence that the TMDs of class I viral fusion proteins, such as spike, contribute to viral fusion by modulating membrane properties. Our simulations indicate an expanded role for the function of the TMD, where it can directly regulate the kinetics of S2 conformational transitions.
]]></description>
</item>
<item rdf:about="https://www.biorxiv.org/content/10.64898/2026.04.02.716054v1?rss=1">
<title>
<![CDATA[
Machine Learning-Driven Antigen Selection Reveals Conserved T-Cell Targets for Broad Coronavirus Vaccination 
]]>
</title>
<link>
https://www.biorxiv.org/content/10.64898/2026.04.02.716054v1?rss=1"
</link>
<dc:creator>Federico, L.</dc:creator>
<dc:creator>Odainic, A.</dc:creator>
<dc:creator>Lund, K. P.</dc:creator>
<dc:creator>Egner, I. M.</dc:creator>
<dc:creator>Wiese, K. E.</dc:creator>
<dc:creator>Cornelissen, L. A. H. M.</dc:creator>
<dc:creator>Kared, H.</dc:creator>
<dc:creator>Stratford, R.</dc:creator>
<dc:creator>Kapell, S.</dc:creator>
<dc:creator>Malone, B.</dc:creator>
<dc:creator>Gheorghe, M.</dc:creator>
<dc:creator>Machart, P.</dc:creator>
<dc:creator>Siarheyeu, R.</dc:creator>
<dc:creator>Tanaka, Y.</dc:creator>
<dc:creator>Clancy, T.</dc:creator>
<dc:creator>Bendjama, K.</dc:creator>
<dc:creator>Munthe, L. A.</dc:creator>
<dc:date>2026-04-03</dc:date>
<dc:identifier>doi:10.64898/2026.04.02.716054</dc:identifier>
<dc:title><![CDATA[Machine Learning-Driven Antigen Selection Reveals Conserved T-Cell Targets for Broad Coronavirus Vaccination]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory Press</dc:publisher>
<prism:publicationDate>2026-04-03</prism:publicationDate>
<prism:section></prism:section>
<description><![CDATA[
Coronavirus outbreaks remain a persistent global threat, while spike-focused vaccines are vulnerable to antigenic variation. Here, we identify conserved non-spike T-cell targets across betacoronaviruses using machine learning-guided antigen prioritization combined with ex vivo immunological validation. Candidate peptides were screened in primary human PBMCs, and top conserved regions were incorporated into multiepitope mRNA constructs. Intracellular expression and HLA class I presentation were confirmed by immunopeptidomics, and immunogenicity was assessed ex vivo and in vivo. Across 97 peptides from 19 viral proteins, evolutionary conservation strongly correlated with functional T-cell immunogenicity. Conserved peptides elicited more frequent and robust CD4+ and CD8+ T-cell responses than taxon-restricted peptides. Multiepitope mRNA constructs were efficiently expressed, presented, and induced T-cell responses in human PBMCs, and generated strong interferon-gamma and interleukin-2 responses in mice. These findings link conservation to cellular immunogenicity and support conservation-guided antigen selection as a scalable strategy for developing T-cell focused vaccines with broad coverage beyond spike-based approaches.
]]></description>
</item>
<item rdf:about="https://www.biorxiv.org/content/10.64898/2026.04.02.716024v1?rss=1">
<title>
<![CDATA[
TF-IDF k-mer-based Classical and Hybrid Machine Learning Models for SARS-CoV-2 Variant Classification under Imbalanced Genomic Data 
]]>
</title>
<link>
https://www.biorxiv.org/content/10.64898/2026.04.02.716024v1?rss=1"
</link>
<dc:creator>Haque, N.</dc:creator>
<dc:creator>Mazed, A.</dc:creator>
<dc:creator>Ankhi, J. N.</dc:creator>
<dc:creator>Uddin, M. J.</dc:creator>
<dc:date>2026-04-02</dc:date>
<dc:identifier>doi:10.64898/2026.04.02.716024</dc:identifier>
<dc:title><![CDATA[TF-IDF k-mer-based Classical and Hybrid Machine Learning Models for SARS-CoV-2 Variant Classification under Imbalanced Genomic Data]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory Press</dc:publisher>
<prism:publicationDate>2026-04-02</prism:publicationDate>
<prism:section></prism:section>
<description><![CDATA[
Accurate classification of SARS-CoV-2 genomic variants is essential for effective genomic surveillance, yet it is challenged by extreme class imbalance, limited representation of rare variants, and distribution shifts in real-world sequencing data. In this study, we employed hybrid RF-SVM framework designed for robust detection of rare SARS-CoV-2 variants. It integrates a random forest and a polynomial-kernel based support vector machine to enhance sensitivity to minority classes while maintaining overall predictive stability. We systematically compared classical machine learning models, deep learning approaches, and hybrid strategies under both standard and distribution-shifted evaluation settings. Our results show that classical models using TF-IDF-based k-mer features outperform deep learning methods on macro-averaged performance metrics. The Random Forest classifier using TF-IDF Feature achieved the best overall performance, with a macro-averaged F1-score of 0.8894 and an accuracy of 96.3%. The model also demonstrated strong generalization ability, as evidenced by stable cross-validation performance (CV accuracy = 0.9637).  Hybrid RF-SVM model further improves rare variant detection under severe class imbalance. Calibration analysis indicates reliable probability estimates for common variants, although challenges persist for minority classes. Overall, this study highlights the limitations of deep learning in highly imbalanced genomic settings and demonstrates that carefully designed hybrid machine learning approaches provide an effective and interpretable solution for rare SARS-CoV-2 variant detection.
]]></description>
</item>
<item rdf:about="https://www.biorxiv.org/content/10.64898/2026.04.01.715984v1?rss=1">
<title>
<![CDATA[
Conserved stem-loops of the SARS-CoV-2 5'-UTR activate OAS1 
]]>
</title>
<link>
https://www.biorxiv.org/content/10.64898/2026.04.01.715984v1?rss=1"
</link>
<dc:creator>Oviedo, A.</dc:creator>
<dc:creator>Bair, C. R.</dc:creator>
<dc:creator>Vasilakopoulos, A. P.</dc:creator>
<dc:creator>Regis, K.</dc:creator>
<dc:creator>VanInsberghe, D.</dc:creator>
<dc:creator>Lowen, A. C.</dc:creator>
<dc:creator>Conn, G. L.</dc:creator>
<dc:date>2026-04-02</dc:date>
<dc:identifier>doi:10.64898/2026.04.01.715984</dc:identifier>
<dc:title><![CDATA[Conserved stem-loops of the SARS-CoV-2 5'-UTR activate OAS1]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory Press</dc:publisher>
<prism:publicationDate>2026-04-02</prism:publicationDate>
<prism:section></prism:section>
<description><![CDATA[
The innate immune system relies on pathogen recognition receptors, such as the 2',5'-oligoadenylate synthetase (OAS) proteins, to detect pathogen-associated molecular patterns like viral double-stranded (ds)RNA. A specific splicing variant of OAS1 (OAS1-p46) has been implicated in initiating an immune response that leads to decreased disease severity during SARS-CoV-2 infection. OAS1-p46 has a C-terminal lipid modification motif that allows for anchoring of the protein to intracellular membranes and thus potential colocalization with immunogenic viral RNA regions such as the SARS-CoV-2 5'-untranslated region (5'-UTR). Here, we show that OAS proteins can detect the 5'-structured elements (5'-SE)--comprising the 5'-UTR and three additional stem-loop structures--and activate the cellular RNase L pathway. Through systematic 3'-end truncations of the 5'-SE, we show that the smallest 5'-SE fragment capable of potently activating OAS1 is the conserved and highly structured SL1-4b region, containing the first four stem-loop structures and their intervening linking sequences (SL1-4), as well as an unstructured region ("SL4b") to the 3'-side of SL4. Analyses of OAS1 activation and RNA secondary structure probing using selective 2'-hydroxyl acylation analyzed by primer extension and mutational profiling (SHAPE-MaP) of additional SL1-4b RNA variants suggests a model in which SL4 acts as the primary OAS1 interaction site, while the unstructured SL4b region and two other stem-loops (SL1 and SL3) are necessary for optimal presentation of this region for OAS1 activation. Our findings reveal a structurally complex viral RNA region that potently activates OAS1, underscoring the potential complexity of RNAs that can strongly activate this innate immune sensor.
]]></description>
</item>
<item rdf:about="https://www.biorxiv.org/content/10.64898/2026.03.31.715419v1?rss=1">
<title>
<![CDATA[
VYD2311 is a promising candidate for passive immunization against COVID-19 in immunocompromised individuals 
]]>
</title>
<link>
https://www.biorxiv.org/content/10.64898/2026.03.31.715419v1?rss=1"
</link>
<dc:creator>Mellis, I. A.</dc:creator>
<dc:creator>Wu, M.</dc:creator>
<dc:creator>Daniel, K.</dc:creator>
<dc:creator>Hong, H.</dc:creator>
<dc:creator>Guo, Y.</dc:creator>
<dc:creator>Ho, D. D.</dc:creator>
<dc:date>2026-04-01</dc:date>
<dc:identifier>doi:10.64898/2026.03.31.715419</dc:identifier>
<dc:title><![CDATA[VYD2311 is a promising candidate for passive immunization against COVID-19 in immunocompromised individuals]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory Press</dc:publisher>
<prism:publicationDate>2026-04-01</prism:publicationDate>
<prism:section></prism:section>
<description><![CDATA[
For millions of immunocompromised individuals, vaccines may not elicit adequate protection from infections, so alternative strategies for pre-exposure prophylaxis are essential. There is only one non-vaccine product authorized in the U.S. as pre-exposure prophylaxis against COVID-19: the monoclonal antibody pemivibart. We previously showed that pemivibart had lower neutralizing activity in vitro against many recent dominant SARS-CoV-2 variants, such as KP.3.1.1, NB.1.8.1, and LP.8.1.1, than it had against JN.1, which was dominant when the antibody was first authorized. The manufacturer of pemivibart (Invivyd) recently initated clinical testing of a new monoclonal antibody derived from pemivibart, VYD2311, but there are no available studies of the activity of VYD2311 against dominant and emerging SARS-CoV-2 variants. Here, using pseudovirus neutralization assays, we measured the neutralizing activity of laboratory-synthesized VYD2311 and pemivibart against dominant and emerging SARS-CoV-2 variants, including XFG, NB.1.8.1, and the genetically distant BA.3.2.2. We found that VYD2311 potently neutralized all tested variants in vitro, dramatically more so than pemivibart. Combined with interpretation of earlier clinical trials of a parental antibody product, we conclude that VYD2311 is a promising candidate for passive immunoprophylaxis against COVID-19, particularly for those who do not respond well to vaccination.
]]></description>
</item>
<item rdf:about="https://www.biorxiv.org/content/10.64898/2026.03.31.715496v1?rss=1">
<title>
<![CDATA[
Omicron-Enhanced Immunosuppressive Effects of SARS-CoV-2 ORF3a and ORF9b Accessory Proteins on Monocytic Inflammatory Response 
]]>
</title>
<link>
https://www.biorxiv.org/content/10.64898/2026.03.31.715496v1?rss=1"
</link>
<dc:creator>Grigas, J.</dc:creator>
<dc:creator>Padilla-Blanco, M.</dc:creator>
<dc:creator>Herran, U. M.</dc:creator>
<dc:creator>Lopez-Ayllon, B. D.</dc:creator>
<dc:creator>Rius, A. d. L.</dc:creator>
<dc:creator>Mendoza Garcia, L.</dc:creator>
<dc:creator>Fernandez Rodriguez, R.</dc:creator>
<dc:creator>Garcia Garcia, T.</dc:creator>
<dc:creator>Garrido, J. J.</dc:creator>
<dc:creator>Pautienius, A.</dc:creator>
<dc:creator>Stankevicius, A.</dc:creator>
<dc:creator>Kucinskaite-Kodze, I.</dc:creator>
<dc:creator>Montoya, M.</dc:creator>
<dc:date>2026-04-01</dc:date>
<dc:identifier>doi:10.64898/2026.03.31.715496</dc:identifier>
<dc:title><![CDATA[Omicron-Enhanced Immunosuppressive Effects of SARS-CoV-2 ORF3a and ORF9b Accessory Proteins on Monocytic Inflammatory Response]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory Press</dc:publisher>
<prism:publicationDate>2026-04-01</prism:publicationDate>
<prism:section></prism:section>
<description><![CDATA[
This study investigates the poorly understood roles of SARS-CoV-2 accessory proteins using monocytic THP-1 cells expressing individual viral ORFs. ORF3a, ORF7b, and ORF9b were identified as major immunomodulators that suppress host inflammatory signaling. Specifically, cells expressing ORF3a or ORF9b exhibited reduced Toll-like receptor 4 (TLR4)-mediated production of key proinflammatory molecules--CCL2, CCL4, and IL-1{beta}--resulting in diminished immune cell recruitment. Importantly, Omicron-associated mutations in ORF3a (T223I) and ORF9b (P10S+{Delta}E27N28A29) amplified this immunosuppressive effect, leading to stronger transcriptomic suppression consistent with Omicrons reduced pathogenicity and clinical outcomes. These findings suggest that SARS-CoV-2 accessory proteins, particularly ORF3a and ORF9b, play pivotal roles in modulating monocytic immune responses. Enhanced suppression in Omicron variants highlights an evolutionary adaptation contributing to immune evasion and milder disease manifestations.
]]></description>
</item>
<item rdf:about="https://www.biorxiv.org/content/10.64898/2026.03.30.715311v1?rss=1">
<title>
<![CDATA[
Intranasal immunization with live-attenuated RSV-vectored SARS-CoV-2 vaccines elicits antigen-specific systemic and mucosal immunity and protects against viral challenge and natural infection 
]]>
</title>
<link>
https://www.biorxiv.org/content/10.64898/2026.03.30.715311v1?rss=1"
</link>
<dc:creator>Botta, D.</dc:creator>
<dc:creator>Schultz, M. D.</dc:creator>
<dc:creator>Silva-Sanchez, A.</dc:creator>
<dc:creator>Kalange, D.</dc:creator>
<dc:creator>Akther, J.</dc:creator>
<dc:creator>Zhou, F.</dc:creator>
<dc:creator>Tipper, J. L.</dc:creator>
<dc:creator>Yang, G.</dc:creator>
<dc:creator>Schaefers, L. T.</dc:creator>
<dc:creator>Barkley, C. A.</dc:creator>
<dc:creator>Qiu, S.</dc:creator>
<dc:creator>Foote, J. B.</dc:creator>
<dc:creator>Tioni, M. F.</dc:creator>
<dc:creator>Weiss, C. M.</dc:creator>
<dc:creator>Phan, S. I.</dc:creator>
<dc:creator>Green, T. J.</dc:creator>
<dc:creator>Leal, S. M.</dc:creator>
<dc:creator>Harrod, K. S.</dc:creator>
<dc:creator>King, R. G.</dc:creator>
<dc:creator>Moore, M. L.</dc:creator>
<dc:creator>Randall, T. D.</dc:creator>
<dc:creator>Tang, R. S.</dc:creator>
<dc:creator>Lund, F. E.</dc:creator>
<dc:date>2026-03-31</dc:date>
<dc:identifier>doi:10.64898/2026.03.30.715311</dc:identifier>
<dc:title><![CDATA[Intranasal immunization with live-attenuated RSV-vectored SARS-CoV-2 vaccines elicits antigen-specific systemic and mucosal immunity and protects against viral challenge and natural infection]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory Press</dc:publisher>
<prism:publicationDate>2026-03-31</prism:publicationDate>
<prism:section></prism:section>
<description><![CDATA[
The emergence of new SARS-CoV-2 variants and breakthrough infections underscores the need for next-generation vaccines capable of protecting from natural infection and/or preventing virus transmission to others. Intranasal vaccination offers a promising approach by eliciting local immune responses in the nasal mucosa, the primary site of infection and reservoir for transmissible virus. We evaluated two live-attenuated, respiratory syncytial virus vectored vaccines in which the RSV F and G surface glycoproteins were replaced with a chimeric SARS-CoV-2 Spike protein from either the ancestral USA/WA-1/2020 strain (MV-014-212) or the Delta variant (MV-014-212-delta). A single intranasal dose of either vaccine elicited systemic and mucosal immunity in K18-hACE2 mice, including serum neutralizing antibodies, Spike-specific memory B cells and plasmablasts, and Spike-specific CD8 lung-resident memory T cells. Although MV-014-212-delta vaccination provided the best protection against Delta variant virus challenge, both vaccines decreased viral loads in nasal discharge, lung and brain, and reduced weight loss and mortality. In naturally acquired infection studies, vaccinated hamsters exposed to infected cagemates exhibited minimal weight loss, limited viral replication within the nasal mucosa, and attenuated lung pathology. Therefore, intranasal RSV-vectored vaccines can elicit broad protective respiratory immunity, suggesting that this platform could be leveraged for other respiratory pathogens.
]]></description>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.03.27.26349516v1?rss=1">
<title>
<![CDATA[
Increased Risk of Pulmonary Embolism Following SARS-CoV-2 Activity in Ontario, Canada 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.03.27.26349516v1?rss=1"
</link>
<dc:creator>Lee, C. E.</dc:creator>
<dc:creator>Wilson, N. J.</dc:creator>
<dc:creator>Fisman, D.</dc:creator>
<dc:date>2026-03-30</dc:date>
<dc:identifier>doi:10.64898/2026.03.27.26349516</dc:identifier>
<dc:title><![CDATA[Increased Risk of Pulmonary Embolism Following SARS-CoV-2 Activity in Ontario, Canada]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory Press</dc:publisher>
<prism:publicationDate>2026-03-30</prism:publicationDate>
<prism:section></prism:section>
<description><![CDATA[
BackgroundSARS-CoV-2 infection is an established prothrombotic trigger, yet the population-level temporal relationship between circulating viral activity and pulmonary embolism (PE) remains poorly characterized. We aimed to evaluate the short-term association between respiratory viral activity and PE hospitalizations, accounting for specific temporal lags.

MethodsWe conducted a population-level time-series analysis of incident PE hospitalizations in Ontario, Canada, from 2011 to 2024. Using distributed lag non-linear models, we assessed the association between standardized weekly activity levels of SARS-CoV-2, influenza A/B, and respiratory syncytial virus (RSV) and PE risk over a 5-week lag period. Relative risks (RR) per standard deviation (SD) increase in viral activity were estimated via negative binomial regression using cross-basis terms to account for both exposure-response and lag-response non-linearities. Models were adjusted for Fourier seasonal terms and secular trends.

FindingsAmong 70,670 incident PE cases identified between 2011 and 2024, SARS-CoV-2 activity demonstrated a significant temporal association with PE. A cumulative RR increase of 20% per SD in SARS-CoV-2 activity was observed over the five weeks following exposure (RR 1.20; 95% CI 1.05-1.37). The risk followed a distinct delay trajectory: weekly cumulative RRs peaked at week 3 (RR 1.21; 95% CI 1.01-1.45). For the 2020-2024 period, influenza A also showed an association peaking at week 3 without statistical significance (RR 1.17; 95% CI 0.95-1.45).

InterpretationIncreased population-level SARS-CoV-2 activity is associated with a heightened risk of PE, peaking at approximately the third week. This delayed peak suggests a protracted thrombo-inflammatory window, likely driven by sustained endothelial injury. These findings highlight the vascular burden of COVID-19 and suggest that infection prevention measures, including vaccination, may provide significant downstream protection against thromboembolic disease.
]]></description>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.03.27.26349524v1?rss=1">
<title>
<![CDATA[
Twelve Distinct Laboratory Methods Used to Measure SARS-CoV-2 in Wastewaters throughout a Three-Year Ontario-Wide, Canada Study: Impact on Public Health Interpretation of Disease Incidence 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.03.27.26349524v1?rss=1"
</link>
<dc:creator>Hegazy, N.</dc:creator>
<dc:creator>Peng, K. K.</dc:creator>
<dc:creator>de Haan-Ward, J.</dc:creator>
<dc:creator>Renouf, E.</dc:creator>
<dc:creator>Mercier, E.</dc:creator>
<dc:creator>Wan, S.</dc:creator>
<dc:creator>Hu, X. J.</dc:creator>
<dc:creator>Dean, C.</dc:creator>
<dc:creator>Servos, M.</dc:creator>
<dc:creator>Edwards, E.</dc:creator>
<dc:creator>Ybazeta, G.</dc:creator>
<dc:creator>Habash, M.</dc:creator>
<dc:creator>Goodridge, L.</dc:creator>
<dc:creator>Brown, R. S.</dc:creator>
<dc:creator>Payne, S. J.</dc:creator>
<dc:creator>Kirkwood, A.</dc:creator>
<dc:creator>Kyle, C.</dc:creator>
<dc:creator>McKay, R. M.</dc:creator>
<dc:creator>Gilbride, K.</dc:creator>
<dc:creator>DeGroot, C.</dc:creator>
<dc:creator>Delatolla, R.</dc:creator>
<dc:date>2026-03-30</dc:date>
<dc:identifier>doi:10.64898/2026.03.27.26349524</dc:identifier>
<dc:title><![CDATA[Twelve Distinct Laboratory Methods Used to Measure SARS-CoV-2 in Wastewaters throughout a Three-Year Ontario-Wide, Canada Study: Impact on Public Health Interpretation of Disease Incidence]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory Press</dc:publisher>
<prism:publicationDate>2026-03-30</prism:publicationDate>
<prism:section></prism:section>
<description><![CDATA[
Wastewater and environmental monitoring (WEM) was a critical public health surveillance tool for SARS-CoV-2 surveillance during the COVID-19 Pandemic. However, substantial methodological heterogeneity across laboratories continues to challenge the interpretation and thus compromise the actionability of resulting WEM measurements. This study quantifies interlaboratory concordance in SARS-CoV-2 WEM measurements using influent wastewater samples collected between September 2021 and January 2024 at a single wastewater treatment facility within the Ontario Wastewater Surveillance Initiative, analyzed independently by 12 laboratories using their routine methods. In the absence of a known true viral concentration, interlaboratory WEM measurements were evaluated against a facility-specific longitudinal benchmark derived from routine surveillance at the source facility and correlated to clinical surveillance metrics. Concordance was assessed across four WEM measurement units commonly used in practice: SARS-CoV-2 copies/mL, SARS-CoV-2 copies/copies of PMMoV, and their standardized counterpart wastewater viral activity level (WVAL) units of WVAL-standardized SARS-CoV-2 copies/mL and WVAL-standardized SARS-CoV-2 copies/copies of PMMoV. Measurements in each unit were analyzed using complementary analytical frameworks, including categorical concordance metrics, principal component analysis, and linear mixed-effects modelling. Across the study period, interlaboratory measurements consistently captured benchmark temporal dynamics, including major peaks and periods of low activity, but showed substantial variation in magnitude and public-health interpretation across laboratory methods. Concordance was strongest during epidemiological extremes and deteriorated during transitional periods, increasing the risk of misclassification with potentially implications for public health decision-making. To explore potential laboratory methodological drivers of agreement, associations between the benchmark concordance and the laboratory-specific concentration, extraction, and RT-qPCR analytical steps were assessed using Fishers exact tests, alongside extracted-mass threshold analyses. No single methodological factor showed a statistically significant association with benchmark concordance in this study; however, several parameters, including RNA template volume, total RT-qPCR reaction volume, and extracted mass of analyzed settled solids, may warrant further investigation in future studies.
]]></description>
</item>
<item rdf:about="https://www.biorxiv.org/content/10.64898/2026.03.29.711974v1?rss=1">
<title>
<![CDATA[
Panmap: Scalable phylogeny-guided alignment, genotyping, and placement on pangenomes 
]]>
</title>
<link>
https://www.biorxiv.org/content/10.64898/2026.03.29.711974v1?rss=1"
</link>
<dc:creator>Kramer, A. M.</dc:creator>
<dc:creator>Zhang, A.</dc:creator>
<dc:creator>Ayala, N.</dc:creator>
<dc:creator>de Sanctis, B.</dc:creator>
<dc:creator>Karim, L. M.</dc:creator>
<dc:creator>Hinrichs, A. S.</dc:creator>
<dc:creator>Walia, S.</dc:creator>
<dc:creator>Turakhia, Y.</dc:creator>
<dc:creator>Corbett-Detig, R.</dc:creator>
<dc:date>2026-03-30</dc:date>
<dc:identifier>doi:10.64898/2026.03.29.711974</dc:identifier>
<dc:title><![CDATA[Panmap: Scalable phylogeny-guided alignment, genotyping, and placement on pangenomes]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory Press</dc:publisher>
<prism:publicationDate>2026-03-30</prism:publicationDate>
<prism:section></prism:section>
<description><![CDATA[
Pangenomes capture population-level variation but remain computationally challenging at scale. We present Panmap, a tool that leverages evolutionary structure to place, align, and genotype sequencing reads against mutation-annotated pangenomes containing up to millions of genomes. Panmap introduces a phylogenetically compressed k-mer index that stores only sequence differences along branches, enabling efficient comparison of reads to both sampled genomes and inferred ancestors. This approach reduces index size by up to 600-fold and construction time by over three orders of magnitude relative to existing tools. Panmap places a 100x coverage SARS-CoV-2 sample onto 20,000 genomes in 0.4 seconds and onto 8 million genomes in under two minutes. Furthermore, it enables accurate haplotype identification and abundance estimation in metagenomic samples and sensitive placement of ancient environmental DNA without prior alignment. Our approach makes large-scale pangenomes directly amenable to read mapping, genome assembly, alignment-free phylogenetic placement, and metagenomic analysis.
]]></description>
</item>
<item rdf:about="https://www.biorxiv.org/content/10.64898/2026.03.28.714969v1?rss=1">
<title>
<![CDATA[
Structure of SARS-CoV-2 spike in complex with its co-receptor the neuronal cell adhesion protein contactin 1 
]]>
</title>
<link>
https://www.biorxiv.org/content/10.64898/2026.03.28.714969v1?rss=1"
</link>
<dc:creator>Krepel, S. T.</dc:creator>
<dc:creator>Hurdiss, D. L.</dc:creator>
<dc:creator>Bosch, B. J.</dc:creator>
<dc:creator>Snijder, J.</dc:creator>
<dc:creator>Janssen, B. J. C.</dc:creator>
<dc:date>2026-03-29</dc:date>
<dc:identifier>doi:10.64898/2026.03.28.714969</dc:identifier>
<dc:title><![CDATA[Structure of SARS-CoV-2 spike in complex with its co-receptor the neuronal cell adhesion protein contactin 1]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory Press</dc:publisher>
<prism:publicationDate>2026-03-29</prism:publicationDate>
<prism:section></prism:section>
<description><![CDATA[
The emergence of SARS-CoV-2 has caused millions of deaths and excess morbidity in the worldwide population. In addition to its respiratory symptoms, SARS-CoV-2 has become known for its neurotropism and long-term neurological sequelae, with a post-acute infection syndrome commonly referred to as long-COVID. Next to the host receptor angiotensin-converting enzyme 2 (ACE2) additional interactions of the SARS-CoV-2 spike (S) protein have been described for neuronal co-receptors specific to the nervous system including cell adhesion protein contactin 1 (CNTN1). Details of the spike-CNTN1 interaction have remained elusive. Here, we quantified the spike-CNTN1 interaction by surface plasmon resonance and resolved the structure of the complex by single particle cryo-electron microscopy (cryo-EM). Spike and CNTN1 interact with nanomolar affinity, driven by an avidity effect and mediated by the horseshoe moiety of CNTN1. The cryo-EM structure reveals that the CNTN1 Ig1-4 horseshoe is wedged in between two receptor binding domains (RBDs) and interacts, through Ig3, with a unique receptor interface at the base of the RBD in the up-conformation. This receptor interface is not previously described for other spike receptors but overlaps with the epitopes of several neutralizing monoclonal antibodies. Comparison of our data with available spike structures suggests one spike trimer can bind three CNTN1 molecules, or alternatively, different co-receptors such as ACE2 and CNTN1, simultaneously. These findings shed new light on the molecular determinants of SARS-CoV-2 neurotropism.
]]></description>
</item>
<item rdf:about="https://www.biorxiv.org/content/10.64898/2026.03.25.714316v1?rss=1">
<title>
<![CDATA[
Characterization of Self-Incompatibility Genes in Brassica rapa var. Toria and Yellow sarson 
]]>
</title>
<link>
https://www.biorxiv.org/content/10.64898/2026.03.25.714316v1?rss=1"
</link>
<dc:creator>Bhalla, H.</dc:creator>
<dc:creator>Ankita, K.</dc:creator>
<dc:creator>Ahlawat, A.</dc:creator>
<dc:creator>Rode, S. S.</dc:creator>
<dc:creator>Singh, K. H.</dc:creator>
<dc:creator>Sankaranarayanan, S.</dc:creator>
<dc:date>2026-03-28</dc:date>
<dc:identifier>doi:10.64898/2026.03.25.714316</dc:identifier>
<dc:title><![CDATA[Characterization of Self-Incompatibility Genes in Brassica rapa var. Toria and Yellow sarson]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory Press</dc:publisher>
<prism:publicationDate>2026-03-28</prism:publicationDate>
<prism:section></prism:section>
<description><![CDATA[
Self-incompatibility (SI), a reproductive mechanism that prevents self-pollen from fertilizing the ovule, is widespread in flowering plants, including the Brassicaceae family, where it promotes outcrossing, genetic diversity, and hybrid vigor. Although prevalent in Brassica rapa, an economically vital crop, it remains poorly characterized in widely grown varieties, such as toria and yellow sarson, with prior studies primarily focused on Brassica napus. Given its potential for hybrid breeding and crop improvement in rapeseed (B. rapa), we characterized key SI-regulatory genes, analyzing their phylogenetic relationships, structure-function dynamics, and expression patterns. Our results indicate sequence, structural, and functional homology as well as conservation with previously known candidates. This study identifies SRK, FER, and ARC1 as essential, while MLPK plays a minor role in SI for the varieties under study. Furthermore, we identified that SRK, FER, and MLPK activate ROS during the SI response, while ARC1 does not. Our findings establish a foundation for harnessing this natural system to integrate agriculturally important traits and sustain them across generations via outcrossing.
]]></description>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.03.26.26347671v1?rss=1">
<title>
<![CDATA[
A protocol for assessment of interventions using a computational phenotype for Long COVID 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.03.26.26347671v1?rss=1"
</link>
<dc:creator>Amitabh Gunjan, A.</dc:creator>
<dc:creator>Huang, L.</dc:creator>
<dc:creator>Appe, A.</dc:creator>
<dc:creator>McKelvey, P. A.</dc:creator>
<dc:creator>Algren, H. A.</dc:creator>
<dc:creator>Berry, M.</dc:creator>
<dc:creator>Mozaffari, E.</dc:creator>
<dc:creator>Wright, B. J.</dc:creator>
<dc:creator>Hadlock, J. J.</dc:creator>
<dc:creator>Goldman, J. D.</dc:creator>
<dc:date>2026-03-27</dc:date>
<dc:identifier>doi:10.64898/2026.03.26.26347671</dc:identifier>
<dc:title><![CDATA[A protocol for assessment of interventions using a computational phenotype for Long COVID]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory Press</dc:publisher>
<prism:publicationDate>2026-03-27</prism:publicationDate>
<prism:section></prism:section>
<description><![CDATA[
BackgroundLong COVID presents with one or multiple symptoms or diagnosable conditions after SARS-CoV-2 infection. To study whether use of the antiviral remdesivir in persons hospitalized with acute COVID-19 is associated with reduced Long COVID, we created a computational phenotype for Long COVID.

MethodsIn electronic health records (EHR) from a multistate healthcare system (US), hospital admissions from 5/1/20 - 9/30/22 were reviewed. The study group was hospitalized with acute COVID-19 and the control group was hospitalized for other reasons without prior SARS-CoV-2 infection. The populations were balanced with overlap weights based on a high-dimensional propensity score of pre-specified variables and the top 100 comorbidities differing between the groups. Hazard ratios (HR) were calculated for the combined primary outcome: U09.9 (Post-Covid Conditions) or any incident secondary outcome from 90 to 365 days after admission. Secondary outcomes included 27 individual incident diagnoses, corrected for multiplicity with Holm-Bonferroni.

ResultsAdmissions included 45,540 with, and 409,186 without COVID-19 during the study period, evaluable for the primary outcome. After weighting, standardized difference was < 0.01 for all measured confounders including demographic and clinical features. In the COVID+ and non-COVID groups 38.0% and 29.3% met the combined primary outcome, respectively. Weighted HR (95%CI) for the primary outcome was 1.37 (1.35, 1.40), p < 0.0001. All secondary outcomes were associated with the COVID+ group, when adjusted for multiplicity. Incident diagnoses with strong associations (HR > 2) included thromboembolism, hair loss, diabetes mellitus, obesity, and hypoxia. Anosmia/dysgeusia was associated with COVID, but wide confidence intervals reflected few charted diagnoses.

ConclusionsManifestations of Long COVID at population scale are detectable as part of routine symptoms and clinical diagnoses in the EHR after admissions for COVID-19, compared with all other hospital admissions. This a prior computational phenotype for Long COVID will be used to assess whether remdesivir use is associated with decreased Long COVID.
]]></description>
</item>
<item rdf:about="https://www.biorxiv.org/content/10.64898/2026.03.27.714475v1?rss=1">
<title>
<![CDATA[
Impact of viral membrane oxidation on SARS-CoV-2 spike protein transmembrane anchoring stability 
]]>
</title>
<link>
https://www.biorxiv.org/content/10.64898/2026.03.27.714475v1?rss=1"
</link>
<dc:creator>Ghasemitarei, M.</dc:creator>
<dc:creator>Gyursanszky, C.</dc:creator>
<dc:creator>Karttunen, M.</dc:creator>
<dc:creator>Ala-Nissila, T.</dc:creator>
<dc:date>2026-03-27</dc:date>
<dc:identifier>doi:10.64898/2026.03.27.714475</dc:identifier>
<dc:title><![CDATA[Impact of viral membrane oxidation on SARS-CoV-2 spike protein transmembrane anchoring stability]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory Press</dc:publisher>
<prism:publicationDate>2026-03-27</prism:publicationDate>
<prism:section></prism:section>
<description><![CDATA[
Reactive oxygen species generated during inflammation can oxidize viral envelope lipids, with outcomes ranging from modulated infectivity to viral inactivation. For SARS-CoV-2, the molecular mechanisms by which membrane lipid oxidation influences spike protein anchoring remain poorly understood. We use all-atom molecular dynamics (MD) simulations to quantify how graded oxidation of 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC) affects the anchoring of the SARS-CoV-2 spike transmembrane (TM) region in an endoplasmic-reticulum-Golgi intermediate compartment (ERGIC)-like multicomponent membrane. Viral envelopes containing 0, 25, 50, 75, and 100% oxidized POPC (PoxnoPC) corresponding to 0 - 55% oxidation of all PO-type phospholipids were simulated with the spike TM helix and cytoplasmic tail embedded in a POPC/POPE/POPI/POPS/cholesterol mixture. Steered MD and umbrella sampling were used to calculate the potential of mean force (PMF) for extracting the TM+CT region along the membrane normal. Partial oxidation (25 - 75% POPC) produced reductions in the detachment barrier that were not statistically distinguishable from the native system within the sampling uncertainty, whereas full POPC oxidation lowered the anchoring free energy by about 23% (from 606 {+/-} 39 to 464 {+/-} 38 kJ mol-1), indicating that oxidation of roughly half of the glycerophospholipids can measurably weaken spike-membrane coupling. Despite this reduction, the remaining barrier (about 180kBT ) is still large, suggesting that oxidation alone may be insufficient for spontaneous spike detachment and likely acts synergistically with mechanical forces during fusion or immune engagement. Analysis of acyl-chain order parameters, area per lipid, membrane thickness, number-density profiles, and lateral lipid clustering reveals that POPC peroxidation decreases lipid order, thins and softens the bilayer, and disrupts cholesterol-stabilized clusters that refer to large cooperative lipid assemblies (>10 lipids) identified via RDF-based clustering. These oxidation-induced changes reduce hydrophobic matching around the TM helix and facilitate its extraction from the viral envelope. Our results provide a mechanistic link between lipid peroxidation, membrane nanostructure, and spike anchoring, supporting lipid oxidation for example during cold atmospheric plasma or ozone treatment as a physically grounded contributing antiviral mechanism against SARS-CoV-2.
]]></description>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.03.24.26349101v1?rss=1">
<title>
<![CDATA[
An Assessment of Correctional Officer's Health Beliefs in Relationship to COVID-19 Vaccine Uptake and Hesitancy. 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.03.24.26349101v1?rss=1"
</link>
<dc:creator>Hedden-Clayton, B.</dc:creator>
<dc:creator>Roddy, A. L.</dc:creator>
<dc:creator>Roddy, J. K.</dc:creator>
<dc:creator>Ngassa, Y.</dc:creator>
<dc:creator>Pickard, B.</dc:creator>
<dc:creator>Tam, R. A.</dc:creator>
<dc:creator>Wurcel, A. G.</dc:creator>
<dc:date>2026-03-26</dc:date>
<dc:identifier>doi:10.64898/2026.03.24.26349101</dc:identifier>
<dc:title><![CDATA[An Assessment of Correctional Officer's Health Beliefs in Relationship to COVID-19 Vaccine Uptake and Hesitancy.]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory Press</dc:publisher>
<prism:publicationDate>2026-03-26</prism:publicationDate>
<prism:section></prism:section>
<description><![CDATA[
IntroductionDuring the COVID-19 pandemic, incarcerated populations faced heightened risk of exposure due to healthcare barriers, restrictive environments, and pre-existing health conditions. Consequently, Correctional Officers (COs) faced increased risk of COVID-19 exposure. Given the health benefits of COVID-19 vaccination and the rise in vaccine hesitancy, this study examined the relationship between COs health beliefs and COVID-19 vaccine uptake.

MethodsA health beliefs survey was administered to Massachusetts-based COs (n=118). Chi-squared Automatic Interaction Detection modeling and logistic regression was utilized to analyze the survey data.

ResultsCOs with higher trust in vaccines and a prior positive COVID-19 test were most likely to get vaccinated voluntarily. Those with low trust in vaccines and no previous positive COVID-19 test were least likely to receive the vaccine.

ConclusionDespite the severe impact of COVID-19 in correctional settings, and the evidence of vaccine efficacy against hospitalization and death, vaccine uptake among COs remains low.
]]></description>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.03.21.26348591v1?rss=1">
<title>
<![CDATA[
Disentangling the Shared and Differential Genetic Architecture Between COVID-19 and Other Respiratory Disorders: A Multi-Omics Genome-Wide Analysis 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.03.21.26348591v1?rss=1"
</link>
<dc:creator>Xue, X.</dc:creator>
<dc:creator>LIN, Y.-P.</dc:creator>
<dc:creator>FENG, Y.</dc:creator>
<dc:creator>SO, H.-C.</dc:creator>
<dc:date>2026-03-26</dc:date>
<dc:identifier>doi:10.64898/2026.03.21.26348591</dc:identifier>
<dc:title><![CDATA[Disentangling the Shared and Differential Genetic Architecture Between COVID-19 and Other Respiratory Disorders: A Multi-Omics Genome-Wide Analysis]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory Press</dc:publisher>
<prism:publicationDate>2026-03-26</prism:publicationDate>
<prism:section></prism:section>
<description><![CDATA[
BackgroundA bidirectional relationship has been observed between COVID-19 and respiratory disorders, where respiratory comorbidities increase severity and COVID-19 induces respiratory sequelae. The underlying biological and genetic mechanisms remain unclear. While previous studies have identified overlapping genetic loci, few have systematically disentangled the genetic factors shared between these conditions versus those specific to COVID-19, particularly at a multi-omics level.

MethodsWe developed and applied a unified analytical framework to compare three COVID-19 phenotypes with eight respiratory disorders (including asthma, COPD, IPF, and pneumonia). Utilizing the cofdr method for shared genetic signal analysis and DDx/mtCOJO for differentiation, we integrated genome-wide association statistics with multi-omics data (transcriptome, splicing, and proteome). This approach allowed for the simultaneous identification of shared genetic signals (concordant or discordant) and disease-specific variants across expression (TWAS), alternative splicing (spTWAS), and protein abundance (PWAS).

ResultsWe delineated a comprehensive atlas of 214 differential and numerous shared loci across 24 pairwise comparisons. The shared genetic architecture was characterized by pleiotropic effects in genes such as ATP11A (exhibiting opposing effects in COVID-19 vs. IPF) and GSDMB (shared with COPD). Crucially, differentiation analysis revealed that severe COVID-19 is genetically distinct from other respiratory infections (e.g., pneumonia and influenza) through dysregulated Type I/III interferon signaling and specific defects in alveolar epithelial and macrophage function, as well as GM-CSF/surfactant metabolism pathways. These findings provide direct genetic evidence supporting the use of GM-CSF modulators and interferon-lambda for COVID-19 treatment, therapies that have already entered clinical trials. Furthermore, multi-trait conditional analysis prioritized FYCO1 and HCN3 as potential COVID-19-specific risk genes. Splicing analysis underscored the critical role of alternative splicing in both shared and differential architectures, highlighting IFNAR2 isoform regulation as a key discriminator between COVID-19 and other respiratory traits.

ConclusionThis study provides the first genome-wide, multi-omics map revealing the shared and differential genetic landscapes of COVID-19 and other respiratory phenotypes. By uncovering specific molecular mechanisms that distinguish COVID-19 pathology, specifically involving surfactant homeostasis and interferon pathways, our findings offer novel insights for targeted drug repurposing and precision risk stratification.
]]></description>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.03.24.26349229v1?rss=1">
<title>
<![CDATA[
A Demographic Look at Cancer Treatment Behaviors during the COVID-19 Pandemic 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.03.24.26349229v1?rss=1"
</link>
<dc:creator>Acosta Morales, J. M.</dc:creator>
<dc:date>2026-03-26</dc:date>
<dc:identifier>doi:10.64898/2026.03.24.26349229</dc:identifier>
<dc:title><![CDATA[A Demographic Look at Cancer Treatment Behaviors during the COVID-19 Pandemic]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory Press</dc:publisher>
<prism:publicationDate>2026-03-26</prism:publicationDate>
<prism:section></prism:section>
<description><![CDATA[
Abstract/SummaryO_ST_ABSBackgroundC_ST_ABSWhile numerous studies have explored the relationship between COVID-19 and cancer, few have specifically examined the significant impact of the pandemic on cancer patients, particularly concerning their treatments and appointments.

ObjectivesThis study aims to investigate cancer treatment behaviors during the COVID-19 pandemic.

MethodsThis retrospective quantitative study utilized data from the Centers for Disease Control and Preventions National Health Interview Survey of 2020. The inclusion criteria were as follows: studies conducted within the United States; patients diagnosed with COVID-19 since the pandemic began; patients diagnosed with cancer within the United States; patients undergoing cancer treatment or in remission since the start of the pandemic; patients who experienced a change, delay, or cancellation of treatment due to the COVID-19 pandemic; patients who experienced a change or delay in cancer care due to the COVID-19 pandemic; patients with a weakened immune system due to prescriptions; and patients who took prescription medication within the past 12 months. The variables were analyzed against population characteristics, including age, race, gender, cancer type, and COVID-19 status. Python Jupyter Notebook (packaged by Anaconda Navigator in R Studio, version 6.4.8), Microsoft Excel for data cleaning and assessment, and SPSS were used for statistical analyses.

ResultsChi-Square Analysis (p<.05) revealed significant associations between cancer treatment and gender (p=0.009), other cancer treatments and age (p<.001) and education (p<.001), changes in other cancer treatments and gender (p=0.045), race (p<.001), age (p<.001), and education (p=.013), and prescribed medication and gender (p=.009), family income (p<.001), and age (p<.001).

ConclusionThe COVID-19 pandemic has significantly impacted cancer care in the U.S., affecting the delivery of treatments. Additional government funding is necessary to help medical facilities develop programs for off-site treatment delivery, to better prepare for future pandemics, and avoid repeating past challenges.
]]></description>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.03.23.26349092v1?rss=1">
<title>
<![CDATA[
Higher SARS-CoV-2 Transmission Burden Among Racialized Individuals: Evidence from Canadian Serology Data 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.03.23.26349092v1?rss=1"
</link>
<dc:creator>Mann, S. K.</dc:creator>
<dc:creator>Wilson, N. J.</dc:creator>
<dc:creator>Lee, C. E.</dc:creator>
<dc:creator>Fisman, D.</dc:creator>
<dc:date>2026-03-25</dc:date>
<dc:identifier>doi:10.64898/2026.03.23.26349092</dc:identifier>
<dc:title><![CDATA[Higher SARS-CoV-2 Transmission Burden Among Racialized Individuals: Evidence from Canadian Serology Data]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory Press</dc:publisher>
<prism:publicationDate>2026-03-25</prism:publicationDate>
<prism:section></prism:section>
<description><![CDATA[
IntroductionCOVID-19 transmission has not been evenly distributed across racial groups, with exposure being shaped by social and structural factors. The emergence of highly transmissible variants (i.e., Omicron) dramatically increased infection rates. However, it remains unclear whether racial disparities in transmission disappeared or persisted over the course of the pandemic.

ObjectiveTo understand how SARS-CoV-2 transmission differed by race in Canada and whether those disparities changed with the Omicron variant.

MethodsWe analyzed cross-sectional SARS-CoV-2 seroprevalence data from the Canadian Blood Services serosurveillance program (June 2020 to April 2023) using a previously described dynamic susceptible-infection model, while accounting for seroreversion. Race-specific force of infection was estimated for the pre-Omicron and Omicron periods (with the emergence of Omicron defined as beginning December 26, 2021).

ResultsPrior to Omicron, racialized individuals had a 74% higher force of infection (IRR = 2.205; 95% CI: 2.115-2.299). During the Omicron period, infection rates rose significantly within each racial group relative to the pre-Omicron period, with a 55.52-fold increase among White individuals and a 31.27-fold increase among racialized individuals. Despite this, racialized individuals remained disproportionately affected following the emergence of Omicron, with 24% higher infection rates than those of their White counterparts (IRR = 1.242; 95% CI: 1.231-1.253).

ConclusionWidespread transmission during Omicron did not result in epidemiologic equity, as racialized populations continued to experience higher infection risk despite crude seroprevalence depicting convergence.
]]></description>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.03.23.26349084v1?rss=1">
<title>
<![CDATA[
Beyond COVID-19 Deaths: Cause-Specific Analysis of Excess Mortality in Russia 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.03.23.26349084v1?rss=1"
</link>
<dc:creator>Degtiareva, E.</dc:creator>
<dc:creator>Timonin, S.</dc:creator>
<dc:creator>Tilstra, A.</dc:creator>
<dc:creator>Aburto, J. M.</dc:creator>
<dc:date>2026-03-25</dc:date>
<dc:identifier>doi:10.64898/2026.03.23.26349084</dc:identifier>
<dc:title><![CDATA[Beyond COVID-19 Deaths: Cause-Specific Analysis of Excess Mortality in Russia]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory Press</dc:publisher>
<prism:publicationDate>2026-03-25</prism:publicationDate>
<prism:section></prism:section>
<description><![CDATA[
During the COVID-19 pandemic, European mortality exhibited a marked East-West divide in both timing and magnitude, echoing longstanding longevity disparities in this region. Russia sits on the Eastern side: early restrictions were short-lived, and vaccine uptake remained low amid historically limited trust in government and science. Using weekly national and monthly regional mortality data disaggregated by age, sex, and cause of death, we estimated excess mortality from March 2020 to December 2021 using generalised additive models. We identify two major mortality peaks (late 2020-early 2021 and late 2021) and estimate 1,044,914 excess deaths, well above the 595,815 officially registered COVID-19 deaths. Non-COVID-19 excess was larger during the first peak, especially at ages 15-44. Cardiovascular diseases accounted for roughly 60% of the non-COVID-19 excess and we find no evidence of excess mortality from cancer or external causes. Among women, excess deaths were concentrated at older ages, whereas among men they clustered at working and older working ages, only partly reflecting differences in age structure. The highest excess mortality was found in the most populous regions, particularly the Central European and Volga parts. Temporal and spatial inconsistencies in cause-of-death coding may obscure indirect mortality burden and hinder the associated policy response.

Highlights- Russia had 1,044,914 excess deaths in 2020-21, about twice official COVID-19 deaths.
- These discrepancies varied over time and across regions.
- Cardiovascular deaths drove most non-COVID excess mortality.
- We find no evidence of excess mortality from external causes of death.
- Autopsy-based COVID-19 assignment may have increased misclassification
]]></description>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.03.23.26349096v1?rss=1">
<title>
<![CDATA[
Wastewater-Based Genomic Surveillance of SARS-CoV-2 Variant Circulation in Two Informal Urban Settlements in Nairobi, Kenya 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.03.23.26349096v1?rss=1"
</link>
<dc:creator>Kingwara, L.</dc:creator>
<dc:creator>Madada, R. S.</dc:creator>
<dc:creator>Morangi, V.</dc:creator>
<dc:creator>Akasa, S.</dc:creator>
<dc:creator>Kiprutto, V.</dc:creator>
<dc:creator>Julie, O.</dc:creator>
<dc:creator>Muthoka, R.</dc:creator>
<dc:creator>Rombo, C.</dc:creator>
<dc:creator>Kimonye, K.</dc:creator>
<dc:creator>Okunga, E.</dc:creator>
<dc:creator>Masika, M.</dc:creator>
<dc:creator>Ochieng, E.</dc:creator>
<dc:creator>Nyaga, R.</dc:creator>
<dc:creator>Otieno, O.</dc:creator>
<dc:creator>Cham, F.</dc:creator>
<dc:creator>Hull, N.</dc:creator>
<dc:creator>Kimenye, K.</dc:creator>
<dc:date>2026-03-25</dc:date>
<dc:identifier>doi:10.64898/2026.03.23.26349096</dc:identifier>
<dc:title><![CDATA[Wastewater-Based Genomic Surveillance of SARS-CoV-2 Variant Circulation in Two Informal Urban Settlements in Nairobi, Kenya]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory Press</dc:publisher>
<prism:publicationDate>2026-03-25</prism:publicationDate>
<prism:section></prism:section>
<description><![CDATA[
BackgroundSARS-CoV-2 genomic surveillance data remain limited in most low and middle-income countries (LMICs), resulting in significant gaps in the understanding of variant circulation and evolution. Wastewater-based epidemiology (WBE) presents a non-invasive, cost-effective, and population-representative surveillance approach that can complement clinical testing, particularly in densely populated urban informal settlements with limited healthcare access. This study aimed to pilot wastewater-based genomic surveillance as a multifaceted public health tool in Kenya.

MethodsA prospective study was conducted using wastewater samples collected from two WHO-validated environmental surveillance sites -- Eastleigh A (Kamukunji sub-county) and Mathare (Starehe sub-county) -- in Nairobi, Kenya, between December 2022 and October 2023. A total of 272 samples were collected using Moore swabs at a frequency of two to three times per week. Samples were concentrated using Nanotrap(R) Magnetic Virus Particles, and nucleic acid was extracted using the Qiagen QIAamp Viral RNA Mini Kit. SARS-CoV-2 was detected using RT-PCR (TaqPath COVID-19 CE-IVD RT-PCR Kit). Library preparation for whole-genome sequencing was performed using the Illumina COVIDSeq kit, and sequencing was conducted on the Illumina MiSeq platform. Bioinformatic analysis was performed using Terra.bio and RStudio, and phylogenetic analysis included sequences abstracted from GISAID.

ResultsOf 272 samples, 238 (87.5%) tested positive with a cycle threshold (Ct) value of less than 36. Genomic analysis of 181 sequences identified Omicron as the predominant circulating variant, detected in 59% of samples. Other variants included XBB (16%), XBB.2.3(10%), XBB.1.9.X (5%), and additional minor variants. These findings were concordant with clinical sequencing data from Kenya over the same period.

ConclusionsWastewater-based genomic surveillance reliably reflected SARS-CoV-2 variant trends observed in clinical data. This approach provides early signals of variant emergence and evolution, offering a cost-effective complement to clinical surveillance in resource-limited settings.
]]></description>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.03.23.26349117v1?rss=1">
<title>
<![CDATA[
Household Size and Age as Primary Drivers of COVID-19 Infection Among Priority Populations in Australia 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.03.23.26349117v1?rss=1"
</link>
<dc:creator>Narayanasamy, S.</dc:creator>
<dc:creator>Altermatt, A.</dc:creator>
<dc:creator>Tse, W. C.</dc:creator>
<dc:creator>Gibbs, L.</dc:creator>
<dc:creator>Wilkinson, A.</dc:creator>
<dc:creator>Heath, K.</dc:creator>
<dc:creator>Stoove, M.</dc:creator>
<dc:creator>Scott, N.</dc:creator>
<dc:creator>Gibney, K.</dc:creator>
<dc:creator>Hellard, M.</dc:creator>
<dc:creator>Pedrana, A.</dc:creator>
<dc:date>2026-03-25</dc:date>
<dc:identifier>doi:10.64898/2026.03.23.26349117</dc:identifier>
<dc:title><![CDATA[Household Size and Age as Primary Drivers of COVID-19 Infection Among Priority Populations in Australia]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory Press</dc:publisher>
<prism:publicationDate>2026-03-25</prism:publicationDate>
<prism:section></prism:section>
<description><![CDATA[
BackgroundThe COVID-19 pandemic exacerbated health disparities globally, with certain populations experiencing disproportionate disease burdens. In Australia, COVID-19 deaths occurred disproportionately among first-generation migrants. This study examined risk factors for COVID-19 infection in a Victorian cohort recruited from priority populations, including healthcare workers, people with chronic health conditions, and culturally and linguistically diverse (CALD) communities.

MethodsWe conducted a cross-sectional analysis of participants from the Optimise longitudinal cohort study (September 2020-December 2023). The primary outcome was the self-reported count of confirmed COVID-19 infections (PCR or rapid antigen test positive) from December 2019 to December 2023. We used Poisson regression to examine associations between baseline sociodemographic characteristics and infection count, calculating unadjusted and adjusted incidence rate ratios (IRRs) with 95% confidence intervals (CIs).

ResultsOf 433 participants (median age 51 years, 75% female), 25% reported no infections, 48% reported one infection, and 27% reported two or more infections. In univariate analysis, CALD status (IRR=1.24,95%CI:1.02-1.50) and larger household size (2-5 people, IRR=1.71,95%CI:1.14-2.50) were associated with higher infection rates, while chronic health conditions (IRR=0.73, 95%CI:0.61-0.88) and older age (IRR=0.54, 95%CI:0.43-0.67) were associated with lower infection rates. In adjusted analysis, younger age (18-34 years vs [&ge;]55 years: aIRR=0.63,95%CI:0.48-0.82) and medium household size (living alone vs 2-5 person household: aIRR=1.42, 95%CI:1.11-1.83) remained significant predictors. CALD status and socioeconomic status showed no independent association with infection risk after adjustment for household size and age.

ConclusionCOVID-19 infection risk in this Victorian cohort was driven by younger age and larger household size rather than CALD status or socioeconomic status, suggesting that housing density and age, rather than cultural or socioeconomic characteristics, determined infection patterns. Future pandemic preparedness should prioritise policies enabling safe quarantine and isolation for individuals in larger households and workplace protections and economic security for younger essential workers.
]]></description>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.03.23.26349139v1?rss=1">
<title>
<![CDATA[
Phylogenetic Insights into SARS-CoV-2 Introductions and Spread in Georgia 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.03.23.26349139v1?rss=1"
</link>
<dc:creator>Veytsel, G. E.</dc:creator>
<dc:creator>Lyu, L.</dc:creator>
<dc:creator>Stott, G.</dc:creator>
<dc:creator>Carmola, L.</dc:creator>
<dc:creator>Dishman, H.</dc:creator>
<dc:creator>Bahl, J.</dc:creator>
<dc:date>2026-03-25</dc:date>
<dc:identifier>doi:10.64898/2026.03.23.26349139</dc:identifier>
<dc:title><![CDATA[Phylogenetic Insights into SARS-CoV-2 Introductions and Spread in Georgia]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory Press</dc:publisher>
<prism:publicationDate>2026-03-25</prism:publicationDate>
<prism:section></prism:section>
<description><![CDATA[
The spread of successive novel COVID-19 variants presented a challenge for outbreak surveillance, epidemiology, and emergency responses. Monitoring the emergence and spread of SARS-CoV-2 variants is essential to allocate limited public health resources and optimize control efforts. Global collaboration among the scientific community enabled large-scale viral surveillance and sequencing efforts. However, translating these vast datasets into actionable public health inferences requires rapid statistical methodologies, scalable workflows, and robust frameworks.

In this study, we focused on the Delta epidemic wave in Georgia by applying a hybrid maximum likelihood (ML) and Bayesian phylodynamic approach. We characterized the Delta variant introduction to Georgia and its subsequent local spread. Our analysis of 9,783 Delta sequences collected between August 1, 2020 and January 25, 2022 detected at least 344 introductions into Georgia, resulting in 34 highly-supported local clusters. On average, clusters circulated for one month before the earliest detected sequence, highlighting critical delays in detection. While most clusters remained small, a few introduction events led to large, sustained outbreaks. We jointly inferred the statewide transmission network, estimated from all locally circulating clusters with a modified Bayesian discrete trait phylogeographic reconstruction of statewide health districts. We showed that South Central, Georgia was a major source of transmission, despite having smaller numbers of infected people, compared to major metropolitan areas.

Our study addresses the urgent need for methodologies and data-driven recommendations for public health practice, particularly given large, dynamic, and integrated datasets. By identifying key geographic sources and sinks of transmission, our findings can guide resource allocation and prepare for future epidemics among high-risk populations. Additionally, by characterizing introduction events, local circulation, and detection lags, we highlight critical gaps in surveillance. These gaps can inform outbreak investigation and response, such as targeted contact tracing and testing.
]]></description>
</item>
<item rdf:about="https://www.biorxiv.org/content/10.64898/2026.03.24.713966v1?rss=1">
<title>
<![CDATA[
SARS-CoV-2 PLpro Drives Epithelial Barrier Disruption Across Drosophila and Mammalian Epithelia 
]]>
</title>
<link>
https://www.biorxiv.org/content/10.64898/2026.03.24.713966v1?rss=1"
</link>
<dc:creator>Ahmad, Q. T.</dc:creator>
<dc:creator>Banerjee, S.</dc:creator>
<dc:creator>Anerao, I. M.</dc:creator>
<dc:creator>Tripathi, J.</dc:creator>
<dc:creator>Parihar, S. S.</dc:creator>
<dc:creator>Bajpai, A.</dc:creator>
<dc:creator>Rizvi, M. S.</dc:creator>
<dc:creator>SINHA, P.</dc:creator>
<dc:date>2026-03-25</dc:date>
<dc:identifier>doi:10.64898/2026.03.24.713966</dc:identifier>
<dc:title><![CDATA[SARS-CoV-2 PLpro Drives Epithelial Barrier Disruption Across Drosophila and Mammalian Epithelia]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory Press</dc:publisher>
<prism:publicationDate>2026-03-25</prism:publicationDate>
<prism:section></prism:section>
<description><![CDATA[
Disruption of epithelial homeostasis and barrier integrity, compounded by maladaptive inflammation, is central to SARS-CoV-2 pathogenesis. Prior reductionist studies relying on mammalian cell lines, which lack the capacity to form architecturally faithful epithelium in vitro, were ill-suited to identify the viral proteins that proximally underpin these epithelial perturbations. We therefore screened all SARS-CoV-2 NSPs and ORFs in the Drosophila larval imaginal disc--an intact epithelium whose conserved junctional architecture and stress signaling circuits closely recapitulate those of human epithelium. This systemic filter identified the papain-like protease (PLpro) of NSP3 as a primary driver of junctional disruption. In imaginal disc epithelium, PLpro expression induced elevated oxidative stress (ROS) and hyperactivation of Akt, JNK, and JAK-STAT pathways--a self-amplifying pathological network that acts as a  cog-in-the-wheel to derail tissue homeostasis. PLpro further induced organ-specific junctional perturbations and dysregulation of stress signaling in the larval tracheal system and the adult midgut, extending its epithelial-disrupting role across three morphologically distinct organs. Targeted genetic suppression of this network restored integrity, establishing these pathways as causal drivers. Critically, PLpro expression in mammalian MDCK epithelium recapitulated these defects, revealing cross-species conservation. These findings redefine PLpro as a  dual-threat pathogen--not merely an immune-evasion factor, but a direct  architect of injury and a previously unrecognized determinant of COVID-19 pathogenesis.
]]></description>
</item>
<item rdf:about="https://www.biorxiv.org/content/10.64898/2026.03.24.713916v1?rss=1">
<title>
<![CDATA[
Coronavirus envelope protein drives iron sensing disorder by hijacking the TAp73-FDXR axis 
]]>
</title>
<link>
https://www.biorxiv.org/content/10.64898/2026.03.24.713916v1?rss=1"
</link>
<dc:creator>Zhu, M.</dc:creator>
<dc:creator>Hu, L.</dc:creator>
<dc:creator>Fu, X.</dc:creator>
<dc:creator>Yuan, B.</dc:creator>
<dc:creator>Guan, G.</dc:creator>
<dc:creator>Han, L.</dc:creator>
<dc:creator>Rong, Z.</dc:creator>
<dc:creator>Tian, R.</dc:creator>
<dc:creator>Li, G.</dc:creator>
<dc:creator>Du, M.</dc:creator>
<dc:creator>Ma, Y.</dc:creator>
<dc:creator>Xu, N.</dc:creator>
<dc:creator>Liu, H.</dc:creator>
<dc:creator>Tian, H.</dc:creator>
<dc:creator>Yin, X.</dc:creator>
<dc:creator>Zhong, J.</dc:creator>
<dc:creator>Sun, M.</dc:creator>
<dc:creator>Yang, S.</dc:creator>
<dc:creator>Liu, S.</dc:creator>
<dc:creator>Liu, Q.</dc:creator>
<dc:creator>Li, J.</dc:creator>
<dc:creator>Fan, B.</dc:creator>
<dc:creator>Chen, Y.</dc:creator>
<dc:creator>Zhao, Q.</dc:creator>
<dc:creator>Zhou, T.</dc:creator>
<dc:creator>Chang, L.</dc:creator>
<dc:creator>Zhao, X.</dc:creator>
<dc:creator>Ran, X.</dc:creator>
<dc:creator>Du, Q.</dc:creator>
<dc:creator>Ding, S.</dc:creator>
<dc:creator>Li, B.</dc:creator>
<dc:creator>Huang, Y.</dc:creator>
<dc:creator>Tong, D.</dc:creator>
<dc:date>2026-03-25</dc:date>
<dc:identifier>doi:10.64898/2026.03.24.713916</dc:identifier>
<dc:title><![CDATA[Coronavirus envelope protein drives iron sensing disorder by hijacking the TAp73-FDXR axis]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory Press</dc:publisher>
<prism:publicationDate>2026-03-25</prism:publicationDate>
<prism:section></prism:section>
<description><![CDATA[
Iron overload is increasingly recognized as a critical contributor to coronavirus pathogenesis1, yet the underlying induction mechanisms remain unclear. Here, we uncover a fundamental pathway by which coronavirus drives IRP1 RNA-binding activity to induce iron accumulation2 via targeting the TAp73-FDXR axis. Specifically, coronavirus infection represses transcription of FDXR (encoding the key rate-limiting enzyme in host iron-sulfur cluster synthesis3), thereby impairing host iron-sulfur cluster generation to trigger the functional conversion of the cytosolic aconitase 1 (ACO1) into iron-regulatory protein 1 (IRP1)4, ultimately leading to the hosts persistently false perception of iron deficiency. We identify TAp73 as the primary transcription factor governing FDXR expression, and demonstrate that the coronavirus envelope protein (CoV-E) orchestrates TAp73 nuclear export. Subsequently, CoV-E binds TAp73 through a critical valine residue within its C-terminal PBM domain, inducing the K48-linked ubiquitination and proteasomal degradation of TAp73. Furthermore, we developed a CoV-E-targeting molecule, DPTP-FC, which blocks CoV-E-TAp73 interaction via forming steric hindrance and effectively alleviates iron accumulation and tissue damage caused by PEDV, PDCoV, and SARS-CoV-2 infection. Our study reveals the central role of the TAp73-FDXR axis in CoV-induced iron accumulation, highlighting CoV-E as an attractive antiviral target and DPTP-FC as a promising therapeutic candidate.
]]></description>
</item>
<item rdf:about="https://www.biorxiv.org/content/10.64898/2026.03.20.713312v1?rss=1">
<title>
<![CDATA[
Somatic evolution of a cross-reactive germline antibody that expands its breadth to neutralize new SARS-CoV-2 variants 
]]>
</title>
<link>
https://www.biorxiv.org/content/10.64898/2026.03.20.713312v1?rss=1"
</link>
<dc:creator>Lv, H.</dc:creator>
<dc:creator>Feng, Z.</dc:creator>
<dc:creator>Teo, Q. W.</dc:creator>
<dc:creator>Chen, C.</dc:creator>
<dc:creator>Gopal, A. B.</dc:creator>
<dc:creator>Choi, D.</dc:creator>
<dc:creator>Tan, T. J. C.</dc:creator>
<dc:creator>Tang, Y. S.</dc:creator>
<dc:creator>Siu, L.</dc:creator>
<dc:creator>Nourmohammad, A.</dc:creator>
<dc:creator>Bruzzone, R.</dc:creator>
<dc:creator>Wilson, I. A.</dc:creator>
<dc:creator>Yuan, M.</dc:creator>
<dc:creator>Wu, N. C.</dc:creator>
<dc:creator>Mok, C. K.-P.</dc:creator>
<dc:date>2026-03-25</dc:date>
<dc:identifier>doi:10.64898/2026.03.20.713312</dc:identifier>
<dc:title><![CDATA[Somatic evolution of a cross-reactive germline antibody that expands its breadth to neutralize new SARS-CoV-2 variants]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory Press</dc:publisher>
<prism:publicationDate>2026-03-25</prism:publicationDate>
<prism:section></prism:section>
<description><![CDATA[
Rapid antigenic drift of the SARS-CoV-2 receptor-binding domain (RBD) underlies immune escape and continues to challenge the durability of antibody-mediated protection. Among the major classes of RBD-directed antibodies, germline-encoded IGHV3-53 responses are highly potent against early SARS-CoV-2 variants but are generally compromised by Omicron-associated mutations. Here, we identify an intrinsically cross-reactive IGHV3-53 germline antibody that recognizes multiple pre-Omicron variants, including SARS-CoV-2 wild-type, Alpha, and Delta. Notably, we demonstrate that targeted somatic evolution can further expand this breadth to overcome the immune escape of different Omicron variants. Guided by integrated structural and sequence analyses, we introduce four somatic mutations (G26E, T28I, S53P, and Y58F) into the germline antibody, resulting in markedly enhanced binding and neutralization of Omicron BA.1, BA.2, and BA.4/5. High-resolution crystal structures reveal that these mutations re-establish critical interactions disrupted by substitutions on Omicron RBD and optimize affinity at a remodeled epitope interface. Collectively, our findings delineate a structural and mechanistic pathway through which an inherently cross-reactive germline antibody lineage can be adaptively refined to counter highly divergent SARS-CoV-2 variants. This work highlights the underappreciated breadth encoded within the naive B-cell repertoire and provides a conceptual framework for engineering and eliciting antibody responses resilient to future antigenic drift.
]]></description>
</item>
<item rdf:about="https://www.biorxiv.org/content/10.64898/2026.03.23.713574v1?rss=1">
<title>
<![CDATA[
Modulation of liposome membranes by the C-terminal domain of the coronavirus envelope protein 
]]>
</title>
<link>
https://www.biorxiv.org/content/10.64898/2026.03.23.713574v1?rss=1"
</link>
<dc:creator>Alag, R.</dc:creator>
<dc:creator>Bui, M. H.</dc:creator>
<dc:creator>Miserez, A.</dc:creator>
<dc:creator>Torres, J.</dc:creator>
<dc:creator>Pervushin, K.</dc:creator>
<dc:creator>Sharma, B.</dc:creator>
<dc:date>2026-03-25</dc:date>
<dc:identifier>doi:10.64898/2026.03.23.713574</dc:identifier>
<dc:title><![CDATA[Modulation of liposome membranes by the C-terminal domain of the coronavirus envelope protein]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory Press</dc:publisher>
<prism:publicationDate>2026-03-25</prism:publicationDate>
<prism:section></prism:section>
<description><![CDATA[
The coronavirus envelope (E) protein is a viroporin that plays a key role in viral assembly, release, budding and pathogenesis. E protein forms oligomeric ion channels that can activate immune responses. However, high-resolution structural data for its extramembrane domains is limited. The C-terminal domain of SARS-CoV has been shown previously to form amyloid fibers, and here we show that these fibers can modulate the shape of liposomes. The propensity to form fibrils, and their effect on liposomes, was examined for sequences belonging to the four clades of coronaviruses. Electron microscopy data shows that the C-terminal domain in E protein adopts a filamentous structure. These findings demonstrate the potential of these peptides to modulate membranes, providing a possible mechanism by which E protein interacts with membranes in the host cell.
]]></description>
</item>
<item rdf:about="https://www.biorxiv.org/content/10.64898/2026.03.23.713300v1?rss=1">
<title>
<![CDATA[
Cross-coronavirus host susceptibility loci influence disease severity through immune mediators 
]]>
</title>
<link>
https://www.biorxiv.org/content/10.64898/2026.03.23.713300v1?rss=1"
</link>
<dc:creator>Risemberg, E. L.</dc:creator>
<dc:creator>Leist, S. R.</dc:creator>
<dc:creator>Schaefer, A.</dc:creator>
<dc:creator>Kamat, K. D.</dc:creator>
<dc:creator>Bell, T. A.</dc:creator>
<dc:creator>Hock, P.</dc:creator>
<dc:creator>Jensen, K. L.</dc:creator>
<dc:creator>Linnertz, C. L.</dc:creator>
<dc:creator>Miller, D. R.</dc:creator>
<dc:creator>Shaw, G. D.</dc:creator>
<dc:creator>Pardo-Manuel de Villena, F.</dc:creator>
<dc:creator>Baric, R. S.</dc:creator>
<dc:creator>Ferris, M. T.</dc:creator>
<dc:creator>Valdar, W.</dc:creator>
<dc:date>2026-03-25</dc:date>
<dc:identifier>doi:10.64898/2026.03.23.713300</dc:identifier>
<dc:title><![CDATA[Cross-coronavirus host susceptibility loci influence disease severity through immune mediators]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory Press</dc:publisher>
<prism:publicationDate>2026-03-25</prism:publicationDate>
<prism:section></prism:section>
<description><![CDATA[
Severe disease following infection with SARS-CoV or SARS-CoV-2 is driven in part by genetically regulated immune responses that promote lung injury. Previously, we showed that genetic risk for severe disease is conserved across viruses and between mouse and human, identifying the HrS43 locus as a shared determinant of severity. Here, to resolve immune pathways linking host loci to disease outcomes, we apply an integrative statistical framework combining Bayesian identification of predictive immune traits with QTL mapping and mediation analysis across infection conditions. This approach identifies immune predictors of disease severity across both viruses, reveals extensive genetic control of the immune system at homeostasis and during infection, and supports locus-specific causal mechanisms of immunopathology. Notably, HrS43 appears to influence disease severity through distinct immune mediators in SARS-CoV versus SARS-CoV-2, demonstrating that conserved genetic susceptibility can drive virus-specific immunopathology with translational relevance across species.
]]></description>
</item>
<item rdf:about="https://www.biorxiv.org/content/10.64898/2026.03.21.713333v1?rss=1">
<title>
<![CDATA[
IL-1β and TNF drive endothelial dysfunction and coagulopathy in acute COVID-19. 
]]>
</title>
<link>
https://www.biorxiv.org/content/10.64898/2026.03.21.713333v1?rss=1"
</link>
<dc:creator>Mostafavi, H.</dc:creator>
<dc:creator>Hill, B.</dc:creator>
<dc:creator>Nalkurthi, C.</dc:creator>
<dc:creator>Bader, S. M.</dc:creator>
<dc:creator>Zhu, Y.</dc:creator>
<dc:creator>Yu, A.</dc:creator>
<dc:creator>Hansbro, P. M.</dc:creator>
<dc:creator>Doerflinger, M.</dc:creator>
<dc:creator>Johansen, M. D.</dc:creator>
<dc:creator>Short, K. R.</dc:creator>
<dc:creator>Chew, K. Y.</dc:creator>
<dc:creator>Gordon, E. J.</dc:creator>
<dc:creator>Labzin, L. I.</dc:creator>
<dc:date>2026-03-25</dc:date>
<dc:identifier>doi:10.64898/2026.03.21.713333</dc:identifier>
<dc:title><![CDATA[IL-1β and TNF drive endothelial dysfunction and coagulopathy in acute COVID-19.]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory Press</dc:publisher>
<prism:publicationDate>2026-03-25</prism:publicationDate>
<prism:section></prism:section>
<description><![CDATA[
Vascular dysfunction and coagulopathy are hallmarks of severe COVID-19. How SARS-CoV-2 infection drives endothelial dysfunction, despite the virus not infecting or replicating in endothelial cells, remains controversial. Here, we used an in vitro co-culture model of the human pulmonary epithelial-endothelial cell barrier to investigate which inflammatory mediators drive endothelial dysfunction during SARS-CoV-2 infection. SARS-CoV-2 infection of primary human bronchial epithelial cells increased adjacent endothelial cell expression of the leukocyte adhesion marker ICAM-1, disrupted endothelial VE-cadherin junctions, promoted endothelial cell death, and promoted platelet adherence to gaps in the endothelial monolayers. Dexamethasone treatment rescued these dysregulated endothelial phenotypes in infected co-cultures, confirming that inflammatory signalling was the primary driver of SARS-CoV-2-induced endothelial dysfunction. Specifically, epithelial-derived TNF and IL-1{beta} promoted endothelial dysfunction, as inhibition of TNF or IL-1R signalling blocked SARS-CoV-2-induced endothelial dysfunction in co-cultures. SARS-CoV-2-infected wild-type mice, but not TNF, IL-1{beta}, or TNF/IL-1{beta}- deficient mice, displayed increased endothelial ICAM-1 expression, while an anti-IL-1{beta} monoclonal antibody prevented SARS-CoV-2-induced ICAM-1 expression and fibrin deposition in aged K18-ACE2 mice. Our data indicate that TNF and IL-1{beta} are the specific cytokines that drive multiple aspects of endothelial dysfunction during acute SARS-CoV-2 infection, and that inhibiting their signalling pathways may provide therapeutic benefit in preventing vascular complications of COVID-19.
]]></description>
</item>
<item rdf:about="https://www.biorxiv.org/content/10.64898/2026.03.19.712934v1?rss=1">
<title>
<![CDATA[
Experimental SARS-CoV-2 infection using horseshoe bats 
]]>
</title>
<link>
https://www.biorxiv.org/content/10.64898/2026.03.19.712934v1?rss=1"
</link>
<dc:creator>Usui, K.</dc:creator>
<dc:creator>Tsuda, M.</dc:creator>
<dc:creator>Uriu, K.</dc:creator>
<dc:creator>Fujita, S.</dc:creator>
<dc:creator>Kashima, Y.</dc:creator>
<dc:creator>Suzuki, Y.</dc:creator>
<dc:creator>Wang, L.</dc:creator>
<dc:creator>Tanaka, S.</dc:creator>
<dc:creator>Ito, J.</dc:creator>
<dc:creator>Sato, K.</dc:creator>
<dc:date>2026-03-25</dc:date>
<dc:identifier>doi:10.64898/2026.03.19.712934</dc:identifier>
<dc:title><![CDATA[Experimental SARS-CoV-2 infection using horseshoe bats]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory Press</dc:publisher>
<prism:publicationDate>2026-03-25</prism:publicationDate>
<prism:section></prism:section>
<description><![CDATA[
Horseshoe bats are known as the natural reservoir of sarbecoviruses. To understand how horseshoe bats coexist with sarbecoviruses in nature, experimental infection can provide direct evidence. However, in vivo infection studies using horseshoe bats have been lacking because of the difficulty of maintaining insectivorous bats in a laboratory setting. Here, we established a stable husbandry system for greater horseshoe bats (Rhinolophus ferrumequinum) and performed experimental infection with SARS-CoV-2. In contrast to Syrian hamsters which showed substantial viral replication, infected horseshoe bats exhibited low-level but persistent viral replication in the lung without overt disease. Histological analyses revealed that inflammatory lesions in the bat lungs were spatially restricted and temporally delayed compared with those in hamsters. Transcriptomic analyses further showed preferential activation of tissue repair pathways but limited inflammatory responses following infection. Notably, bats expressed several interferon-stimulated genes prior to infection. Our results suggest that a host strategy combining constitutive antiviral state, limited inflammation and enhanced tissue repair may result in controlled viral replication without overt disease, likely enabling horseshoe bats to coexist with sarbecoviruses.
]]></description>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.03.20.26348947v1?rss=1">
<title>
<![CDATA[
Shifts in the pathogen spectrum and epidemiology of respiratory tract infections in the post-COVID-19 era: A study from Quzhou, Eastern China 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.03.20.26348947v1?rss=1"
</link>
<dc:creator>Yang, R.</dc:creator>
<dc:creator>Wang, M.</dc:creator>
<dc:creator>Lyu, L.</dc:creator>
<dc:creator>You, J.</dc:creator>
<dc:creator>Huang, S.</dc:creator>
<dc:creator>Zhan, B.</dc:creator>
<dc:date>2026-03-24</dc:date>
<dc:identifier>doi:10.64898/2026.03.20.26348947</dc:identifier>
<dc:title><![CDATA[Shifts in the pathogen spectrum and epidemiology of respiratory tract infections in the post-COVID-19 era: A study from Quzhou, Eastern China]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory Press</dc:publisher>
<prism:publicationDate>2026-03-24</prism:publicationDate>
<prism:section></prism:section>
<description><![CDATA[
BackgroundAlthough the relaxation of COVID-19 containment measures in China has altered the transmission dynamics of respiratory pathogens, regional data on post-pandemic epidemiological characteristics remain limited.

ObjectiveThis study aimed to investigate the pathogen spectrum and epidemiological characteristics of acute respiratory infections (ARIs) in Quzhou City from 2023 to 2024, providing a scientific basis for local prevention and control strategies.

MethodsA total of 2,800 respiratory specimens were collected from November 2023 to July 2024, comprising 1,960 influenza-like illness (ILI) cases from outpatient/emergency departments and 840 severe acute respiratory infection (SARI) cases from inpatient departments. All samples were tested for 13 common respiratory pathogens using multiplex fluorescence quantitative PCR. Etiological and epidemiological analyses were performed based on detection results and case information.

ResultsThe overall ARI positivity rate was 59.28% (1,660/2,800), with a male-to-female ratio of 1.07:1 (1,447/1,353). The three most prevalent pathogens were influenza virus (Flu, 23.21%, 650/2,800), Streptococcus pneumoniae (SP, 13.14%, 368/2,800), and adenovirus (ADV, 8.39%, 235/2,800). Single pathogen infections accounted for 73.55% (1,221/1,660) of positive cases, while co-infections with two or more pathogens accounted for 26.45% (439/1,660), yielding an overall co-infection rate of 15.68% (439/2,800). No significant gender difference was observed in detection rates. However, significant differences were found across case types, temporal periods, age groups, and geographic regions (P < 0.01). Children aged [&le;]5 years exhibited the highest positivity rate (78.00%, 378/525), while adults aged [&ge;]65 years showed the lowest (34.53%, 144/417). Among surveillance regions, Kaihua County had the highest positivity rate (72.47%), and Changshan County the lowest (40.55%).

ConclusionsMultiple respiratory pathogens and co-infections are prevalent in Quzhou City, with distinct age-specific and seasonal patterns. These findings underscore the need for continuous multi-pathogen surveillance and integrated prevention strategies for influenza and other respiratory infectious diseases in the post-pandemic era.
]]></description>
</item>
<item rdf:about="https://www.biorxiv.org/content/10.64898/2026.03.19.712870v1?rss=1">
<title>
<![CDATA[
SARS-CoV-2 Defective Viral Genomes from Distinct Genomic Regions Drive Divergent Interferon Responses 
]]>
</title>
<link>
https://www.biorxiv.org/content/10.64898/2026.03.19.712870v1?rss=1"
</link>
<dc:creator>Brennan, J. W.</dc:creator>
<dc:creator>Spandau, S.</dc:creator>
<dc:creator>Wang, X.</dc:creator>
<dc:creator>Aull, H.</dc:creator>
<dc:creator>Connor, S.</dc:creator>
<dc:creator>Pryhuber, G.</dc:creator>
<dc:creator>Mariani, T. J.</dc:creator>
<dc:creator>Serra-Moreno, R.</dc:creator>
<dc:creator>Sun, Y.</dc:creator>
<dc:date>2026-03-24</dc:date>
<dc:identifier>doi:10.64898/2026.03.19.712870</dc:identifier>
<dc:title><![CDATA[SARS-CoV-2 Defective Viral Genomes from Distinct Genomic Regions Drive Divergent Interferon Responses]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory Press</dc:publisher>
<prism:publicationDate>2026-03-24</prism:publicationDate>
<prism:section></prism:section>
<description><![CDATA[
Defective viral genomes (DVGs) are naturally generated during genomic replication of many RNA viruses. When produced early in infection or supplemented at the onset of infection, DVGs can attenuate viral pathogenesis by stimulating IFN responses and antagonizing wild type (WT) virus replication, highlighting their potential as antiviral therapeutics. However, during natural infection DVGs can exert both antiviral and proviral effects depending on their generation kinetics, species, and abundance, underscoring the need to better understand their roles in viral pathogenesis. Coronaviruses (CoVs) remain a major global health threat and ubiquitously generate DVGs, yet DVGs roles during CoV infection are largely unknown. Using SARS-CoV-2 as a model, we previously identified DVGs in vitro and in patient samples and discovered two major genomic hotspots (A and B) for their generation. Here, we first showed that overall DVG abundance tended to positively correlate with COVID-19 severity, with approximately 40% of DVGs originating from a specific genomic region designated hotspot B. Analysis of a publicly available single-cell RNA-seq datasets revealed that DVGs from hotspot B, but not hotspot A, were associated with elevated IFN responses, suggesting that DVGs derived from different genomic regions vary in their ability to stimulate innate immunity. To test this directly, we constructed two representative DVGs corresponding to hotspots A and B. Both DVGs suppressed the replication of co-infecting WT virus; however, only DVG-B induced robust IFN responses, exceeding those triggered by WT virus alone. This was further confirmed in human precision-cut lung slices. Mechanistically, DVG-B-derived dsRNA exhibited a distinct subcellular distribution compared with WT virus. Complementation with the nucleocapsid (N) partially restored dsRNA organization but did not alter the IFN response. Together, our findings demonstrate that DVGs arising from distinct genomic hotspots differentially regulate IFN responses, potentially contributing to varied pathogenic outcomes during SARS-CoV-2 infection.

Author summaryDefective viral genomes (DVGs) are naturally produced during RNA virus infection and can suppress viral pathogenesis by stimulating innate immune responses. However, their roles in coronavirus infection, particularly SARS-CoV-2, remain poorly understood. This study investigated the species-specific function of DVGs generated during SARS-CoV-2 infection and their impact on disease outcomes. Cohort analysis revealed that overall DVG abundance tended to positively correlate with COVID-19 severity, with approximately 40% of DVGs originating from a specific genomic region designated hotspot B. Single-cell RNA sequencing showed that DVGs from hotspot B, but not hotspot A, were associated with elevated IFN responses, suggesting that DVGs from different genomic regions vary in their immunostimulatory capacity. To directly test this, we constructed representative DVGs from both hotspots. While both suppressed wild-type virus replication, only DVG-B induced robust IFN responses both in vitro and ex vivo. Mechanistically, DVG-B produced dsRNA with distinct subcellular distribution compared to wild-type virus. Interestingly, complementation with the viral nucleocapsid protein partially restored dsRNA organization but did not alter IFN responses. These findings demonstrate that SARS-CoV-2 DVGs arising from different genomic hotspots differentially regulate innate immunity, potentially contributing to varied pathogenic outcomes during infection.
]]></description>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.03.18.26348530v1?rss=1">
<title>
<![CDATA[
Microtesla Magnetic Therapy for cognitive impairment in post-acute sequelae of SARS CoV-2: A randomized controlled feasibility study 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.03.18.26348530v1?rss=1"
</link>
<dc:creator>Canori, A.</dc:creator>
<dc:creator>Watson, E.</dc:creator>
<dc:creator>Patel, D.</dc:creator>
<dc:creator>Fiorentino, A.</dc:creator>
<dc:creator>Santiago, C.</dc:creator>
<dc:creator>Maltz, D.</dc:creator>
<dc:creator>Gurfein, B.</dc:creator>
<dc:creator>Putrino, D.</dc:creator>
<dc:creator>Becker, J.</dc:creator>
<dc:date>2026-03-23</dc:date>
<dc:identifier>doi:10.64898/2026.03.18.26348530</dc:identifier>
<dc:title><![CDATA[Microtesla Magnetic Therapy for cognitive impairment in post-acute sequelae of SARS CoV-2: A randomized controlled feasibility study]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory Press</dc:publisher>
<prism:publicationDate>2026-03-23</prism:publicationDate>
<prism:section></prism:section>
<description><![CDATA[
BackgroundCognitive impairment has significant implications for function and quality of life and is common in individuals with post-acute sequelae of SARS CoV-2, also known as long COVID (LC). Emerging evidence suggests that sustained neuroinflammation, cerebrovascular dysfunction, and mitochondrial impairment are contributors to cognitive symptoms. Microtesla Magnetic Therapy (MMT) is a low-amplitude radiofrequency magnetic field intervention that has demonstrated anti-inflammatory and neuroprotective effects in preclinical models, suggesting it may be valuable in the management of cognitive impairment from LC and other neurological disorders. This study is the first randomized controlled trial to evaluate MMT for LC-related cognitive impairment.

ObjectiveTo evaluate the feasibility, safety, and preliminary efficacy of an at-home MMT intervention in individuals with moderate-to-severe cognitive impairment from LC.

MethodsIn this prospective feasibility study, 30 participants with LC-related cognitive impairment were randomized (2:1) to receive active or sham MMT. Participants self-administered 15-minute treatments at home with remote monitoring twice weekly for 4 weeks using a head-worn device that delivered a nonthermal radiofrequency magnetic field to the whole brain. Feasibility was defined as completion of at least 80% of prescribed treatments and all study visits. Secondary outcomes included safety, cognitive function, and self-reported mood and quality of life assessed at baseline, post-treatment (Week 4), and follow-up (Week 8).

ResultsFeasibility was high, with 100% treatment adherence among participants who completed the study and strong usability ratings for at-home administration. There were no device-related adverse events. Compared with sham, participants receiving active MMT showed significantly greater improvements from baseline to Week 8 in WAIS-IV Digit Span Sequencing (p= 0.026), HVLT-R Recall (p= 0.044), and D-KEFS Color Naming (p= 0.049). Additional measures of attention, processing speed, and executive function demonstrated favorable trends in the active group. Emotional well-being, assessed by the SF-36, improved significantly in the active group at Week 8 compared with sham (p= 0.017), and mood symptoms showed clinically meaningful improvement.

ConclusionsAdministration of the MMT intervention at home was feasible, safe, and well tolerated in individuals with cognitive impairment from LC. Preliminary findings suggest sustained clinically meaningful improvements in multiple cognitive domains and mood following treatment.

Trial RegistrationClinicalTrials.gov NCT06739668, https://clinicaltrials.gov/study/NCT06739668, 2024-12-17
]]></description>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.03.16.26348020v1?rss=1">
<title>
<![CDATA[
Feasibility, Acceptability, and Cost of Community-Based Self-monitoring among Sex Workers Testing Positive for COVID-19 in Zimbabwe: A Mixed-methods Study. 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.03.16.26348020v1?rss=1"
</link>
<dc:creator>Kabonga, I.</dc:creator>
<dc:creator>Mangenah, C.</dc:creator>
<dc:creator>Watadzaushe, C.</dc:creator>
<dc:creator>Madanhire, C.</dc:creator>
<dc:creator>Ruhode, N.</dc:creator>
<dc:creator>Dunkley, Y.</dc:creator>
<dc:creator>Karin, H.</dc:creator>
<dc:creator>Corbett, E. L.</dc:creator>
<dc:creator>Cowan, F. M.</dc:creator>
<dc:creator>Sibanda, E. L.</dc:creator>
<dc:date>2026-03-23</dc:date>
<dc:identifier>doi:10.64898/2026.03.16.26348020</dc:identifier>
<dc:title><![CDATA[Feasibility, Acceptability, and Cost of Community-Based Self-monitoring among Sex Workers Testing Positive for COVID-19 in Zimbabwe: A Mixed-methods Study.]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory Press</dc:publisher>
<prism:publicationDate>2026-03-23</prism:publicationDate>
<prism:section></prism:section>
<description><![CDATA[
BackgroundSex workers struggled to adhere to isolation guidelines following COVID-19 diagnosis because of financial pressure to keep working. We co-developed and evaluated for feasibility, acceptability, and cost an intervention for promoting isolation and community-based self-monitoring for COVID-19.

MethodsSex workers testing positive for COVID-19 received the following co-developed intervention: i) risk-differentiated support, including immediate hospitalization and/or treatment for serious illness, and community-based self-monitoring for those at risk of progressing to severe illness, ii) food packs lasting two weeks. Using Proctors Framework, we interviewed purposively selected health-workers and sex workers before intervention implementation (26 sex workers and 24 health workers) and during implementation (8 sex workers of whom 5 tested positive, and 5 health workers) to evaluate the intervention. We determined intervention development and implementation costs using program data.

ResultsThe intervention was implemented between March-June 2023. Sex workers and health workers reported that the intervention was highly acceptable and was implemented with fidelity. Food packs were highly appreciated; participants said they promoted isolation although vulnerability to non-food financial pressures persisted. Unanticipated impacts were increased testing uptake following introduction of food packs. Self-monitoring at home was acceptable although fear of stigma prevented some participants from seeking the needed support. The cost per sex worker testing positive was $49 and $54 respectively excluding/including intervention co-development costs.

ConclusionA co-developed intervention for promoting isolation and community-based self-monitoring for COVID-19 was feasible and acceptable, with costs comparing favorably with similar interventions. Addressing stigma could optimise implementation and potential for future pandemics.
]]></description>
</item>
<item rdf:about="https://www.biorxiv.org/content/10.64898/2026.03.22.712163v1?rss=1">
<title>
<![CDATA[
Resistome, Virulome, Mobilome, And Biosynthetic Gene Clusters Adaptations of Acinetobacter Baumannii Mexican Strains Across the Pre- and of the COVID-19 Period: Insights from Whole-Genome Sequencing 
]]>
</title>
<link>
https://www.biorxiv.org/content/10.64898/2026.03.22.712163v1?rss=1"
</link>
<dc:creator>Alejo, M. A.</dc:creator>
<dc:creator>Lozano Gamboa, M. S.</dc:creator>
<dc:creator>Munoz Gomez, B. E.</dc:creator>
<dc:creator>Hernandez Magro Gil, K. G.</dc:creator>
<dc:creator>Garcia Contreras, R.</dc:creator>
<dc:creator>Whitaker, R.</dc:creator>
<dc:creator>Palacios Marmolejo, A.</dc:creator>
<dc:creator>Ceapa, C. D.</dc:creator>
<dc:date>2026-03-23</dc:date>
<dc:identifier>doi:10.64898/2026.03.22.712163</dc:identifier>
<dc:title><![CDATA[Resistome, Virulome, Mobilome, And Biosynthetic Gene Clusters Adaptations of Acinetobacter Baumannii Mexican Strains Across the Pre- and of the COVID-19 Period: Insights from Whole-Genome Sequencing]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory Press</dc:publisher>
<prism:publicationDate>2026-03-23</prism:publicationDate>
<prism:section></prism:section>
<description><![CDATA[
BackgroundAcinetobacter baumannii is a critical multidrug-resistant pathogen whose genomic landscape in Mexico has been reshaped by the COVID-19 pandemic. While global studies have highlighted distinctive sequence type distributions, systematic analyses in Mexico remain limited.

MethodsWe analyzed 194 genomes, including 47 newly sequenced post-COVID isolates (MIQ), alongside 147 publicly available genomes (HPG). Whole-genome sequencing was combined with phylogenetic reconstruction, resistome and virulome profiling based on gene presence and absence, mobilome analysis, and biosynthetic gene cluster (BGC) characterization.

ResultsTwo major clades dominated by Oxford STs 758, 208, 417, and 369 were identified. Resistome profiling uncovered 128 distinct resistome profiles (combinations of genes) and 44 emerging antimicrobial resistance genes (ARGs), with an increased number of resistance genes in the strains obtained during the pandemic. Virulome analysis revealed enrichment of metabolic adaptation genes (argG, carA, ilvC) in MIQ strains. Mobilome profiling demonstrated enrichment of ISAbA1 and ISAbA3 elements, known to mobilize carbapenemase genes. BGC analysis showed conserved siderophores involved in virulence, alongside diversification of the secondary metabolite repertoires in MIQ genomes. Additional observations included geographic mixing of clades across Jalisco, Aguascalientes, and Mexico City and referral bias toward carbapenemase-positive isolates.

ConclusionThe genomic landscape of A. baumannii in Mexico has diversified post-COVID, with evidence of inter-regional transmission, referral bias, virulome expansion, mobilome-driven ARG dissemination, and metabolic adaptation. These findings underscore the urgent need for coordinated genomic surveillance, functional and clinical validation of adaptation signals, and regionally integrated infection control strategies to mitigate resistance trajectories.

Graphical abstractIntegrative genomic profiling of A. baumannii isolates from Mexico. Workflow summarizing the analysis of 194 genomes (147 historic public genomes, 47 novel MIQ strains). Clinical isolates were identified by MALDI Biotyper and tested with BD Phoenix M50. Whole genome sequencing enabled phylogenetic and MLST analyses, resistome and virulome profiling, mobilome characterization, and BGC identification using BIGSCAPE and antiSMASH. Outputs include phylogenetic clustering, resistance/virulence gene distributions, and biosynthetic potential across Mexican regions.



O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=84 SRC="FIGDIR/small/712163v1_ufig1.gif" ALT="Figure 1">
View larger version (27K):
org.highwire.dtl.DTLVardef@74c87borg.highwire.dtl.DTLVardef@1160aa7org.highwire.dtl.DTLVardef@1564c1org.highwire.dtl.DTLVardef@89e91b_HPS_FORMAT_FIGEXP  M_FIG C_FIG
]]></description>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.03.19.26348776v1?rss=1">
<title>
<![CDATA[
Physiotherapy service during the COVID-19 pandemic in Nepal: An onsite survey and the lived experience among clinicians 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.03.19.26348776v1?rss=1"
</link>
<dc:creator>Shakya, N. R.</dc:creator>
<dc:creator>Dahal, S.</dc:creator>
<dc:creator>Shrestha, N.</dc:creator>
<dc:creator>Webb, G.</dc:creator>
<dc:creator>Stensdotter, A.-K.</dc:creator>
<dc:date>2026-03-22</dc:date>
<dc:identifier>doi:10.64898/2026.03.19.26348776</dc:identifier>
<dc:title><![CDATA[Physiotherapy service during the COVID-19 pandemic in Nepal: An onsite survey and the lived experience among clinicians]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory Press</dc:publisher>
<prism:publicationDate>2026-03-22</prism:publicationDate>
<prism:section></prism:section>
<description><![CDATA[
BackgroundThe COVID-19 pandemic significantly disrupted healthcare services globally, particularly in low-resource settings. This study explores the impact of the pandemic on physiotherapy services in Nepal.

MethodsA cross-sectional study was conducted. Qualitative data were collected through semi-structured interviews with 12 physiotherapists, while quantitative data were gathered from an onsite survey of 29 health facilities at six different districts of Province III of Nepal. Inductive thematic analysis approach was used to analyze the qualitative data, and descriptive statistics were used for the closed ended questions.

ResultsThe findings were categorized into sub-themes under two major themes: i) Pandemic effect on physiotherapy services and patient care and ii) Adaptation, innovation and collaboration. The study revealed a significant disruption in physiotherapy services with a notable decline in patient flow and service availability. Most patients, especially those with disabilities and post-operative needs, experienced worsening conditions due to limited access to care. There was an increased recognition of the role of physiotherapy in acute respiratory care and post-COVID-19 recovery. Tele-rehabilitation was explored as an alternative care method but faced challenges in implementation. More than half (62.07%) of the centers reported uninterrupted physiotherapy services, whereas almost one third (31.03%) experienced service suspension. Most centers (89.7%) had personal protective equipment available, and majority (86.2%) of the physiotherapists worked in multidisciplinary team: fever clinics, triage, emergency care, respiratory physical therapy, and nursing and administrative support were among the expanded roles. Several centers (37.9%) used virtual care with telephone consultation serving as the primary modality. Virtual service was mostly absent in centers where in-person services persisted.

ConclusionThe COVID-19 pandemic significantly impacted physiotherapy services in Nepal, leading to service disruptions and compromised patient care. It highlighted the need to further incorporate physiotherapy into the healthcare system and enhance rehabilitation services to improve continued patient care.
]]></description>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.03.19.26348823v1?rss=1">
<title>
<![CDATA[
SARS-CoV-2 and the Pandemic Surge in Invasive Group A Streptococcal Disease 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.03.19.26348823v1?rss=1"
</link>
<dc:creator>Fisman, D.</dc:creator>
<dc:creator>Lee, C. E.</dc:creator>
<dc:creator>Wilson, N.</dc:creator>
<dc:creator>Barton, M.</dc:creator>
<dc:creator>Mann, S. K.</dc:creator>
<dc:creator>Tuite, A.</dc:creator>
<dc:date>2026-03-22</dc:date>
<dc:identifier>doi:10.64898/2026.03.19.26348823</dc:identifier>
<dc:title><![CDATA[SARS-CoV-2 and the Pandemic Surge in Invasive Group A Streptococcal Disease]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory Press</dc:publisher>
<prism:publicationDate>2026-03-22</prism:publicationDate>
<prism:section></prism:section>
<description><![CDATA[
BackgroundMultiple countries reported unprecedented increases in invasive group A streptococcal (iGAS) disease following widespread SARS-CoV-2 circulation. Whether this surge reflects reduced pathogen exposure during non-pharmaceutical interventions ("immunity debt") or effects of SARS-CoV-2 infection on host immunity remains unresolved.

MethodsWe conducted a population-based time-series analysis of weekly iGAS incidence in central Ontario, Canada (population {approx}11 million) from March 2011 through March 2024 (676 weeks). Using negative binomial panel regression, we modeled acute (2-week lagged) and cumulative SARS-CoV-2 exposure while adjusting for seasonality, secular trends, age, and sex. Population attributable fractions (PAFs) were estimated by counterfactual prediction. Specificity was assessed through negative control analyses (influenza, RSV). The immunity debt hypothesis was evaluated using cumulative streptococcal exposure as a predictor of iGAS.

ResultsAmong 2,906 iGAS episodes, 34.3% during the pandemic period were associated with acute SARS-CoV-2 effects (range by age group: 16.5-39.1%). Models incorporating cumulative SARS-CoV-2 burden showed markedly better fit ({Delta}AIC=-157.5); cumulative exposure was strongly associated with iGAS (IRR 1.193, 95% CI 1.151-1.235), increasing the estimated PAF to 66.7%. Cumulative effects were strongest in children (IRR 1.309). SARS-CoV-2 was comparably associated with non-invasive streptococcal disease, with no increase in invasion propensity. Cumulative streptococcal exposure was not protective (overall IRR 1.000, p=0.730); where significant, the association was positive, opposite to immunity debt predictions.

ConclusionsCumulative SARS-CoV-2 burden was strongly associated with pandemic-era iGAS incidence. Cumulative streptococcal exposure did not support the immunity debt hypothesis. These ecological findings are consistent with SARS-CoV-2-associated immune dysregulation and warrant individual-level confirmation.
]]></description>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.03.19.26348833v1?rss=1">
<title>
<![CDATA[
Autoantibody landscapes in neurological Long COVID and post-COVID cognitive impairment show heterogeneity without a shared disease signature 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.03.19.26348833v1?rss=1"
</link>
<dc:creator>Chakravarty, D.</dc:creator>
<dc:creator>Dandekar, R.</dc:creator>
<dc:creator>Lashkari, V. D.</dc:creator>
<dc:creator>Tilton, I.</dc:creator>
<dc:creator>McAlpine, L.</dc:creator>
<dc:creator>Chiarella, J.</dc:creator>
<dc:creator>Nelson, A.</dc:creator>
<dc:creator>Ngo, T.</dc:creator>
<dc:creator>Chen, P.</dc:creator>
<dc:creator>Wang, G.</dc:creator>
<dc:creator>Saxena, A.</dc:creator>
<dc:creator>Castillo-Rojas, B.</dc:creator>
<dc:creator>Zorn, K.</dc:creator>
<dc:creator>Tribble, D. R.</dc:creator>
<dc:creator>Burgess, T. H.</dc:creator>
<dc:creator>Rubin, L. H.</dc:creator>
<dc:creator>Richard, S. A.</dc:creator>
<dc:creator>Agan, B. K.</dc:creator>
<dc:creator>Pollett, S. D.</dc:creator>
<dc:creator>Farhadian, S.</dc:creator>
<dc:creator>Spudich, S.</dc:creator>
<dc:creator>Pleasure, S. J.</dc:creator>
<dc:creator>Wilson, M. R.</dc:creator>
<dc:date>2026-03-22</dc:date>
<dc:identifier>doi:10.64898/2026.03.19.26348833</dc:identifier>
<dc:title><![CDATA[Autoantibody landscapes in neurological Long COVID and post-COVID cognitive impairment show heterogeneity without a shared disease signature]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory Press</dc:publisher>
<prism:publicationDate>2026-03-22</prism:publicationDate>
<prism:section></prism:section>
<description><![CDATA[
BackgroundNeurological Long COVID (n-LC) includes persistent cognitive and autonomic symptoms after SARS-CoV-2 infection. Prior studies of post-COVID conditions have described diverse humoral autoreactivity, but findings are heterogeneous, and it remains unclear whether n-LC is associated with a consistent CNS-directed humoral signature.

MethodsWe performed a cross-cohort case-control analysis to detect autoantibodies in cerebrospinal fluid (CSF) and serum from n-LC participants. In the Yale COVID Mind Study cohort, CSF from n-LC participants and from pre-pandemic and post-COVID asymptomatic controls was assessed by mouse brain immunofluorescence and proteome-wide phage immunoprecipitation sequencing (PhIP-Seq), with candidate reactivities evaluated by orthogonal assays and supervised modeling. In the Epidemiology, Immunology, and Clinical Characteristics of Emerging Infectious Diseases with Pandemic Potential (IDCRP EPICC) cohort, post-COVID sera collected prior to iPhone- or iPad-based cognitive screening were profiled by PhIP-Seq and compared between participants with and without cognitive impairment.

ResultsCSF immunoreactivity on mouse brain tissue was observed in both n-LC and controls, with similar overall frequencies, although n-LC participants more often showed nuclear-predominant staining patterns. PhIP-Seq identified sparse, largely patient-specific peptide reactivities to nuclear and neuronal proteins in CSF and serum. Supervised models provided limited discrimination between cases and controls. Candidate autoantigens had limited disease specificity on orthogonal testing. EPICC serum autoantibody profiling similarly failed to distinguish individuals with and without cognitive impairment.

ConclusionsAcross cohorts and compartments, n-LC did not exhibit a shared autoantibody signature. These findings support the absence of a dominant, common CNS autoantibody-mediated mechanism in n-LC.

FundingGrants HU00012020067, HU00012120103, HU00011920111, R01NS125693, R01MH125737, R01AI157488 from Defense health program and NIH.
]]></description>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.03.18.26348767v1?rss=1">
<title>
<![CDATA[
Prediction of confirmed, hospitalized, and severe COVID-19 cases and mechanistic insights from viral concentrations and variant dynamics in wastewater 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.03.18.26348767v1?rss=1"
</link>
<dc:creator>Murakami, M.</dc:creator>
<dc:creator>Watanabe, R.</dc:creator>
<dc:creator>Iwamoto, R.</dc:creator>
<dc:creator>Chung, U.-i.</dc:creator>
<dc:creator>Kitajima, M.</dc:creator>
<dc:creator>Yoo, B.-K.</dc:creator>
<dc:date>2026-03-20</dc:date>
<dc:identifier>doi:10.64898/2026.03.18.26348767</dc:identifier>
<dc:title><![CDATA[Prediction of confirmed, hospitalized, and severe COVID-19 cases and mechanistic insights from viral concentrations and variant dynamics in wastewater]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory Press</dc:publisher>
<prism:publicationDate>2026-03-20</prism:publicationDate>
<prism:section></prism:section>
<description><![CDATA[
BackgroundFollowing the end of a public health emergency of international concern, divergence emerged between reported coronavirus disease 2019 (COVID-19) cases and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) RNA concentrations in wastewater. Exploring viral, clinical, patient, and surveillance-related factors underlying this divergence, we developed models to predict clinically confirmed infections, hospitalizations, and severe cases.

MethodsIn this observational study, we analyzed [~]2 years of data from January 2022 in Kanagawa Prefecture, Japan, assessing associations between wastewater SARS-CoV-2 RNA concentrations and confirmed, hospitalized, and severe cases, adjusting for wave and variant effects.

FindingsOur models based on wastewater viral RNA concentrations showed high predictive accuracy (R{superscript 2} = 0.8199-0.9961), closely tracking confirmed, hospitalized, and severe cases. Models derived from earlier waves were applied to subsequent waves with residual correction based on prior prediction errors and maintained good predictive performance (root mean square error = 0.0665-0.2065). Divergence between wastewater viral RNA concentrations and reported cases was not explained by changes in viral shedding. Declines in patients healthcare-seeking behavior and testing were associated with trends in confirmed cases, whereas milder clinical presentation was associated with severe case trends. The lineages XBB.1.9.2 and BA.2.86 were identified as candidates associated with reduced virulence.

InterpretationBy incorporating understanding of viral, clinical, and surveillance-related mechanisms, wastewater surveillance may enable prediction of case trends approximately one week earlier than official reporting and inform healthcare capacity planning.
]]></description>
</item>
<item rdf:about="https://www.biorxiv.org/content/10.64898/2026.03.19.712895v1?rss=1">
<title>
<![CDATA[
Natural selection driven by escape from shifting antibody classes shapes SARS-CoV-2 evolution 
]]>
</title>
<link>
https://www.biorxiv.org/content/10.64898/2026.03.19.712895v1?rss=1"
</link>
<dc:creator>Hamilton, C.</dc:creator>
<dc:creator>Ghafari, M.</dc:creator>
<dc:creator>Ledda, A.</dc:creator>
<dc:creator>Lythgoe, K.</dc:creator>
<dc:creator>Fraser, C.</dc:creator>
<dc:creator>Ferretti, L.</dc:creator>
<dc:date>2026-03-20</dc:date>
<dc:identifier>doi:10.64898/2026.03.19.712895</dc:identifier>
<dc:title><![CDATA[Natural selection driven by escape from shifting antibody classes shapes SARS-CoV-2 evolution]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory Press</dc:publisher>
<prism:publicationDate>2026-03-20</prism:publicationDate>
<prism:section></prism:section>
<description><![CDATA[
The phenotypic fitness landscape defines the action of natural selection on pathogens, linking changes in their phenotypes to transmission and evolution. The rapidly changing nature of epidemic spread and antigenic landscapes pushes viruses to evolve on fitness seascapes. As a result, evolution of viruses such as SARS-CoV-2 proceeds in a neverending series of waves, driven by epistatic interactions and by the arms race between viral adaptation and human immunity. Phenotypic characterisation of these rapidly changing fitness seascapes is an open challenge. Using a Phenotypic Selection Inference framework that links phylogenetic estimates of mutation fitness effects with deep mutational scanning data, we traced how selective pressures on viral phenotypes have shifted throughout the COVID-19 pandemic. Natural selection has favoured enhanced ACE2 binding since the emergence of SARS-COV-2, with relatively constant selective pressure even for the most recent variants. The strength of selection for antibody escape was comparable to ACE2 binding during early evolution, but as population immunity rose, escape from class 3 and then class 2 antibodies became dominant. For variants circulating in 2024, natural selection shifted toward class 3 antibody escape, while those circulating in 2025 have experienced dynamic, rapidly changing pressures for escape from all antibody classes. These transitions reflect an ongoing arms race between viral adaptation and human immunity. Our findings reveal that SARS-CoV-2 antigenic evolution is governed by dynamic, class-specific immune pressures, and that selection for replication capacity has been continuously present during the pandemic, presumably to compensate for the effects of antigenic escape on viral replication. Our approach for the inference of phenotypic selection provides a framework to understand and anticipate the evolution of future variants.
]]></description>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.03.12.26346895v1?rss=1">
<title>
<![CDATA[
Prenatal exposure to SARS-CoV-2, early relational health, and child socio-emotional functioning in the first 6 months 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.03.12.26346895v1?rss=1"
</link>
<dc:creator>Lavallee, A.</dc:creator>
<dc:creator>Warmingham, J. M.</dc:creator>
<dc:creator>Owens, J. B.</dc:creator>
<dc:creator>Xu, R. L.</dc:creator>
<dc:creator>Ahmed, I.</dc:creator>
<dc:creator>Atwood, G. D.</dc:creator>
<dc:creator>Kyle, M. H.</dc:creator>
<dc:creator>Hussain, M.</dc:creator>
<dc:creator>Chaves, V.</dc:creator>
<dc:creator>Arduin, E.</dc:creator>
<dc:creator>Lanoff, M. R.</dc:creator>
<dc:creator>Hyman, S. P.</dc:creator>
<dc:creator>Coskun, L. Z.</dc:creator>
<dc:creator>Shearman, N. D.</dc:creator>
<dc:creator>Russo, J. E.</dc:creator>
<dc:creator>Ettinger, S.</dc:creator>
<dc:creator>Greenman, E. A.</dc:creator>
<dc:creator>Serota, D. E.</dc:creator>
<dc:creator>Bence, M. L.</dc:creator>
<dc:creator>Hott, V.</dc:creator>
<dc:creator>Hu, Y.</dc:creator>
<dc:creator>Kurman, G.</dc:creator>
<dc:creator>Lara, M.</dc:creator>
<dc:creator>Tzul Lopez, H.</dc:creator>
<dc:creator>Mollicone, I.</dc:creator>
<dc:creator>Ravi, R.</dc:creator>
<dc:creator>Rodriguez, C.</dc:creator>
<dc:creator>Smotrich, G. C.</dc:creator>
<dc:creator>Lawless, A.</dc:creator>
<dc:creator>Ontiveros-Angel, P.</dc:creator>
<dc:creator>Curtin, A.</dc:creator>
<dc:creator>Austin, J.</dc:creator>
<dc:creator>Firestein, M. R.</dc:creator>
<dc:creator>Shuffery, L. C.</dc:creator>
<dc:creator>Fernandez, C. R.</dc:creator>
<dc:creator>Battarbee, A. N.</dc:creator>
<dc:creator>Bruno, A.</dc:creator>
<dc:creator>Dawood, F. S.</dc:creator>
<dc:creator>Maniatis, P.</dc:creator>
<dc:creator>Morrill, T. C.</dc:creator>
<dc:creator>Newes-Adeyi, G.</dc:creator>
<dc:creator>Reichle, L.</dc:creator>
<dc:creator>Sem</dc:creator>
<dc:date>2026-03-19</dc:date>
<dc:identifier>doi:10.64898/2026.03.12.26346895</dc:identifier>
<dc:title><![CDATA[Prenatal exposure to SARS-CoV-2, early relational health, and child socio-emotional functioning in the first 6 months]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory Press</dc:publisher>
<prism:publicationDate>2026-03-19</prism:publicationDate>
<prism:section></prism:section>
<description><![CDATA[
ImportanceParent/caregiver-infant early relational health (ERH) is known to play a critical role in the promotion of socio-emotional functioning and wellbeing across the life course. The negative impact of the COVID-19 pandemic on maternal mental health and secondarily on ERH and child socio-emotional functioning is clear. However, the direct impact of maternal viral exposure during pregnancy on ERH has not been investigated.

ObjectiveThe goal of this study was to determine the impact of prenatal SARS-CoV-2 exposure on ERH and infant socio-emotional functioning in the first 6 months of life.

DesignMothers with and without SARS-CoV-2 exposure during pregnancy who gave birth from 02/2020 to 09/2021 were enrolled from 05/2020 to 09/2021 in one of two parallel prospective studies (the COVID-19 Mother Baby Outcomes [COMBO] Initiative or the Respiratory Syndrome Coronavirus 2 in Pregnancy and Infancy [ESPI] COMBO sub-study). Mothers reported on their health and the socioemotional functioning of their infant via online surveys (REDCap) at enrollment, 1, 2, 4, and 6 months. At 4 to 6 months, dyads were invited to participate in a video-based, remote assessment of ERH.

Participants884 mother-infant dyads from three U.S. States (Alabama, New York, and Utah).

ExposurePrenatal SARS-CoV-2.

Main Outcomes and MeasuresMaternal-reported ERH (parental stress, parenting confidence and bonding) and observer-based ERH (video-coded quality of maternal caregiving behaviors and mother-infant emotional connection). Infant socio-emotional development assessed using the 6-month Ages and Stages Questionnaire: Socio-Emotional 2nd Edition (ASQ:SE-2).

Results316 (36%) mothers had a positive prenatal SARS-CoV-2 exposure. Prenatal SARS-CoV-2 exposure was associated with an adjusted estimate of [~]5% reduction (incidence rate ratio=0.95, 95% confidence interval [0.90, 1.00], p=0.03) in observed maternal caregiving quality, after accounting for postnatal maternal mental health and sociodemographic factors. We found no evidence of effect on other ERH constructs or infant socio-emotional functioning.

Conclusions and RelevanceIn this large prospective cohort study, prenatal SARS-CoV-2 was associated with a small decrement in caregiving quality, but not other ERH constructs or infant socioemotional functioning. These findings should be interpreted as hypothesis generating and will require replication in independent studies.

Key PointsO_LIQuestion: Is SARS-CoV-2 exposure during pregnancy associated with maternal-reported and observer-based measures of early relational health (ERH) and infant socio-emotional functioning at 4-6 months postpartum?
C_LIO_LIFindings: Prenatal SARS-CoV-2 exposure was associated with a [~]5% reduction in observed quality of maternal caregiving after accounting for postnatal mental health symptomatology and sociodemographic factors.
C_LIO_LIMeaning: A small reduction in maternal caregiving quality, but not other ERH constructs (parental stress, parenting confidence, bonding and emotional connection) or infant socio-emotional functioning, was associated with prenatal SARS-CoV-2 exposure. Results should be interpreted as hypothesis generating and will require replication in independent studies.
C_LI
]]></description>
</item>
<item rdf:about="https://www.biorxiv.org/content/10.64898/2026.03.18.712739v1?rss=1">
<title>
<![CDATA[
An AI-Driven Decision-Support Tool for Triage of COVID-19 Patients Using Respiratory Microbiome Data 
]]>
</title>
<link>
https://www.biorxiv.org/content/10.64898/2026.03.18.712739v1?rss=1"
</link>
<dc:creator>Avina-Bravo, E. G.</dc:creator>
<dc:creator>Garcia-Lorenzo, I.</dc:creator>
<dc:creator>Alfaro-Ponce, M.</dc:creator>
<dc:creator>Breton-Deval, L.</dc:creator>
<dc:date>2026-03-19</dc:date>
<dc:identifier>doi:10.64898/2026.03.18.712739</dc:identifier>
<dc:title><![CDATA[An AI-Driven Decision-Support Tool for Triage of COVID-19 Patients Using Respiratory Microbiome Data]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory Press</dc:publisher>
<prism:publicationDate>2026-03-19</prism:publicationDate>
<prism:section></prism:section>
<description><![CDATA[
Accurate clinical triage is critical for optimizing decision-making and resource allocation during infectious disease outbreaks such as COVID-19. In this study, we present an AI-driven decision-support tool for the triage of COVID-19 patients based on respiratory microbiome profiles derived from shotgun metagenomic sequencing. We analyzed 477 shotgun respiratory metagenomes from three independent public cohorts and generated genus-level taxonomic profiles, which were integrated with minimal clinical metadata to train supervised machine-learning models, including Random Forest, Support Vector Machine, and XGBoost. Model performance was evaluated using standard classification metrics, cross-validation, and particle swarm optimization for hyperparameter tuning. Across cohorts, we observed a consistent transition from microbiomes dominated by commensal taxa to dysbiotic states enriched in opportunistic and clinically relevant genera, particularly Acinetobacter and Staphylococcus, in severe and deceased patients. Among the evaluated models, XGBoost consistently achieved the best performance, reaching up to 96.1% accuracy, 97.6% F1-score, and 98.2% ROC-AUC in individual cohorts. When trained on the integrated dataset, XGBoost maintained robust performance (95.1% accuracy, 97.2% F1-score, 94.3% ROC-AUC) and demonstrated greater stability and lower variance compared to alternative models. Feature-importance analyses identified a compact and interpretable set of recurrent microbial predictors, and reduced-feature models retained substantial discriminative power when augmented with key clinical variables. These results support the respiratory microbiome as a valuable source of information for outcome-oriented clinical triage and position microbiome-informed machine learning as a scalable and interpretable decision-support approach for managing COVID-19 and future infectious disease scenarios.
]]></description>
</item>
<item rdf:about="https://www.biorxiv.org/content/10.64898/2026.03.17.712263v1?rss=1">
<title>
<![CDATA[
De novo design of therapeutic scFvs and multi-specific engagers from sequence alone 
]]>
</title>
<link>
https://www.biorxiv.org/content/10.64898/2026.03.17.712263v1?rss=1"
</link>
<dc:creator>Fujiwara, T.</dc:creator>
<dc:creator>Shimizu, H.</dc:creator>
<dc:date>2026-03-18</dc:date>
<dc:identifier>doi:10.64898/2026.03.17.712263</dc:identifier>
<dc:title><![CDATA[De novo design of therapeutic scFvs and multi-specific engagers from sequence alone]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory Press</dc:publisher>
<prism:publicationDate>2026-03-18</prism:publicationDate>
<prism:section></prism:section>
<description><![CDATA[
The discovery of functional antibody therapeutics is fundamentally constrained by the astronomical complexity of the sequence landscape and the inefficiency of empirical screening. While structure-based computational design has made significant strides, its reliance on high-resolution co-complex data restricts its utility against the vast undruggable proteome and rapidly evolving pathogens. Here, we introduce IASO, a sequence-centric generative framework for the de novo design of diverse biotherapeutic modalities, including single-chain variable fragments and multi-specific engagers, requiring only antigen sequence as input. IASO integrates an evolutionary-informed generative engine that constructs antigen-steered candidate libraries with a high-fidelity interaction module capturing synergistic physicochemical motifs. We demonstrate the frameworks robustness by identifying novel binders against diverse clinical targets, where IASO successfully discriminates atomic-level mutations to overcome established drug resistance in EGFR and distinguishes single-residue variants of SARS-CoV-2. Furthermore, we extend this approach to the in silico construction of a complex bispecific T-cell engager that exhibits developability profiles comparable to clinically approved therapeutics, including enhanced solubility and minimal immunogenicity. By transforming serendipitous exploration into predictable high-resolution engineering, IASO establishes a scalable foundation for the rapid development of next-generation biopharmaceuticals directly from sequence data alone.
]]></description>
</item>
<item rdf:about="https://www.biorxiv.org/content/10.64898/2026.03.13.711660v1?rss=1">
<title>
<![CDATA[
SARS-CoV-2 virus infection of Peromyscus leucopus demonstrates that infection tolerance is not limited to agents for which deermice are reservoirs 
]]>
</title>
<link>
https://www.biorxiv.org/content/10.64898/2026.03.13.711660v1?rss=1"
</link>
<dc:creator>Milovic, A.</dc:creator>
<dc:creator>Gach, J. S.</dc:creator>
<dc:creator>Chatzistamou, I.</dc:creator>
<dc:creator>Olivarria, G. M.</dc:creator>
<dc:creator>Lane, T. E.</dc:creator>
<dc:creator>Forthal, D. N.</dc:creator>
<dc:creator>Barbour, A. G.</dc:creator>
<dc:date>2026-03-15</dc:date>
<dc:identifier>doi:10.64898/2026.03.13.711660</dc:identifier>
<dc:title><![CDATA[SARS-CoV-2 virus infection of Peromyscus leucopus demonstrates that infection tolerance is not limited to agents for which deermice are reservoirs]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory Press</dc:publisher>
<prism:publicationDate>2026-03-15</prism:publicationDate>
<prism:section></prism:section>
<description><![CDATA[
The North American deermouse Peromyscus leucopus is reservoir for several zoonotic agents, including bacterial, protozoan, and viral. It is remarkable for indiscernible or limited fitness consequences of these infections, a trait known as infection tolerance. But experimental infections have largely been of pathogens that P. leucopus naturally harbors. We asked whether infection tolerance extended to an agent, like SARS-CoV-2 virus, it had presumably not encountered before. Following protocols for experiments with mice and hamsters, we infected 8 female and 8 male P. leucopus of heterogeneous stock and compared responses of these animals on days 3 or 6 to those of 14 controls inoculated with virus-free medium. Serologic and virologic confirmation of infection was obtained for all exposed deermice. Moderate inflammation in lungs was histologically evident in infected animals, but no histological changes were noted in brains, even when viral RNA was present. Fourteen (88%) animals displayed no or only mild sickness; two had more severe illness. Genome-wide RNA-seq revealed an interferon-stimulated response on day 3 superceded mainly by a cell-mediated response by day 6. In brains transcription of the interferon-stimulated genes Isg15 and Mx2 positively correlated with viral RNA levels. The findings confirmed susceptibility of this species of Peromyscus to SARS-CoV-2 virus. For most infected outbred animals the immune response was swift and effective in controlling the pathogen and without evidence of excessive inflammation. Whatever is the basis for P. leucopus trait of infection tolerance, it extended to at least one pathogen that for it would be novel.

ImportancePeromyscus leucopus is North American rodent that is reservoir for several agents of human disease, while exhibiting minimal illness, a phenotype termed infection tolerance. Whether this trait is pathogen-specific or represents a broader strategy has remained uncertain. By experimentally infecting P. leucopus with SARS-CoV-2 virus, which it is unlikely to have encountered, we investigated whether infection tolerance extends to a novel virus. Despite disseminated infection and lung pathology, most animals showed only mild or no disease. Expression analyses revealed early interferon-stimulated responses followed by cell-mediated responses with only limited production of inflammatory mediators interferon-gamma and nitric oxide synthase 2. Compared with results with a mouse model of infection, deermice displayed higher baseline expression of antiviral genes and quicker resolution of interferon responses. These findings suggest that infection tolerance is a strategy that limits immunopathology generally while resisting microbes, which has implications for understanding reservoir competence and host resilience.
]]></description>
</item>
<item rdf:about="https://www.biorxiv.org/content/10.64898/2026.03.14.711762v1?rss=1">
<title>
<![CDATA[
TMEM106B mediates ACE2-independent replication of the SARS-CoV-2 S-E484D variant in airway-derived cell models 
]]>
</title>
<link>
https://www.biorxiv.org/content/10.64898/2026.03.14.711762v1?rss=1"
</link>
<dc:creator>Xia, M.</dc:creator>
<dc:creator>Wang, Q.</dc:creator>
<dc:creator>Puray-Chavez, M.</dc:creator>
<dc:creator>LaPak, K.</dc:creator>
<dc:creator>Palakurty, S.</dc:creator>
<dc:creator>Liu, Z.</dc:creator>
<dc:creator>Cornejo Pontelli, M.</dc:creator>
<dc:creator>Hui, S.</dc:creator>
<dc:creator>Fremont, D. H.</dc:creator>
<dc:creator>Diamond, M. S.</dc:creator>
<dc:creator>Whelan, S. P. J.</dc:creator>
<dc:creator>Major, M. B.</dc:creator>
<dc:creator>Goldfarb, D.</dc:creator>
<dc:creator>Kutluay, S. B.</dc:creator>
<dc:date>2026-03-15</dc:date>
<dc:identifier>doi:10.64898/2026.03.14.711762</dc:identifier>
<dc:title><![CDATA[TMEM106B mediates ACE2-independent replication of the SARS-CoV-2 S-E484D variant in airway-derived cell models]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory Press</dc:publisher>
<prism:publicationDate>2026-03-15</prism:publicationDate>
<prism:section></prism:section>
<description><![CDATA[
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continues to cause significant respiratory disease, particularly in vulnerable populations. Although ACE2 is the primary receptor for viral entry, previous studies have identified a naturally occurring, ACE2-independent entry pathway in certain airway-derived cell lines. Utilization of this pathway depends on surface heparan sulfates and requires the E484D substitution within the receptor-binding domain of the viral Spike (S) protein. In this study, we expand the panel of airway-derived cell lines that support ACE2-independent, S-E484D-dependent replication and identify the host lysosomal transmembrane protein TMEM106B as a critical host factor for infection. Knockout of TMEM106B completely abolishes infection by SARS-CoV-2 SE484D in NCI-H522 and NCI-H661 cells. Moreover, ectopic expression of the luminal C-terminal domain (CTD) of TMEM106B-either alone or redirected to the plasma membrane - is sufficient to enable viral entry and infection in otherwise non-permissive cells. We further show that Fc-TMEM106B-CTD decoy protein blocks infection by SARS-CoV-2 SE484D, supporting a direct interaction between the S-E484D protein and TMEM106B-CTD. Finally, passaging experiments with a chimeric VSV-SARS-CoV-2 SE484D identify additional mutations within the heptad repeat 1 that enhance TMEM106B utilization and viral spread in the ACE2-independent cell models. Together, these findings demonstrate that TMEM106B is a key mediator of a naturally occurring ACE2-independent pathway in multiple airway-derived cells lines and suggest that variation in the Spike protein can expand receptor usage by SARS-CoV-2.

IMPORTANCESevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continues to acquire mutations in the viral spike (S) protein as it circulates in humans. How these mutations influence the cell and tissue tropism of SARS-CoV-2 remains poorly understood. While ACE2 is the canonical host cell receptor for SARS-CoV-2, previous studies revealed the presence of a naturally occurring ACE2-independent entry pathway in multiple airway-derived cell lines that can be utilized only by a SARS-CoV-2 variant bearing the E484D substitution within the viral S protein. Here we expand the airway-derived cell line models that support ACE2-independent and S-E484D-dependent entry and show that the host lysosomal transmembrane protein, TMEM106B, is an essential viral entry factor. Although the E484D substitution is currently rare in human isolates, our findings raise the possibility that small mutations in SARS-CoV-2 S can allow the utilization of alternative entry pathways that broadens its cell and tissue tropism.
]]></description>
</item>
<item rdf:about="https://www.biorxiv.org/content/10.64898/2026.03.13.711550v1?rss=1">
<title>
<![CDATA[
Identification and Masking of Artefactual and Misleading Within-Host Variants in Deep-Sequencing SARS-CoV-2 Data 
]]>
</title>
<link>
https://www.biorxiv.org/content/10.64898/2026.03.13.711550v1?rss=1"
</link>
<dc:creator>Anker, K. M.</dc:creator>
<dc:creator>Hall, M.</dc:creator>
<dc:creator>Evans Pena, R.</dc:creator>
<dc:creator>Kemp, S. A.</dc:creator>
<dc:creator>Clarke, J.</dc:creator>
<dc:creator>Zhao, L.</dc:creator>
<dc:creator>Bonsall, D.</dc:creator>
<dc:creator>Grayson, N.</dc:creator>
<dc:creator>Bashton, M.</dc:creator>
<dc:creator>The COVID-19 Genomics UK (COG-UK) Consortium,</dc:creator>
<dc:creator>Walker, A. S.</dc:creator>
<dc:creator>Golubchik, T.</dc:creator>
<dc:creator>Lythgoe, K.</dc:creator>
<dc:date>2026-03-13</dc:date>
<dc:identifier>doi:10.64898/2026.03.13.711550</dc:identifier>
<dc:title><![CDATA[Identification and Masking of Artefactual and Misleading Within-Host Variants in Deep-Sequencing SARS-CoV-2 Data]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory Press</dc:publisher>
<prism:publicationDate>2026-03-13</prism:publicationDate>
<prism:section></prism:section>
<description><![CDATA[
Deep sequencing data are increasingly used to study within-host viral diversity and to inform evolutionary inference. For SARS-CoV-2, analyses based on intra-host single-nucleotide variants (iSNVs) have been widely applied to quantify within-host diversity and infer transmission dynamics. However, these applications critically depend on the reliable identification of low-frequency variants, which remain vulnerable to systematic and technical artefacts. In this study, we show that recurrent artefactual iSNVs are common in large-scale SARS-CoV-2 sequencing data and can persist even under conservative minor allele frequency (MAF) thresholds. Using data from the UKs Office for National Statistics COVID-19 Infection Survey, we demonstrate that such artefacts are predominantly sequencing centre-rather than protocol-specific. Each centre exhibits a modest, distinct set of recurrent artefactual variants showing little overlap with sites routinely masked at the consensus level. To address this, we developed a systematic, dataset-aware framework that uses recurrence within sequencing datasets to identify small, noise-adapted sets of artefactual iSNVs to mask. Applying this framework reduces spurious sharing of low-frequency variants between samples and qualitatively alters downstream inferences, including estimates of within-host diversity and transmission bottleneck sizes. Together, these findings highlight the importance of explicit, dataset-aware artefact control for robust inference from within-host variation, particularly as genomic studies increasingly seek to exploit sub-consensus diversity in rapidly evolving pathogens such as SARS-CoV-2.
]]></description>
</item>
<item rdf:about="https://www.biorxiv.org/content/10.64898/2026.03.12.711354v1?rss=1">
<title>
<![CDATA[
Epistasis and the changing fitness landscapes of SARS-CoV-2 
]]>
</title>
<link>
https://www.biorxiv.org/content/10.64898/2026.03.12.711354v1?rss=1"
</link>
<dc:creator>Sesta, L.</dc:creator>
<dc:creator>Neher, R. A.</dc:creator>
<dc:date>2026-03-13</dc:date>
<dc:identifier>doi:10.64898/2026.03.12.711354</dc:identifier>
<dc:title><![CDATA[Epistasis and the changing fitness landscapes of SARS-CoV-2]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory Press</dc:publisher>
<prism:publicationDate>2026-03-13</prism:publicationDate>
<prism:section></prism:section>
<description><![CDATA[
Since its emergence in late 2019, millions of SARS-CoV-2 genomes have been generated as part of global efforts to monitor the evolution and spread of the virus. This unprecedented volume of data provides a unique opportunity to study viral evolution at unparalleled resolution. In particular, individual genomic sites can be observed to have mutated independently thousands of times. These mutation counts have been used to estimate site-specific mutation rates and fitness effects for most mutations across the viral genome. Here, we use these data to investigate how the landscape of mutational fitness costs has changed over the course of the pandemic. SARS-CoV-2 evolution over the past six years has been characterized by the emergence of distinct variants separated by long branches corresponding to evolutionary saltations involving up to 50 mutations. We compare inferred fitness landscapes across these variants and find that shifts in the estimated effects of non-synonymous mutations are linked to genetic differences between them. Sites with altered fitness costs are enriched near positions where the genetic backgrounds differ. To explain the observed changes, we introduce a model with pairwise epistatic interactions between mutations and residues that differ between variants. This model is able to explain about half of the variance in the shifts of fitness effects and suggests that each mismatch between variants substantially alters mutation effects at typically 1 to 3 additional positions.
]]></description>
</item>
<item rdf:about="https://www.biorxiv.org/content/10.64898/2026.03.13.711527v1?rss=1">
<title>
<![CDATA[
Spike Antibody Fc Drives Protection from SARS-CoV-2 Challenge in Macaques 
]]>
</title>
<link>
https://www.biorxiv.org/content/10.64898/2026.03.13.711527v1?rss=1"
</link>
<dc:creator>Brady, C.</dc:creator>
<dc:creator>Govender, M.</dc:creator>
<dc:creator>Mellors, J.</dc:creator>
<dc:creator>Tipton, T.</dc:creator>
<dc:creator>Gooch, K.</dc:creator>
<dc:creator>Tomic, A.</dc:creator>
<dc:creator>Carroll, M. W.</dc:creator>
<dc:date>2026-03-13</dc:date>
<dc:identifier>doi:10.64898/2026.03.13.711527</dc:identifier>
<dc:title><![CDATA[Spike Antibody Fc Drives Protection from SARS-CoV-2 Challenge in Macaques]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory Press</dc:publisher>
<prism:publicationDate>2026-03-13</prism:publicationDate>
<prism:section></prism:section>
<description><![CDATA[
A definitive correlate of protection (CoP) for SARS-CoV-2 has yet to be formally established. Previously, using data from a series of non-human primate vaccine challenge studies, we reported that neutralising antibodies (NAbs) are the strongest candidate for clinical protection against COVID-19 and that spike binding antibody is the strongest candidate CoP for viral burden post-challenge. In this study, we further characterised the protective binding antibody profile by analysing spike antibody-dependent complement deposition, Fc{gamma}R binding, isotype and antibody glycosylation. Using the machine learning platform SIMON, we demonstrate that antibody-dependent complement deposition (ADCD) and Fc{gamma}R binding are strong candidate co-correlates for each of the post-challenge outcomes; viral load and lung pathology. We found that spike antibody sialylation closely followed by Fc{gamma}R2A, was the spike antibody feature with the strongest negative correlation with histopathology score. Spike antibody ADCD, Fc{gamma}R binding, isotype and glycosylation significantly differed by immunisation regimen and sex, which demonstrates the heterogeneity of immune mechanisms induced by different immunisation platforms. We conclude that spike binding antibody, with the protective functional characteristics described herein, is a candidate CoP that captures both protection from severe clinical disease and protection against a high viral burden. These findings should be taken into consideration for future SARS-CoV-2 vaccine development.
]]></description>
</item>
<item rdf:about="https://www.biorxiv.org/content/10.64898/2026.03.11.711006v1?rss=1">
<title>
<![CDATA[
Deep mutational scanning of recent SARS-CoV-2 variants highlights changing amino acid preferences within epistatic hotspot residues 
]]>
</title>
<link>
https://www.biorxiv.org/content/10.64898/2026.03.11.711006v1?rss=1"
</link>
<dc:creator>Taylor, A.</dc:creator>
<dc:creator>Starr, T. N.</dc:creator>
<dc:date>2026-03-13</dc:date>
<dc:identifier>doi:10.64898/2026.03.11.711006</dc:identifier>
<dc:title><![CDATA[Deep mutational scanning of recent SARS-CoV-2 variants highlights changing amino acid preferences within epistatic hotspot residues]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory Press</dc:publisher>
<prism:publicationDate>2026-03-13</prism:publicationDate>
<prism:section></prism:section>
<description><![CDATA[
Deep mutational scans across receptor-binding domains (RBDs) of diverging SARS-CoV-2 variants reveal ongoing changes to the effects of mutations, a phenomenon known as epistasis. Careful accounting for these altered mutational effects is important in viral surveillance and forecasting, and more broadly, for understanding the impacts of epistasis on real-world viral evolutionary trajectories. Using a yeast-display RBD deep mutational scanning (DMS) platform, we measure the impacts of virtually all single amino acid mutations and single-residue deletions in the Omicron KP.3.1.1 and LP.8.1 RBDs on folded RBD expression and binding affinity for the human ACE2 receptor. Our comprehensive maps reveal patterns of evolutionary accessibility and constraint at single-residue resolution and when compared to prior datasets, highlight sites whose amino acid preferences continue to change across viral variants. Notably, sites 455, 456, and 493 - which have exhibited repeated substitutions and epistatic dependencies across Omicron subvariants going back to BA.1 - again demonstrate altered patterns of mutational accessibility and constraint. Therefore, it appears that these hotspots of repeated RBD evolution have not yet converged on fixed amino acid solutions, but instead remain sites of ongoing epistatic reconfiguration. We compare our measurements of direct RBD:ACE2 affinity with recently published measurements of mutation impacts on ACE2 binding in the full quaternary spike context, which also integrates the effects of spike conformational dynamics; our analysis uncovers mutations like H505W that could favor adoption of the down/closed RBD conformation as a viral strategy for future antigenic evolution.
]]></description>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.03.04.26347529v1?rss=1">
<title>
<![CDATA[
Physician-scientist hiring practices at US universities before and after the COVID-19 pandemic 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.03.04.26347529v1?rss=1"
</link>
<dc:creator>Noch, E. K.</dc:creator>
<dc:creator>Obradovic, A.</dc:creator>
<dc:creator>Jain, S.</dc:creator>
<dc:creator>Kwan, J. M.</dc:creator>
<dc:date>2026-03-12</dc:date>
<dc:identifier>doi:10.64898/2026.03.04.26347529</dc:identifier>
<dc:title><![CDATA[Physician-scientist hiring practices at US universities before and after the COVID-19 pandemic]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory Press</dc:publisher>
<prism:publicationDate>2026-03-12</prism:publicationDate>
<prism:section></prism:section>
<description><![CDATA[
Poor retention of physician-scientists in the work force is a major impediment to progress in biomedical research, and the leaky pipeline of junior physician-scientists was exacerbated after the COVID-19 pandemic. We report the results of a multi-institutional survey aimed at assessing hiring practice patterns among academic deans and department chairs, with 34 responses before and 70 responses after the COVID-19 pandemic. We found that private institutions tend to provide greater startup support across all areas of research, including basic science, translational, and clinical arenas, with NIH funding and publication volume predicting the level of support. We found that half of respondents provide research RVUs. The COVID-19 pandemic adversely impacted the availability of supplemental internal funding and bridge funding, which catalyzed institutions to support junior faculty through endowments. Yet, we found that junior faculty had to rearrange clinical schedules to increase clinical productivity. We also found that childcare policies were more robust at private institutions. These data highlight hiring practices across a cohort of academic deans and department chairs to improve transparency of the hiring process for junior faculty candidates approaching their first independent position. Providing greater transparency in hiring practices can help physician-scientist trainees find a good fit for their faculty position and can help stave off attrition from this pipeline.
]]></description>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.03.11.26348121v1?rss=1">
<title>
<![CDATA[
Horizon-dependent forecast ranking under structural change: a rolling-origin benchmark for global COVID-19 incidence 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.03.11.26348121v1?rss=1"
</link>
<dc:creator>Sesay, M. M.</dc:creator>
<dc:creator>Wembo, M. S.</dc:creator>
<dc:date>2026-03-12</dc:date>
<dc:identifier>doi:10.64898/2026.03.11.26348121</dc:identifier>
<dc:title><![CDATA[Horizon-dependent forecast ranking under structural change: a rolling-origin benchmark for global COVID-19 incidence]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory Press</dc:publisher>
<prism:publicationDate>2026-03-12</prism:publicationDate>
<prism:section></prism:section>
<description><![CDATA[
Short-horizon epidemic forecasting is difficult when surveillance series are highly nonstationary and affected by structural change and evolving reporting conditions. This study evaluates statistical models for global daily COVID-19 incidence using a rolling-origin benchmark designed to approximate real-time forecasting under such conditions. Using global incidence data from 22 January to 27 July 2020, we compare naive, seasonal naive, drift, ARIMA(log1p), ETS(log1p), and Prophet(log1p) forecasts at horizons h [isin] {1, 3, 7, 14} days. Structural phases are identified retrospectively on a variance-stabilized scale and used only to stratify forecast errors. Forecast ranking is strongly horizon-dependent. In the full-sample benchmark, drift performs best at the 1-, 7-, and 14-day horizons, while seasonal naive performs best at 3 days. Among the transformed statistical models, ARIMA(log1p) is competitive at short horizons, whereas ETS(log1p) becomes stronger at 7 and 14 days. Diebold-Mariano tests confirm that several of these differences are statistically meaningful, particularly in favor of drift at short and long horizons and in favor of ETS(log1p) over ARIMA(log1p) at longer horizons. Prophet(log1p) is not competitive in point forecasting and achieves high nominal interval coverage mainly through very wide prediction intervals. Robustness analyses show that the main ranking patterns are broadly stable to alternative segmentation settings, training-window policies, coverage-stabilized subsamples, and alternative target construction based on cumulative confirmed counts. Overall, the results show that simple baselines remain difficult to outperform in epidemic surveillance data and that horizon-specific rolling evaluation is essential for credible forecast comparison under structural change.

Author summaryForecasting infectious disease incidence is difficult when case data change rapidly over time and when reporting systems are still evolving. In this study, I examined how several common statistical forecasting models perform on global daily COVID-19 incidence during the early pandemic. Rather than asking which model is best overall, I focused on whether model ranking changes across forecast horizons and whether those conclusions remain stable under different evaluation choices. I compared simple baselines, including naive, seasonal naive, and drift forecasts, with ARIMA, exponential smoothing, and Prophet models using a rolling-origin benchmark that mimics real-time forecasting. I found that forecast ranking depends strongly on the horizon: drift performed best at 1, 7, and 14 days, while seasonal naive performed best at 3 days. Among the transformed statistical models, ARIMA was more competitive at shorter horizons, whereas exponential smoothing was stronger at longer horizons. I also found that these conclusions remained broadly stable under alternative segmentation settings, training windows, coverage-stabilized subsamples, and target definitions. These results show that simple baselines can remain highly competitive in epidemic surveillance data and that horizon-specific evaluation is essential for fair forecast comparison under structural change.
]]></description>
</item>
<item rdf:about="https://www.biorxiv.org/content/10.64898/2026.03.11.711159v1?rss=1">
<title>
<![CDATA[
Discovery of Semicarbazone and Thiosemicarbazone Analogs as Competitive SARS-CoV-2 Virus Main Protease (Mpro) Inhibitors 
]]>
</title>
<link>
https://www.biorxiv.org/content/10.64898/2026.03.11.711159v1?rss=1"
</link>
<dc:creator>Barreto, L. V.</dc:creator>
<dc:creator>Lourenco, E. M. G.</dc:creator>
<dc:creator>da Silva, E. B.</dc:creator>
<dc:creator>de Godoy, M. O.</dc:creator>
<dc:creator>Martins, L. C.</dc:creator>
<dc:creator>Laureano de Souza, M.</dc:creator>
<dc:creator>Almeida, R. G.</dc:creator>
<dc:creator>Cunha, V. L. S.</dc:creator>
<dc:creator>Pires, M. C.</dc:creator>
<dc:creator>Lavorato, S. N.</dc:creator>
<dc:creator>de Souza, T. B.</dc:creator>
<dc:creator>Bretas, A. C. O.</dc:creator>
<dc:creator>Ottoni, F. M.</dc:creator>
<dc:creator>Junior, E. N. S.</dc:creator>
<dc:creator>Oliva, G.</dc:creator>
<dc:creator>Alves, R. J.</dc:creator>
<dc:creator>de Oliveira, R. B.</dc:creator>
<dc:creator>Guido, R. V. C.</dc:creator>
<dc:creator>Ferreira, R. S.</dc:creator>
<dc:date>2026-03-12</dc:date>
<dc:identifier>doi:10.64898/2026.03.11.711159</dc:identifier>
<dc:title><![CDATA[Discovery of Semicarbazone and Thiosemicarbazone Analogs as Competitive SARS-CoV-2 Virus Main Protease (Mpro) Inhibitors]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory Press</dc:publisher>
<prism:publicationDate>2026-03-12</prism:publicationDate>
<prism:section></prism:section>
<description><![CDATA[
Despite the development of vaccines and antivirals, coronavirus disease 2019 (COVID-19) continues to affect populations worldwide. Given the high mutation rate of the SARS-CoV-2 virus and reports of drug resistance, there is a continued need for new therapeutic options. SARS-CoV-2 main protease (Mpro) is essential for viral replication and is a conserved target among coronaviruses. Most known Mpro inhibitors target the active site, although allosteric sites have already been identified. In this study, we conducted a virtual screening of 2,060 compounds targeting an allosteric site of SARS-CoV-2 Mpro. From this screen, 41 computational hits and analogs were selected and evaluated using biochemical assays against SARS-CoV-2 Mpro. Among them, compound 25, a semicarbazone, demonstrated a half-maximal inhibitory concentration (IC50) of 99 M. Additionally, two thiosemicarbazone analogs (compounds 50 and 51) inhibited SARS-CoV-2 Mpro with IC50 values of 61 M and 70 M. Biochemical assays suggest that these compounds act as noncovalent competitive inhibitors of SARS-CoV-2 Mpro. Molecular dynamics simulations revealed that compound 25 is unstable at the allosteric site of SARS-CoV-2 Mpro but forms stable and favorable interactions at the active site, supporting its potential as a competitive inhibitor, a finding subsequently confirmed by biochemical assays. Our structure-based computational and biochemical approach identified semicarbazone and thiosemicarbazone scaffolds as promising candidates for the development of reversible SARS-CoV-2 Mpro inhibitors.
]]></description>
</item>
<item rdf:about="https://www.biorxiv.org/content/10.64898/2026.03.09.707564v1?rss=1">
<title>
<![CDATA[
Persistent SARS-CoV-2 Spike is Associated with Localized Immune Dysregulation in Long COVID Gut Biopsies 
]]>
</title>
<link>
https://www.biorxiv.org/content/10.64898/2026.03.09.707564v1?rss=1"
</link>
<dc:creator>Abraham Soria, S.</dc:creator>
<dc:creator>Peterson, P.</dc:creator>
<dc:creator>VanElzakker, M. B.</dc:creator>
<dc:creator>Tankelevich, M.</dc:creator>
<dc:creator>Mehandru, S.</dc:creator>
<dc:creator>Proal, A.</dc:creator>
<dc:creator>Putrino, D.</dc:creator>
<dc:creator>Freire, M.</dc:creator>
<dc:date>2026-03-12</dc:date>
<dc:identifier>doi:10.64898/2026.03.09.707564</dc:identifier>
<dc:title><![CDATA[Persistent SARS-CoV-2 Spike is Associated with Localized Immune Dysregulation in Long COVID Gut Biopsies]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory Press</dc:publisher>
<prism:publicationDate>2026-03-12</prism:publicationDate>
<prism:section></prism:section>
<description><![CDATA[
SARS-CoV-2 persistence is a proposed driver of Long COVID (LC), but the in-situ relationship between residual viral antigen and immune dysregulation remains poorly defined. To address this critical gap, we employed a high-resolution, multi-modal approach--combining RNAscope, GeoMx Digital Spatial Profiling (DSP), spatial transcriptomics, and multiplex immunofluorescence--on 25 terminal ileum and left colon biopsies from a clinical cohort of 8 LC participants and 5 healthy controls. We confirmed the persistence of SARS-CoV-2 Spike transcript and protein in the gut tissue of all LC cases and controls tested. Yet, comparison of Spike-positive (Spike+) regions in LC versus healthy control colon tissues revealed a differential, symptomatic state-associated signature, with 57 differentially expressed genes (DEGs) (26 upregulated, 31 downregulated), revealing genes that disrupt the immune response in LC subjects. LC colon Spike+ regions demonstrated increased expression of AQP8 and other absorptive-related genes (SLC26A3, SLC26A2, and CLCA4) which are involved with Chrons disease along with transcripts involved in tumorigenesis (GUCA2A, S100P, TSPAN1). Simultaneous downregulation of key homeostatic chemokines (CXCL13, CCL19, CCL21), and other transcripts reported to exhibit low expression in colorectal cancers (TMEM88B, NIBAN3, DMBT1), suggesting a paradox of epithelial tissue stress yet dysfunctional immune trafficking. Further analysis comparing Spike+ versus Spike-regions within LC colon tissue demonstrated an active, localized, antigen-driven immune microenvironment, identifying 122 DEGs (82 upregulated, 40 downregulated), including tumorigenesis genes. Cellular deconvolution of Spike+ regions revealed a statistically significant focal enrichment of myeloid-derived cells (macrophages, non-classical/intermediate monocytes), plasma cells, and regulatory T cells, coupled with significant enrichment in T-cell-related pathways, including "Antigen processing and presentation," and "Th1/Th2/Th17 cell differentiation." The ileum displayed a similar, though less pronounced, signature, demonstrating these statistically significant findings are specific to the colon of LC subjects. In contrast, corresponding Spike+ vs. Spike-analysis in healthy control colon tissues showed a more modest transcriptional response with 38 DEGs. Our data provide robust evidence that persistent SARS-CoV-2 Spike protein detection in the gut is not immunologically inert. Instead, it is actively associated with distinct, immune cell composition shifts and a dysfunctional pro-inflammatory transcriptional profile, supporting the hypothesis that retained viral antigen drives chronic immune dysregulation in tissue of Long COVID subjects.
]]></description>
</item>
<item rdf:about="https://www.biorxiv.org/content/10.64898/2026.03.11.711036v1?rss=1">
<title>
<![CDATA[
Preliminary stability studies of a ss-SARS-CoV-2 virus-like particle vaccine 
]]>
</title>
<link>
https://www.biorxiv.org/content/10.64898/2026.03.11.711036v1?rss=1"
</link>
<dc:creator>Torresi, J.</dc:creator>
<dc:creator>Edeling, M. A.</dc:creator>
<dc:creator>Earnest-Silveira, L.</dc:creator>
<dc:creator>Carrera, J.</dc:creator>
<dc:creator>Yap, A. H. Y.</dc:creator>
<dc:creator>Hans, D.</dc:creator>
<dc:date>2026-03-12</dc:date>
<dc:identifier>doi:10.64898/2026.03.11.711036</dc:identifier>
<dc:title><![CDATA[Preliminary stability studies of a ss-SARS-CoV-2 virus-like particle vaccine]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory Press</dc:publisher>
<prism:publicationDate>2026-03-12</prism:publicationDate>
<prism:section></prism:section>
<description><![CDATA[
We aimed to study the stability of a {beta}-SARS-CoV-2 virus-like particle (VLP) vaccine in a series of preliminary experiments using select stabilising excipients. {beta}-SARS-CoV-2 VLPs were produced and purified using established methodologies. The thermostability of VLPs was tested at 4{degrees}C and -30{degrees}C in the presence or absence of stabilizers polysorbate 80, sorbitol or L-histidine in the presence of a physiological NaCl concentration of 137mM. The integrity of VLPs was assessed using ELISA, Western immunoblot and dynamic light scatter (DLS). {beta}-SARS-CoV-2 VLPs were stable at 4{degrees}C for 14 days and the addition of stabilizing excipients improved stability compared to VLPs in PBS alone. Storage of VLPs at -80{degrees}C maintained particle integrity by DLS analysis for up to 2 years. Excipients helped to maintain the immunogenicity of the VLPs by ELISA and Western immunoblot and DLS analysis revealed that VLPs retained their particulate structure.

ImportanceSARS-CoV-2 continues to circulate globally and cause significant illness. The problem of waning immunity to mRNA/LNPs has necessitated frequent boosters to keep pace of emerging variants. The development of alternative vaccines therefore remans a priority. Protein based vaccines, like VLPs, offer a safe alternative able to produce longer lasting immune responses. In this preliminary stability analysis, the {beta}-SARS-CoV-2 VLPs were found to be stable at 4{degrees}C and the addition of excipients improved VLP stability. Storage of VLPs at -30{degrees}C and -80{degrees}C also showed that the VLPs are stable for very long periods. Our findings will be of importance for the ongoing development of a SARS-CoV-2 VLP based vaccine.
]]></description>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.03.10.26348071v1?rss=1">
<title>
<![CDATA[
Evaluation of pre-Omicron population immunity for SARS-CoV-2 in the Household Influenza Vaccine Evaluation (HIVE) cohort 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.03.10.26348071v1?rss=1"
</link>
<dc:creator>Yang, Y.</dc:creator>
<dc:creator>Juntila-Raymond, C.</dc:creator>
<dc:creator>Callear, A.</dc:creator>
<dc:creator>Smith, M.</dc:creator>
<dc:creator>Atkinson, R. K.</dc:creator>
<dc:creator>Zhao, Y.</dc:creator>
<dc:creator>Shah, R.</dc:creator>
<dc:creator>Santos, J. J. S.</dc:creator>
<dc:creator>Hensley, S.</dc:creator>
<dc:creator>Monto, A. S.</dc:creator>
<dc:creator>Martin, E. T.</dc:creator>
<dc:date>2026-03-11</dc:date>
<dc:identifier>doi:10.64898/2026.03.10.26348071</dc:identifier>
<dc:title><![CDATA[Evaluation of pre-Omicron population immunity for SARS-CoV-2 in the Household Influenza Vaccine Evaluation (HIVE) cohort]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory Press</dc:publisher>
<prism:publicationDate>2026-03-11</prism:publicationDate>
<prism:section></prism:section>
<description><![CDATA[
BackgroundContinued serosurvey for SARS-CoV-2 population immunity is critical for vaccine strain selection and identification of susceptible groups such as young children. We aim to evaluate the use of a high-throughput, low-volume assay to describe strain-specific IgG measurement in a longitudinally followed community-based cohort.

MethodsThe longitudinal Household Influenza Vaccine Evaluation study has observed around 300 households annually for acute respiratory illness. SARS-CoV-2 variant-specific IgG (including original, delta, beta, and omicron variants) concentrations were measured using multiplex electrochemiluminescence (ECL), pseudoviral neutralization (PN), and ACE2 inhibition assays in participants who had serum samples drawn between July 1 and December 31, 2021. Spearmans rank correlation coefficient assessed correlation within and between ECL, ACE2, and PN assays. Receiver operating characteristic (ROC) analysis evaluated the performance of ECL and ACE2 assays. Generalized Additive Mixed Models estimated population immunity by age against SARS-CoV-2 variants.

ResultsA total of 156 serum samples from 117 participants were selected for this study. Most were from adults and a majority received vaccination during the analysis period. High correlations were observed within ECL (0.99-1.0), ACE2 (0.87-0.99), and between panels: ECL vs. PN (0.95-1.00), ACE2 vs. PN (0.85-0.96). ROC analysis showed medium to high areas under the curve, sensitivity, and specificity for ECL (0.85-0.87; 0.89-0.90; 0.87-0.88) and ACE2 (0.85-0.96; 0.94-1.0; 0.42-0.92). SARS-CoV-2 IgG concentrations are higher in older individuals, plateauing at age 20.

ConclusionWe found a high correlation between ECL, ACE2, and PN across variants. Age-specific IgG quantities reflected behavior and infection histories collected by active surveillance.
]]></description>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.03.10.26348047v1?rss=1">
<title>
<![CDATA[
Assessing Attention Process Training Efficacy in Improving Brain Fog Symptoms in Individuals with Long Covid: A Study Protocol for a Randomized Controlled Trial 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.03.10.26348047v1?rss=1"
</link>
<dc:creator>Magee, K.</dc:creator>
<dc:creator>Roth, E.</dc:creator>
<dc:creator>Cherney, L. R.</dc:creator>
<dc:creator>Cohen-Zimerman, S.</dc:creator>
<dc:date>2026-03-11</dc:date>
<dc:identifier>doi:10.64898/2026.03.10.26348047</dc:identifier>
<dc:title><![CDATA[Assessing Attention Process Training Efficacy in Improving Brain Fog Symptoms in Individuals with Long Covid: A Study Protocol for a Randomized Controlled Trial]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory Press</dc:publisher>
<prism:publicationDate>2026-03-11</prism:publicationDate>
<prism:section></prism:section>
<description><![CDATA[
BackgroundLong Covid, also referred to as post-acute sequelae of SARS-CoV-2 infection (PASC), is characterized by symptoms that persist or emerge weeks to months following acute COVID-19 illness. Cognitive impairments affecting attention, memory, and executive functioning--commonly described as "brain fog"--are frequently reported. Currently, limited evidence-based cognitive rehabilitation interventions specifically target these impairments.

ObjectivesThis pilot randomized controlled trial aims to evaluate the feasibility and acceptability, and to develop preliminary data regarding efficacy of Attention Process Training-3 (APT-3), a computerized attention training program, for individuals with Long Covid-related brain fog.

MethodsThis study uses a three-arm randomized controlled design. Participants are randomized to (1) Immediate Attention Training, (2) Delayed Attention Training, or (3) Music Activity. Participants complete comprehensive cognitive assessments at baseline, post-intervention, and one-month follow-up. The Immediate Attention Training group completes a 4-week APT-3 intervention, while the Music Activity group engages in a 4-week music-based listening activity. The Delayed Attention Training group dont receive any intervention for 4 weeks. Following completion of the final assessment, participants in the Music Activity and Delayed Attention Training groups are offered the APT-3 intervention. Feasibility and acceptability outcomes include recruitment, retention, and adherence numbers, and participant satisfaction. Preliminary data regarding efficacy will be determined using objective cognitive tests and subjective self-report measures.

ConclusionsThis pilot trial will inform the feasibility and acceptability of APT-3 and generate preliminary efficacy data to guide the design of a future fully powered randomized controlled trial targeting brain fog associated with Long Covid.
]]></description>
</item>
<item rdf:about="https://www.biorxiv.org/content/10.64898/2026.03.10.710948v1?rss=1">
<title>
<![CDATA[
Constrained Diffusion as a Paradigm for Evolution 
]]>
</title>
<link>
https://www.biorxiv.org/content/10.64898/2026.03.10.710948v1?rss=1"
</link>
<dc:creator>Lazarev, D.</dc:creator>
<dc:creator>Sappington, A.</dc:creator>
<dc:creator>Chau, G.</dc:creator>
<dc:creator>Zhang, R.</dc:creator>
<dc:creator>Berger, B.</dc:creator>
<dc:date>2026-03-11</dc:date>
<dc:identifier>doi:10.64898/2026.03.10.710948</dc:identifier>
<dc:title><![CDATA[Constrained Diffusion as a Paradigm for Evolution]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory Press</dc:publisher>
<prism:publicationDate>2026-03-11</prism:publicationDate>
<prism:section></prism:section>
<description><![CDATA[
A foundational question in computational biology is how to utilize data to describe the forces driving evolution. Here, we view evolution as a novel diffusion process constrained by many biological, physical, and environmental factors affecting organism viability at any given time. We introduce DiffEvol, a framework that models evolution as constrained diffusion over a discrete genotype space. Using real-world genomic sequence data alone, DiffEvol estimates complex evolutionary constraints by inverting the diffusion dynamics to recover a constrained subspace representing the viable genotype manifold, as well as its evolution over time. Applied to SARS-CoV-2 sequence data from 2020-2024, DiffEvol reconstructs constraint functions that recapitulate known viral fitness trends, including a pronounced "phase transition" that occurred following the widespread adoption of the SARS-CoV-2 vaccine. Our constraint subspace representation of the data characterizes such features and trends more clearly. This framework could be used not only to improve forecasting of emergent pathogenic strains, but also to produce more accurate reverse time analyses of their evolutionary dynamics to help identify ancestral variants and the forces having shaped a pathogens evolutionary trajectory. More generally, this formulation provides a method for linking observed sequence mutations to an evolving fitness landscape. Thus, constrained subspace diffusion offers a mathematical language for evolutionary dynamics in any system where random variation interacts with slowly-changing structural or global constraints, and can be applied to more complex evolutionary phenomena such as vaccine resistance, viral escape, and protein evolution.
]]></description>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.03.03.26347530v1?rss=1">
<title>
<![CDATA[
Effectiveness of COVID-19 Vaccination Schedules Against Severe COVID-19 in Children Aged 6 Months to 4 Years in Brazil: A Population-Based Cohort Study (2023-2024) 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.03.03.26347530v1?rss=1"
</link>
<dc:creator>Negretto Schrarstzhaupt, I.</dc:creator>
<dc:creator>Diaz-Quijano, F. A.</dc:creator>
<dc:date>2026-03-10</dc:date>
<dc:identifier>doi:10.64898/2026.03.03.26347530</dc:identifier>
<dc:title><![CDATA[Effectiveness of COVID-19 Vaccination Schedules Against Severe COVID-19 in Children Aged 6 Months to 4 Years in Brazil: A Population-Based Cohort Study (2023-2024)]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory Press</dc:publisher>
<prism:publicationDate>2026-03-10</prism:publicationDate>
<prism:section></prism:section>
<description><![CDATA[
BackgroundAlthough the impact of COVID-19 vaccination is widely documented in the general population, the evidence on its effectiveness in children under 5 years of age is still limited. In this context, the continuation of vaccination programs in this age group has been debated globally. Consequently, we estimated the effectiveness of the 3-dose series of BNT162b2 (Pfizer-BioNTech) in children aged 6 months to 4 years and the complete 2-dose series of CoronaVac (Sinovac) in children aged 3 to 4 in reducing the risk of hospitalizations due to COVID-19-attributed severe acute respiratory infection (SARI) in Brazil.

MethodsWe conducted a retrospective cohort study in 24 Brazilian municipalities, using surveillance data. We evaluated vaccine effectiveness in reducing the incidence rate of COVID-19-attributed SARI hospitalizations from July 2023 to December 2024. Covariate adjustments, defined a priori based on a conceptual model represented by a directed acyclic graph (DAG), were implemented using random-effects Poisson regression models. We also analyzed alternative vaccination schedules and obtained age-specific estimates of effectiveness.

ResultsThe cohort comprised 37.6 million person-months of follow-up and 1,384 COVID-19-attributed SARI hospitalizations, including 27 associated deaths. The 3-dose series of BNT162b2 vaccine had an effectiveness of 97% (IRR 0.03, 95%CI 0.01-0.10) in the group aged 6 months to 4 years, with no significant differences among age-specific estimates. No deaths occurred among children who completed the 3-dose series, whereas four deaths were observed among those with fewer doses. The effectiveness of CoronaVac was small and not statistically significant (IRR 0.96, 95%CI 0.57-1.62). However, no deaths were recorded among children who received any number of CoronaVac doses, and no COVID-19-attributed SARI hospitalizations were observed among those who received a third dose of this vaccine.

ConclusionsThe 3-dose series of the mRNA vaccine (BNT162b2) had high and consistent effectiveness in protecting against severe COVID-19 in children aged 6 months to 4 years. These findings support the maintenance of routine COVID-19 vaccination in this age group.
]]></description>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.03.04.26347154v1?rss=1">
<title>
<![CDATA[
Assessment of accuracy of detection dog signaling behavior for the diagnosis of SARS-CoV-2 infection: A Canadian study 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.03.04.26347154v1?rss=1"
</link>
<dc:creator>Mbutiwi, F. I. N.</dc:creator>
<dc:creator>Otis, C.</dc:creator>
<dc:creator>Schiller, I.</dc:creator>
<dc:creator>LaChance, M.</dc:creator>
<dc:creator>Martin, L.</dc:creator>
<dc:creator>Jammal, A.</dc:creator>
<dc:creator>Odita, A.</dc:creator>
<dc:creator>Agbaje, N.</dc:creator>
<dc:creator>Khatib, A.</dc:creator>
<dc:creator>Dendukuri, N.</dc:creator>
<dc:creator>Tamim, H.</dc:creator>
<dc:creator>Troncy, E.</dc:creator>
<dc:creator>Carabin, H.</dc:creator>
<dc:date>2026-03-10</dc:date>
<dc:identifier>doi:10.64898/2026.03.04.26347154</dc:identifier>
<dc:title><![CDATA[Assessment of accuracy of detection dog signaling behavior for the diagnosis of SARS-CoV-2 infection: A Canadian study]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory Press</dc:publisher>
<prism:publicationDate>2026-03-10</prism:publicationDate>
<prism:section></prism:section>
<description><![CDATA[
BackgroundDogs trained to metabolomics detection can identify pathological changes through their refined smelling sense. During the COVID-19 pandemic, studies worldwide evaluated Detection Dog Signaling Behavior (DDSB) for SARS-CoV-2. However, most statistical approaches failed to account for key sources of bias, potentially distorting performance estimates. This study aimed to estimate DDSB accuracy for SARS-CoV-2 infection in a Canadian population while assessing the impact of selected sources of bias on performance estimates.

MethodsParticipants attending the COVID-19 assessment clinic at St. Josephs Health Centre, Toronto, were recruited between October and December 2021. Each provided a nasopharyngeal swab for reverse transcription-polymerase chain reaction (RT-PCR) testing and three sweat samples for canine detection. Three dogs were trained to detect SARS-CoV-2 in sweat samples. Validation sessions were video recorded and independently reviewed by two blinded observers. DDSB diagnostic accuracy was estimated against RT-PCR, evaluating the impact of ignoring its imperfect accuracy and repeated sniffing of the same samples during validation.

ResultsAmong 2,358 participants (mean age: 34.7 years; 55.7% female), 437 contributed to training. Validation tests included 146 unique participants (25 RT-PCR positive, 121 negative). Assuming RT-PCR was imperfect, DDSB posterior median sensitivity ranged from 67% (95% credible interval [CrI]: 29%-97%) to 78% (95% CrI: 41%-99%), and specificity from 67% (95% CrI: 53%-79%) to 77% (95% CrI: 65%-87%) across the three dogs. Assuming RT-PCR was perfect, sensitivity decreased by 7.9% to 9%, while specificity remained unchanged. Including repeated positive samples without adjustment did not affect specificity estimates but overestimated sensitivity by 7.9% to 13.4% (imperfect RT-PCR) and 11.4% to 18.3% (perfect RT-PCR).

ConclusionDDSB shows potential as a non-invasive screening tool for SARS-CoV-2 infection. Our results highlight the challenges of designing such studies and the need for standardized training and validation procedures to ensure the reliability and validity of DDSB.
]]></description>
</item>
<item rdf:about="https://www.biorxiv.org/content/10.64898/2026.03.08.709729v1?rss=1">
<title>
<![CDATA[
Anthracyclines inhibit -1 programmed ribosomal frameshifting and restrict HCoV-OC43 infection 
]]>
</title>
<link>
https://www.biorxiv.org/content/10.64898/2026.03.08.709729v1?rss=1"
</link>
<dc:creator>Scheller, D.</dc:creator>
<dc:creator>Islam, K.</dc:creator>
<dc:creator>Lindgren, L.</dc:creator>
<dc:creator>Arnberg, N.</dc:creator>
<dc:creator>Johansson, J.</dc:creator>
<dc:date>2026-03-10</dc:date>
<dc:identifier>doi:10.64898/2026.03.08.709729</dc:identifier>
<dc:title><![CDATA[Anthracyclines inhibit -1 programmed ribosomal frameshifting and restrict HCoV-OC43 infection]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory Press</dc:publisher>
<prism:publicationDate>2026-03-10</prism:publicationDate>
<prism:section></prism:section>
<description><![CDATA[
Human coronavirus OC43 (HCoV-OC43) constitutes one of the most common causes of the seasonal cold but can also cause severe disease among elderly and immuno-compromised. Currently, there are no approved antiviral drugs to combat HCoV-OC43 infection. Coronaviruses are positive single-stranded RNA (+ssRNA) viruses and utilize -1 programmed ribosomal frameshifting (-1 PRF) to obtain the correct stoichiometry of viral protein components. As such, the ribosomal frameshifting stimulation element (FSE) is a promising target for antiviral drug discovery, due to its high conservation. By repurposing available drugs, we identified a group of anthracycline compounds that can reduce -1 PRF of HCoV-OC43 and reduce viral infection of cells. Furthermore, we show that anthracyclines that reduce infection also bind the FSE and reduce frameshift frequency. We also show that the selected anthracyclines reduce SARS-CoV-2 infection, but without affecting -1 PRF frequency. All together, we demonstrate that a subset of anthracyclines selectively binds and inhibit the HCoV-OC43 FSE and could thus serve as a robust framework when developing new antivirals targeting coronaviruses.
]]></description>
</item>
<item rdf:about="https://www.biorxiv.org/content/10.64898/2026.03.09.709481v1?rss=1">
<title>
<![CDATA[
One and Done: A safe, adaptable single-cycle SARS-CoV-2 vaccine platform blocks XBB.1.5 infection and transmission 
]]>
</title>
<link>
https://www.biorxiv.org/content/10.64898/2026.03.09.709481v1?rss=1"
</link>
<dc:creator>Schoen, J.</dc:creator>
<dc:creator>Halwe, N. J.</dc:creator>
<dc:creator>Britzke, T.</dc:creator>
<dc:creator>Breithaupt, A.</dc:creator>
<dc:creator>Ulrich, L.</dc:creator>
<dc:creator>Kochmann, J.</dc:creator>
<dc:creator>Corleis, B.</dc:creator>
<dc:creator>Kipfer, E. T.</dc:creator>
<dc:creator>Klimkait, T.</dc:creator>
<dc:creator>Hoffmann, D.</dc:creator>
<dc:creator>Otte, F.</dc:creator>
<dc:creator>Beer, M.</dc:creator>
<dc:creator>Hauser, D.</dc:creator>
<dc:date>2026-03-10</dc:date>
<dc:identifier>doi:10.64898/2026.03.09.709481</dc:identifier>
<dc:title><![CDATA[One and Done: A safe, adaptable single-cycle SARS-CoV-2 vaccine platform blocks XBB.1.5 infection and transmission]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory Press</dc:publisher>
<prism:publicationDate>2026-03-10</prism:publicationDate>
<prism:section></prism:section>
<description><![CDATA[
A next-generation SARS-CoV-2 vaccine must address the currently inadequate prevention of virus transmission, particularly against emerging variants of concern, a challenge that none of the licensed commercial vaccines fully meet. Effective control of respiratory pandemics necessitates vaccines that 1) can be rapidly adapted, 2) have high patient compliance with simple and non-invasive administration, and 3) block transmission in a virus challenge.

We describe here the characterization of an updated single-cycle SARS-CoV-2 vaccine candidate (scVac), engineered as a replication-defective virus with targeted deletions of the E gene and ORF6 and ORF7a, along with a truncation of ORF3a. The candidate carries an Omicron XBB.1.5 Spike (scVacXBB), maintaining all essential antigenic properties. The vaccine demonstrated an excellent safety profile in K18-hACE2 transgenic mice, the most sensitive virulence model, with no clinical signs or adverse events observed. In the Syrian hamster model, potent systemic and mucosal immune responses were induced, along with a strong neutralizing antibody response. Notably, there was no virus transmission to co-housed naive animals, which outperforms a bivalent Omicron mRNA vaccine reference.

Our results demonstrate that scVacXBB-induced immunity not only prevents disease but also effectively blocks transmission. Furthermore, the successful introduction of the XBB.1.5 Spike protein into the scVac platform demonstrates the pipelines ability to adapt quickly to any emerging variant. These findings highlight the potential of this single-cycle concept as a next-generation COVID-19 vaccine, offering robust protection with a strong safety profile.
]]></description>
</item>
<item rdf:about="https://www.biorxiv.org/content/10.64898/2026.03.09.710039v1?rss=1">
<title>
<![CDATA[
A Universal, AI-based Design Framework for Efficient Manufacturing of mRNA Therapeutics 
]]>
</title>
<link>
https://www.biorxiv.org/content/10.64898/2026.03.09.710039v1?rss=1"
</link>
<dc:creator>Liao, K.-C.</dc:creator>
<dc:creator>Maccari, G.</dc:creator>
<dc:creator>Ciano, G.</dc:creator>
<dc:creator>Huber, R.</dc:creator>
<dc:creator>von der Haar, T.</dc:creator>
<dc:creator>Tham, C.-Y.</dc:creator>
<dc:creator>Ting Xun Ong, N.</dc:creator>
<dc:creator>Florez de Sessions, P.</dc:creator>
<dc:creator>Yih Saw, T.</dc:creator>
<dc:creator>Wei Lim, T.</dc:creator>
<dc:creator>Martin, C.</dc:creator>
<dc:creator>Dickman, M.</dc:creator>
<dc:creator>Kis, Z.</dc:creator>
<dc:creator>Makatsoris, H.</dc:creator>
<dc:creator>van Asbeck, A.</dc:creator>
<dc:creator>Wan, Y.</dc:creator>
<dc:creator>Medini, D.</dc:creator>
<dc:date>2026-03-10</dc:date>
<dc:identifier>doi:10.64898/2026.03.09.710039</dc:identifier>
<dc:title><![CDATA[A Universal, AI-based Design Framework for Efficient Manufacturing of mRNA Therapeutics]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory Press</dc:publisher>
<prism:publicationDate>2026-03-10</prism:publicationDate>
<prism:section></prism:section>
<description><![CDATA[
The growth of mRNA therapeutics is limited by bespoke manufacturing processes. To overcome this barrier to access and innovation, we introduce an AI-driven framework that decouples sequence design from manufacturing, analogous to the universal design principles that revolutionized the semiconductor industry. We performed a large-scale screen, quantifying the in vitro transcription (IVT) efficiency of one million diverse sequences. We then trained an interpretable deep learning model that accurately predicts manufacturability from sequences alone and learned underlying molecular mechanisms. An algorithm using this model prospectively improved the IVT yield of a vaccine and a gene-editing therapeutic by over 7.5-fold. Co-optimization for manufacturability and translation efficiency provided improvements over state-of-the-art commercial mRNA products. Our AI-driven framework establishes a universal design paradigm with the promise to democratize and accelerate the development of mRNA medicines, potentially unlocking a new era in biotechnology.
]]></description>
</item>
<item rdf:about="https://www.biorxiv.org/content/10.64898/2026.03.09.710460v1?rss=1">
<title>
<![CDATA[
The serum from critical COVID-19 patients induces proteomic changes in olfactory neuroepithelial cells that resemble post-covid neurological complications 
]]>
</title>
<link>
https://www.biorxiv.org/content/10.64898/2026.03.09.710460v1?rss=1"
</link>
<dc:creator>Beltran-Camacho, L.</dc:creator>
<dc:creator>Bhosale, S.</dc:creator>
<dc:creator>Hidalgo-Figueroa, M.</dc:creator>
<dc:creator>Delgado-Sequera, A.</dc:creator>
<dc:creator>Sanchez-Morillo, D.</dc:creator>
<dc:creator>Perez-Revuelta, J.</dc:creator>
<dc:creator>Romero Lopez-Alberca, C.</dc:creator>
<dc:creator>Larsen, M.</dc:creator>
<dc:creator>Moreno-Luna, R.</dc:creator>
<dc:creator>Berrocoso, E.</dc:creator>
<dc:creator>Duran-Ruiz, M. C.</dc:creator>
<dc:date>2026-03-10</dc:date>
<dc:identifier>doi:10.64898/2026.03.09.710460</dc:identifier>
<dc:title><![CDATA[The serum from critical COVID-19 patients induces proteomic changes in olfactory neuroepithelial cells that resemble post-covid neurological complications]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory Press</dc:publisher>
<prism:publicationDate>2026-03-10</prism:publicationDate>
<prism:section></prism:section>
<description><![CDATA[
Post-acute sequelae of SARS-CoV-2 infection (PASC), commonly referred to as Long COVID, comprise a constellation of persistent, recurrent, or newly emerging symptoms that may endure for months or years following acute infection. Beyond respiratory impairment, PASC is characterized by a wide spectrum of extrapulmonary manifestations, among which neurological and neuropsychiatric symptoms are highly prevalent. Reported features include olfactory dysfunction with loss of smell and taste, fatigue, neuroinflammation, cognitive and memory impairment, depression, and anxiety, with some symptoms persisting up to one year post-infection.

Despite increasing recognition of these complications, the molecular mechanisms underlying post-COVID neurological sequelae remain poorly defined. In this study, we employed a label-free quantitative (LFQ) proteomics approach to investigate protein alterations in olfactory neuroepithelium-derived stem cells (ONEs), a unique population of neural progenitors located in the olfactory mucosa at the interface between the respiratory system and both the peripheral and central nervous systems. Due to their anatomical exposure and susceptibility to SARS-CoV-2, ONEs represent a highly relevant translational model for exploring virus-associated neurobiological processes.

ONEs derived from healthy donors were incubated with serum from either asymptomatic PCR-positive individuals (AS; n=4) or critically ill hospitalized patients (CR; n=6). Proteomic profiling revealed a distinct differential protein expression pattern in ONEs exposed to CR serum compared with AS serum. Altered pathways were associated with viral infection responses, respiratory and cardiovascular dysfunction, and notably, cerebrovascular and nervous system disorders. These findings highlight the vulnerability of ONEs to systemic factors associated with severe COVID-19 and provide molecular insight into mechanisms potentially contributing to persistent neurological sequelae in PASC.

GRAPHICAL ABSTRACT

O_FIG O_LINKSMALLFIG WIDTH=200 HEIGHT=110 SRC="FIGDIR/small/710460v1_ufig1.gif" ALT="Figure 1">
View larger version (31K):
org.highwire.dtl.DTLVardef@12cfda5org.highwire.dtl.DTLVardef@c0636borg.highwire.dtl.DTLVardef@bf303eorg.highwire.dtl.DTLVardef@1f861e9_HPS_FORMAT_FIGEXP  M_FIG C_FIG
]]></description>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.03.06.26347822v1?rss=1">
<title>
<![CDATA[
Predictors of COVID-19 hospital outcomes: a machine learning analysis of the National COVID Cohort Collaborative 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.03.06.26347822v1?rss=1"
</link>
<dc:creator>Vazquez, J.</dc:creator>
<dc:creator>Taylor, L.</dc:creator>
<dc:creator>Chen, Y.-Y. K.</dc:creator>
<dc:creator>Araya, K.</dc:creator>
<dc:creator>Farnsworth, M. G.</dc:creator>
<dc:creator>Xue, X.</dc:creator>
<dc:creator>Hasan, M.</dc:creator>
<dc:creator>N3C Consortium,</dc:creator>
<dc:date>2026-03-09</dc:date>
<dc:identifier>doi:10.64898/2026.03.06.26347822</dc:identifier>
<dc:title><![CDATA[Predictors of COVID-19 hospital outcomes: a machine learning analysis of the National COVID Cohort Collaborative]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory Press</dc:publisher>
<prism:publicationDate>2026-03-09</prism:publicationDate>
<prism:section></prism:section>
<description><![CDATA[
Predicting hospital outcomes for patients with severe acute respiratory infections is critical for risk stratification and resource planning, yet heterogeneous electronic health record (EHR) data, class imbalance, and evolving clinical practice present persistent methodological challenges for machine learning (ML) approaches.

We conducted a retrospective cohort study using EHR data harmonized to the OMOP common data model from the National COVID Cohort Collaborative (N3C; May 2020-June 2025), including 263,619 adults hospitalized with COVID-19 across 51 contributing sites. We developed penalized linear regression (elastic net), random forest, XGBoost, and multilayer perceptron (MLP) models to predict hospital length of stay (LOS) and mortality (in-hospital and 60-day), using demographics, comorbidities, prior healthcare utilization, COVID-19 vaccination status, and hospital site as predictors. Missing data were handled via multiple imputation by chained equations (MICE) and class imbalance was addressed using SMOTE. Model performance was evaluated using area under the ROC curve (AUROC), Brier score, calibration plots, and decision curve analysis, following the TRIPOD reporting framework.

Mortality prediction achieved moderate discrimination across all models (test AUROC = 0.71-0.73 for in-hospital mortality; 0.72-0.73 for 60-day all-cause mortality). Models trained without SMOTE achieved the highest AUROCs but assigned virtually no patients to the mortality class at the default 0.5 threshold. SMOTE improved recall and F-1 score at the cost of reduced AUROC and precision. LOS was poorly explained by available structured predictors (best R2 = 0.059). Remdesivir-treated patients (n = 103,536; 39.3%) were older, had higher comorbidity burden, and had higher unadjusted mortality than untreated patients.

Common structured EHR features offer moderate utility for mortality risk stratification in hospitalized COVID-19 patients but are insufficient for LOS prediction. The consistent SMOTE-related tradeoff between discrimination and calibration underscores the need to report threshold-dependent metrics alongside AUROC in clinical ML studies, with implications for operational planning during future respiratory disease emergencies.
]]></description>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.03.06.26347802v1?rss=1">
<title>
<![CDATA[
Would Lifting Versus Maintaining COVID-19 Containment Policies Have Reduced Psychological Distress in the US? 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.03.06.26347802v1?rss=1"
</link>
<dc:creator>Cudic, M.</dc:creator>
<dc:creator>de la Hoz, J. F.</dc:creator>
<dc:creator>Dall'Aglio, L.</dc:creator>
<dc:creator>Tubbs, J. D.</dc:creator>
<dc:creator>Ebrahimi, O. V.</dc:creator>
<dc:creator>Madsen, E. M.</dc:creator>
<dc:creator>Fatori, D.</dc:creator>
<dc:creator>Zuccolo, P. F.</dc:creator>
<dc:creator>Lian, J.</dc:creator>
<dc:creator>Kabir, D. K.</dc:creator>
<dc:creator>Zhou, Y.</dc:creator>
<dc:creator>Watts, D.</dc:creator>
<dc:creator>Choi, K. W.</dc:creator>
<dc:creator>Manfro, G. G.</dc:creator>
<dc:creator>Sweeney, E.</dc:creator>
<dc:creator>Lin, Y.-F.</dc:creator>
<dc:creator>Fancourt, D.</dc:creator>
<dc:creator>COVID-19 Global Mental Health Consortium (CGMHC),</dc:creator>
<dc:creator>Patel, V.</dc:creator>
<dc:creator>Kessler, R. C.</dc:creator>
<dc:creator>Bauermeister, S.</dc:creator>
<dc:creator>Brunoni, A. R.</dc:creator>
<dc:creator>Lee, Y. H.</dc:creator>
<dc:creator>Smoller, J. W.</dc:creator>
<dc:date>2026-03-09</dc:date>
<dc:identifier>doi:10.64898/2026.03.06.26347802</dc:identifier>
<dc:title><![CDATA[Would Lifting Versus Maintaining COVID-19 Containment Policies Have Reduced Psychological Distress in the US?]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory Press</dc:publisher>
<prism:publicationDate>2026-03-09</prism:publicationDate>
<prism:section></prism:section>
<description><![CDATA[
BackgroundBoth the COVID-19 pandemic and containment policies caused widespread psychological distress, yet their independent effects remain unclear. Disentangling these effects could inform future responses that balance physical and mental health. This study sought to estimate the effect of lifting versus maintaining containment policies on psychological distress, independent of pandemic severity.

MethodsWe conducted a state-level longitudinal analysis using the Behavioral Risk Factor Surveillance System (BRFSS), a representative survey of US adults, restricted to the pandemic period preceding widespread vaccine availability (April 2020 to April 2021). The exposure was lifting versus maintaining containment policies (school closures, workplace closures, event cancellations, and full lockdown) from the Oxford COVID-19 Government Response Tracker. Exposure was measured during periods of low (<25/100,000 new cases) or declining (>14 days) pandemic severity. The primary outcome was prevalence of psychological distress, derived from a BRFSS survey item corresponding to a PHQ-4 score [&ge;]6.

FindingsThree causal inference approaches yielded consistent evidence of transient policy-lifting effects: (1) synthetic control analysis of Maine showed a temporary 5.5 percentage-point reduction in psychological distress lasting three months before returning to counterfactual levels; (2) within-state fixed effects found immediately after lifting full lockdown, distress decreased by 5.68 [-8.67, -2.69] percentage points, declining by 30 days (-3.24 [-6.88, 0.39]) and negligible at 60 days (-0.94 [-3.77, 1.89]); (3) target trial emulation detected no significant effects from lifting versus maintaining policies for 90 days.

InterpretationLifting containment policies in the first year of the pandemic produced immediate but transient reductions in psychological distress. These results suggest that extended containment policies were unlikely to account for persistent increases in distress during this period.
]]></description>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.03.07.26347844v1?rss=1">
<title>
<![CDATA[
Sex differences in COVID-19 infection and mortality in Hong Kong 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.03.07.26347844v1?rss=1"
</link>
<dc:creator>Law, A. H. T.</dc:creator>
<dc:creator>Wong, J. Y.</dc:creator>
<dc:creator>Lin, Y.</dc:creator>
<dc:creator>Cowling, B. J.</dc:creator>
<dc:creator>Wu, P.</dc:creator>
<dc:date>2026-03-09</dc:date>
<dc:identifier>doi:10.64898/2026.03.07.26347844</dc:identifier>
<dc:title><![CDATA[Sex differences in COVID-19 infection and mortality in Hong Kong]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory Press</dc:publisher>
<prism:publicationDate>2026-03-09</prism:publicationDate>
<prism:section></prism:section>
<description><![CDATA[
BackgroundVariation in COVID-19 mortality rates by sex could have several explanations. We aimed to determine sex differences in infection and mortality patterns across different COVID-19 epidemics in Hong Kong, and to evaluate potential hypotheses.

MethodsWe estimated age- and sex-specific incidence rates of cases, hospitalizations, and deaths per 100,000 population. Case-hospitalization, case-fatality risks (CFRs), and hospital-fatality risks of the COVID-19 pandemic were also estimated. Adjusted and unadjusted risks were estimated and compared to explore the relationships between mortality and health-related variables. We also explored the sex ratio of COVID-19 mortality rates of respiratory diseases from 2000 to 2019.

ResultsHong Kong recorded 2876110 COVID-19 cases and 12737 deaths between January 2020 and January 2023, with 1317368 cases (45.8%) and 7523 (59.1%) fatal cases occurring in males. The incidence rate of cases was similar by sex across waves. The CFRs and hospital-fatality risks were higher in men across all waves. Males had a significantly higher mortality risk after adjusting for sex, COVID-19 vaccination status, and pre-existing chronic diseases. The ratio of COVID-19 mortality rates in men versus women from 2020 to 2023 was similar to the mortality ratio for other respiratory diseases in the pre-pandemic period.

ConclusionsWhile infection rates were similar for males and females, males experienced higher mortality risks even after adjusting for differences in other known risk factors. COVID-19 shares a similar sex ratio of mortality with respiratory diseases excluding COVID-19.
]]></description>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.03.07.26347857v1?rss=1">
<title>
<![CDATA[
A phase 2a double-blind, placebo-controlled randomized trial of the SARS-CoV-2-specific monoclonal antibody AER002 in people with Long COVID 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.03.07.26347857v1?rss=1"
</link>
<dc:creator>Peluso, M. J.</dc:creator>
<dc:creator>Ryder, D.</dc:creator>
<dc:creator>Dalhuisen, T.</dc:creator>
<dc:creator>Chu, D. H. T.</dc:creator>
<dc:creator>Williams, M. C.</dc:creator>
<dc:creator>Rodriguez, A. E.</dc:creator>
<dc:creator>LaFranchi, B.</dc:creator>
<dc:creator>Vinden, J.</dc:creator>
<dc:creator>Fehrman, E. A.</dc:creator>
<dc:creator>Huang, B.</dc:creator>
<dc:creator>Hoh, R.</dc:creator>
<dc:creator>Asare, K. A.</dc:creator>
<dc:creator>Bellon Pizarro, K.</dc:creator>
<dc:creator>Rahman, M.</dc:creator>
<dc:creator>de Narvaez, E.</dc:creator>
<dc:creator>Painter, M. M.</dc:creator>
<dc:creator>Wherry, E. J.</dc:creator>
<dc:creator>Swank, Z. N.</dc:creator>
<dc:creator>Hansen, L. L.</dc:creator>
<dc:creator>Walt, D. R.</dc:creator>
<dc:creator>Fukazawa, Y.</dc:creator>
<dc:creator>Sekar, A.</dc:creator>
<dc:creator>Bellan, S. E.</dc:creator>
<dc:creator>Tieu, H.</dc:creator>
<dc:creator>Asiago, J.</dc:creator>
<dc:creator>Bhuyan, P.</dc:creator>
<dc:creator>Venkayya, R.</dc:creator>
<dc:creator>Flavell, R. R.</dc:creator>
<dc:creator>VanBrocklin, H.</dc:creator>
<dc:creator>Kelly, J. D.</dc:creator>
<dc:creator>Hsue, P. Y.</dc:creator>
<dc:creator>Durstenfeld, M. S.</dc:creator>
<dc:creator>Hunt, P. W.</dc:creator>
<dc:creator>Calabrese, L.</dc:creator>
<dc:creator>Somsouk, M.</dc:creator>
<dc:creator>Martin, J. N.</dc:creator>
<dc:creator>Glidden, D. V.</dc:creator>
<dc:creator>Deitchman, A. N.</dc:creator>
<dc:creator>Henrich, T. J.</dc:creator>
<dc:creator>Deeks, S. G.</dc:creator>
<dc:date>2026-03-09</dc:date>
<dc:identifier>doi:10.64898/2026.03.07.26347857</dc:identifier>
<dc:title><![CDATA[A phase 2a double-blind, placebo-controlled randomized trial of the SARS-CoV-2-specific monoclonal antibody AER002 in people with Long COVID]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory Press</dc:publisher>
<prism:publicationDate>2026-03-09</prism:publicationDate>
<prism:section></prism:section>
<description><![CDATA[
Long COVID is a disabling chronic illness with no proven treatments. Persistence of SARS-CoV-2 has been proposed as a biological driver of the disease. We conducted a placebo-controlled, double-blind, 2:1 randomized mechanistic trial of the SARS-CoV-2-specific monoclonal antibody AER002 in 36 participants who met the World Health Organization case definition of Long COVID. After baseline characterization, participants received a single infusion and were followed for 360 days. The primary endpoint was the PROMIS-29 Physical Health Summary Score (PHSS) at 90 days; secondary and exploratory endpoints included patient-reported and objective measures of physical, cognitive, and neurologic function as well as blood-, imaging-, and tissue-based biomarkers. While AER002 was safe and well tolerated, no significant differences in physical health, quality of life, objective measures of physical function or cognition, or blood-based biomarkers were demonstrated between the treatment and control arms. In a post-hoc analysis, participants with a lower baseline SARS-CoV-2 antibody level and higher drug exposure were more likely to express a perceived treatment benefit based on the Patient Global Impression of Change scale (p<0.05 for anti-S, S1, and RBD). Although AER002 was not efficacious in this proof-of-concept study of people with broadly defined Long COVID, our findings could inform recruitment or dosing strategies employed in future trials using monoclonal antibodies to target viral persistence as a driver of Long COVID.
]]></description>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.03.07.26347841v1?rss=1">
<title>
<![CDATA[
Long COVID Prevalence among U.S. Adults: A State-level Ecological Analysis of the Contribution of COVID-19 Incidence, Severity of Acute Illness, COVID-19 Vaccination, and Chronic Conditions 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.03.07.26347841v1?rss=1"
</link>
<dc:creator>Zhao, X.</dc:creator>
<dc:creator>Deng, L.</dc:creator>
<dc:creator>Ford, N. D.</dc:creator>
<dc:creator>Saydah, S.</dc:creator>
<dc:date>2026-03-09</dc:date>
<dc:identifier>doi:10.64898/2026.03.07.26347841</dc:identifier>
<dc:title><![CDATA[Long COVID Prevalence among U.S. Adults: A State-level Ecological Analysis of the Contribution of COVID-19 Incidence, Severity of Acute Illness, COVID-19 Vaccination, and Chronic Conditions]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory Press</dc:publisher>
<prism:publicationDate>2026-03-09</prism:publicationDate>
<prism:section></prism:section>
<description><![CDATA[
BackgroundLong COVID has emerged as a major public-health concern in the United States, yet geographic variation in its prevalence remains poorly understood. This study examines how state-level differences in COVID-19 vaccination, SARS-CoV-2 incidence, COVID-19 hospitalization, and chronic disease burden relate to adult Long COVID prevalence in the United States.

MethodsWe conducted an ecological analysis using data from the 2023 Behavioral Risk Factor Surveillance System (BRFSS), from which we estimated state-level prevalence of self-reported Long COVID among adults. These estimates were linked with publicly available data on SARS-CoV-2 incidence, COVID-19 hospitalizations, COVID-19 vaccine coverage, and a multimorbidity indicator (>= 3 chronic conditions e.g., diabetes, obesity, chronic kidney disease) associated with higher risk for severe SARS-CoV-2. Multivariable linear regression models were fitted to assess the contribution of each factor adjusted for age and sex distribution, incorporating Rubins rules to account for uncertainty in prevalence estimates.

ResultsAll examined factors--including SARS-CoV-2 incidence, hospitalization rates, and multimorbidity, vaccine coverage--varied by state. When modeled simultaneously and adjusting for age and sex distribution, only COVID-19 vaccine coverage and SARS-CoV-2 incidence were significantly associated with Long COVID prevalence. COVID-19 vaccine coverage showed a strong protective association, while SARS-CoV-2 incidence showed a modest positive association. Multimorbidity and hospitalization rates were not independently associated with adjustment.

ConclusionsState-level variation in Long COVID burden appears most strongly driven by COVID-19 vaccine coverage and SARS-CoV-2 incidence. Promoting COVID-19 vaccination remains essential to reduce long-term impacts from SARS-CoV-2 infections.
]]></description>
</item>
<item rdf:about="https://www.biorxiv.org/content/10.64898/2026.03.03.709420v1?rss=1">
<title>
<![CDATA[
Computational Study of Antibody Binding to SARS-CoV-2 Variants 
]]>
</title>
<link>
https://www.biorxiv.org/content/10.64898/2026.03.03.709420v1?rss=1"
</link>
<dc:creator>Chiu, C.</dc:creator>
<dc:creator>Jawaid, M. Z.</dc:creator>
<dc:creator>Cox, D. L.</dc:creator>
<dc:date>2026-03-09</dc:date>
<dc:identifier>doi:10.64898/2026.03.03.709420</dc:identifier>
<dc:title><![CDATA[Computational Study of Antibody Binding to SARS-CoV-2 Variants]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory Press</dc:publisher>
<prism:publicationDate>2026-03-09</prism:publicationDate>
<prism:section></prism:section>
<description><![CDATA[
Background/ObjectivesThe unprecedented structural and binding data for antibodies to the SARS-COV2 virus taken together with the mutations for the spike protein allows for a broad simulation study of antibody-spike protein binding. This provides an understanding of the co-evolution of human immunity and viral immunity escape.

MethodsWe utilized the YASARA molecular dynamics program to generate initial antibody-spike structures and simulate to equilibration for six SARS-COV2 variants and 10 different antibodies sampling two different binding regions to the receptor binding domain of the spike (especially for the Class I antibodies in the same part of the spike which attaches to the ACE2 receptor protein) and one to the N-terminal of the spike. Starting structures for antibody binding to variant spike proteins are perturbatively achieved through point mutations and insertions/deletions in the YASARA program. We employed YASARA to measure interfacial hydrogen bound counts between antibodies and variant spike proteins, and the HawkDock MMGBSA program to characterize trends in binding energies with mutation for four of the antibodies. We utilized the VMD program to analyze the time course of hydrogen bond populations.

ResultsAs seen in previous studies, interfacial hydrogen bond counts serve as an excellent proxy for binding energies without the large systematic error inherent in the latter. We find that there is generally a decline in antibody binding strength, as measured by interfacial hydrogen bond counts, with viral evolution, but that a modest re-entrance of binding strength is present for most antibodies studied. Generically, the antibody heavy chain binds more strongly to the spike protein, through for approximately half the antibodies the light chain binding strength converges to the heavy chain strength with viral evolution.

ConclusionsThe key conclusion is that the identified re-entrant immunity, speculatively arising from a balancing of maintenance of ACE2-spike binding while escaping antibodies through mutation, allows for some maintenance and even strengthening of immunity for later viral strains from early infection or vaccination.
]]></description>
</item>
<item rdf:about="https://www.biorxiv.org/content/10.64898/2026.03.06.710084v1?rss=1">
<title>
<![CDATA[
Molecular Characterization of SARS-CoV-2 N Protein Interfaces: Implications for Oligomerization, RNA Binding, and Phase Separation 
]]>
</title>
<link>
https://www.biorxiv.org/content/10.64898/2026.03.06.710084v1?rss=1"
</link>
<dc:creator>Bairy, S. G.</dc:creator>
<dc:creator>Prasad, T. K.</dc:creator>
<dc:creator>Saravana Kumar, Y.</dc:creator>
<dc:creator>Ganavi, B.</dc:creator>
<dc:creator>S, S.</dc:creator>
<dc:creator>S, S.</dc:creator>
<dc:creator>Baskaran, S. P.</dc:creator>
<dc:creator>Sounderrajan, V.</dc:creator>
<dc:creator>Parthasarathy, K.</dc:creator>
<dc:creator>Kamariah, N.</dc:creator>
<dc:date>2026-03-06</dc:date>
<dc:identifier>doi:10.64898/2026.03.06.710084</dc:identifier>
<dc:title><![CDATA[Molecular Characterization of SARS-CoV-2 N Protein Interfaces: Implications for Oligomerization, RNA Binding, and Phase Separation]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory Press</dc:publisher>
<prism:publicationDate>2026-03-06</prism:publicationDate>
<prism:section></prism:section>
<description><![CDATA[
The SARS-CoV-2 nucleocapsid (N) protein is central to genomic RNA recognition, condensation, and packaging, yet the molecular organization of its multivalent N-N and N-RNA interaction network involved in this process remains unclear. Here, we define the oligomerization and RNA-binding interfaces of the C-terminal domain (CTD) and its flanking intrinsically disordered regions (IDRs), the leucine-rich helix (LH) and the C-terminal IDR (C-IDR), using size-exclusion chromatography (SEC), cross-linking, mutational studies and NMR spectroscopy. We identify discrete oligomerization interfaces within the CTD and C-IDR that drive higher-order assembly, and show, through liquid-liquid phase separation (LLPS) and electron microscopy (EM), that C-IDR residues are essential for RNA-induced condensate formation. Moreover, the mapping of RNA-binding residues highlights Arg277 as a conserved determinant of CTD-RNA recognition. Notably, the two IDRs exert opposing regulatory effects on RNA binding, with the C-IDR enhancing and the LH attenuating CTD-RNA interactions. Together, these findings reveal how cooperative interfaces between the CTD and its flanking IDRs orchestrate N-protein oligomerization and RNA condensate formation and highlight potential intervention sites for disrupting SARS-CoV-2 ribonucleoprotein assembly.
]]></description>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.03.04.26347661v1?rss=1">
<title>
<![CDATA[
Chronic absenteeism in Canadian kindergarten classes, pre- and post-COVID-19, and its association with concurrent developmental vulnerability 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.03.04.26347661v1?rss=1"
</link>
<dc:creator>Reid-Westoby, C.</dc:creator>
<dc:creator>Duku, E.</dc:creator>
<dc:creator>Gaskin, A.</dc:creator>
<dc:creator>Janus, M.</dc:creator>
<dc:date>2026-03-05</dc:date>
<dc:identifier>doi:10.64898/2026.03.04.26347661</dc:identifier>
<dc:title><![CDATA[Chronic absenteeism in Canadian kindergarten classes, pre- and post-COVID-19, and its association with concurrent developmental vulnerability]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory Press</dc:publisher>
<prism:publicationDate>2026-03-05</prism:publicationDate>
<prism:section></prism:section>
<description><![CDATA[
Students who frequently miss school are at greater risk for academic difficulty. High levels of absenteeism as early as kindergarten have been associated with long-term consequences, such as low reading proficiency in Grade 3 and low academic achievement in Grade 5, both of which have been associated with lower rates of high school graduation and enrollment in post-secondary education. The prevalence of school absenteeism has increased significantly since the COVID-19 pandemic and there have been sustained shifts in student attendance rates from kindergarten to Grade 12 since 2020. The goals of this population-level, repeated cross-sectional cohort study were to compare rates of chronic absenteeism, defined as being absent from school at least 10% of the time, in kindergarten in Canada before and after the onset of the COVID-19 pandemic, and examine the association between childrens chronic absenteeism and their concurrent developmental vulnerability. A total of 513,159 kindergarten children participated in the study, with 284,712 (55.5%) being in the pre-COVID-19 cohort (2017-2020) and 228,447 (44.5%) in the post-COVID-19 cohort (2020-2023). Across Canada, rates of chronic absenteeism increased from pre- to post-COVID-19, from 17.7% to 41.3%, with differences by jurisdiction. The greatest increase was seen in Ontario, while the smallest increase was seen in British Columbia. Children attending kindergarten in the post-COVID-19 cohort were three times more likely to be chronically absent compared to their peers attending kindergarten before the onset of the pandemic. Despite this, chronic absenteeism in the post-COVID-19 period was associated with reduced odds of overall developmental vulnerability, a pattern that is likely attributable to shifts in the composition of chronically absent children. In the post-COVID-19 cohort, a greater percentage of children who were chronically absent resided in higher SES neighbourhoods compared to their chronically absent peers attending school before the onset of the pandemic. While increasing rates of school absenteeism should not be ignored, our results suggest that chronic absenteeism following COVID-19 might be more nuanced than before. The jurisdictional differences in rates of chronic absenteeism observed in this study could be due to the various public health measures put in place by the various provincial and territorial governments. It is also possible that the children from higher SES neighbourhoods missed more school after the onset of the COVID-19 pandemic because their parents had the capability to work from home, making it easier to keep their child(ren) home from school. The decreased association between chronic absenteeism and developmental vulnerability post-COVID-19 may reflect improved access to online resources, which enables students to stay on track academically from home. Gaining a better understanding of the reasons behind missing school and the relation between absenteeism and academic achievement at various developmental stages is crucial to support successful learning trajectories.
]]></description>
</item>
<item rdf:about="https://www.biorxiv.org/content/10.64898/2026.03.04.703990v1?rss=1">
<title>
<![CDATA[
A macrocyclic peptide-based fusion inhibitor targeting SARS-CoV-2 Spike S2 subunit 
]]>
</title>
<link>
https://www.biorxiv.org/content/10.64898/2026.03.04.703990v1?rss=1"
</link>
<dc:creator>Ohashi, H.</dc:creator>
<dc:creator>Kawamura, T.</dc:creator>
<dc:creator>Ohuchi, M.</dc:creator>
<dc:creator>Kurasaki, H.</dc:creator>
<dc:creator>Iwata-Yoshikawa, N.</dc:creator>
<dc:creator>Hirata, Y.</dc:creator>
<dc:creator>Moriyama, S.</dc:creator>
<dc:creator>Shionoya, K.</dc:creator>
<dc:creator>Nagatomo, K.</dc:creator>
<dc:creator>Nagasawa, T.</dc:creator>
<dc:creator>Yamamoto, J.</dc:creator>
<dc:creator>Sudo, K.</dc:creator>
<dc:creator>Nakamura, N.</dc:creator>
<dc:creator>Matsui, K.</dc:creator>
<dc:creator>Ogawa, H.</dc:creator>
<dc:creator>Yoshida, K.</dc:creator>
<dc:creator>Shimada, Y.</dc:creator>
<dc:creator>Maruyama, T.</dc:creator>
<dc:creator>Higuchi, T.</dc:creator>
<dc:creator>Ito, S.</dc:creator>
<dc:creator>Takahashi, Y.</dc:creator>
<dc:creator>Kawamura, N.</dc:creator>
<dc:creator>Reid, P. C.</dc:creator>
<dc:creator>Murakami, M.</dc:creator>
<dc:creator>Suzuki, T.</dc:creator>
<dc:creator>Nagata, N.</dc:creator>
<dc:creator>Kitamura, H.</dc:creator>
<dc:creator>Watashi, K.</dc:creator>
<dc:date>2026-03-05</dc:date>
<dc:identifier>doi:10.64898/2026.03.04.703990</dc:identifier>
<dc:title><![CDATA[A macrocyclic peptide-based fusion inhibitor targeting SARS-CoV-2 Spike S2 subunit]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory Press</dc:publisher>
<prism:publicationDate>2026-03-05</prism:publicationDate>
<prism:section></prism:section>
<description><![CDATA[
Continuous emergence of SARS-CoV-2 variants carrying mutations in Spike presents a significant challenge for durable antiviral agents. Here we screen for random 13-amino acid non-mimetic macrocyclic peptides that bind to Spike and identify PA-001 that inhibits SARS-CoV-2 infection with high potency at 0.23-2.9 nM as 50% inhibitory concentration (IC50). PA-001 bound to Spike S2 subunit and inhibited the membrane fusion during virus entry. Through drug-resistant selection, we revealed that PA-001 targeted the fusion peptide proximal region (FPPR) in S2, which has not been recognized as a drug target to date. Consistent with its highly conserved amino acid sequences beyond strains, PA-001 exhibited broad antiviral activity against all tested SARS-CoV-2 variants, in contrast to clinically-approved S1-targeting antibodies that lost activity to Omicron variants. PA-001 suppressed SARS-CoV-2 propagation and disease progression in mouse- and hamster-infection models, both by administration prophylactically and therapeutically. Combination therapy with remdesivir further enhanced antiviral profiles. In clinical phase-I trial, PA-001 was well-tolerated and showed high systemic exposure, with 4,300-10,300-fold concentration of IC50 as maximum plasma concentration by single administration to healthy volunteers. These evidence propose FPPR as an unexpected antiviral drug target accessible by macrocyclic peptides and identify PA-001 as a potent anti-SARS-CoV-2 fusion inhibitor.
]]></description>
</item>
<item rdf:about="https://www.biorxiv.org/content/10.64898/2026.03.04.709710v1?rss=1">
<title>
<![CDATA[
Investigating the use of human COVID-19 rapid assays to detect antibody and antigen in domesticated dogs (Canis lupus familiaris) and cats (Felis catus) 
]]>
</title>
<link>
https://www.biorxiv.org/content/10.64898/2026.03.04.709710v1?rss=1"
</link>
<dc:creator>Cybulska, L. C.</dc:creator>
<dc:creator>Hamer, S. A.</dc:creator>
<dc:creator>Teasdale, C.</dc:creator>
<dc:creator>Johnson, G.</dc:creator>
<dc:creator>Hamer, G.</dc:creator>
<dc:creator>Grassman, J.</dc:creator>
<dc:date>2026-03-05</dc:date>
<dc:identifier>doi:10.64898/2026.03.04.709710</dc:identifier>
<dc:title><![CDATA[Investigating the use of human COVID-19 rapid assays to detect antibody and antigen in domesticated dogs (Canis lupus familiaris) and cats (Felis catus)]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory Press</dc:publisher>
<prism:publicationDate>2026-03-05</prism:publicationDate>
<prism:section></prism:section>
<description><![CDATA[
Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), the virus that causes coronavirus disease-2019 (COVID-19) in humans, is also known to infect animals including dogs (Canis lupus familiaris) and cats (Felis catus). This study evaluated the efficacy of human COVID-19 rapid antigen and antibody tests in dogs and cats. Nasal/oral swabs from 60 animals (32 dogs, 28 cats) and serum from 40 animals (20 dogs, 20 cats) were tested. Rapid antigen tests used on respiratory swabs showed low-to-moderate sensitivity (75% dogs, 57% cats) and moderate-to-high specificity (79% dogs, 95% cats) compared to RT-PCR. Rapid antibody tests used on serum samples demonstrated low-to-moderate sensitivity (70% dogs, 50% cats) and moderate-high specificity (60% dogs, 100% cats) compared to PRNT. While imperfect, these test kits may have some utility for field surveillance studies, particularly when species-specific rapid SARS-CoV-2 assays for dogs and cats are unavailable. These test characteristics in dogs and cats are similar to the findings from studies of the same types of tests in humans which have found an average sensitivity and specificity of common commercially available kits in the US range from 50.0-84.3% and 64.5-74.3%, respectively, when used with human samples (1,2).
]]></description>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.02.27.26346872v1?rss=1">
<title>
<![CDATA[
Outburst of serotype 4 IPD after COVID-19 is driven by ST15063/GPSC162 lineage associated with high-risk behaviors and greater virulence linked to influenza H3N2 virus coinfection and cigarette smoke 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.02.27.26346872v1?rss=1"
</link>
<dc:creator>Perez-Garcia, C.</dc:creator>
<dc:creator>Llorente, J.</dc:creator>
<dc:creator>Aguirre Alustuey, M. E.</dc:creator>
<dc:creator>Llamosi, M.</dc:creator>
<dc:creator>Gil, R.</dc:creator>
<dc:creator>Lahlali, G.</dc:creator>
<dc:creator>El-Ayache, F.</dc:creator>
<dc:creator>Yan, V.</dc:creator>
<dc:creator>Schotsaert, M.</dc:creator>
<dc:creator>Del Diego, J.</dc:creator>
<dc:creator>Cisneros, J. M.</dc:creator>
<dc:creator>Garcia-Sastre, A.</dc:creator>
<dc:creator>Domenech, M.</dc:creator>
<dc:creator>Sempere, J.</dc:creator>
<dc:creator>Yuste, J.</dc:creator>
<dc:date>2026-03-04</dc:date>
<dc:identifier>doi:10.64898/2026.02.27.26346872</dc:identifier>
<dc:title><![CDATA[Outburst of serotype 4 IPD after COVID-19 is driven by ST15063/GPSC162 lineage associated with high-risk behaviors and greater virulence linked to influenza H3N2 virus coinfection and cigarette smoke]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory Press</dc:publisher>
<prism:publicationDate>2026-03-04</prism:publicationDate>
<prism:section></prism:section>
<description><![CDATA[
The emergence of vaccine covered serotypes causing invasive pneumococcal disease (IPD) is a serious concern worldwide. We investigated the unexpected rise of serotype 4 causing IPD primarily in non-vaccinated young adults after the COVID-19 pandemic that further spread to adults [&ge;] 65 years in recent years. For this purpose, we conducted a retrospective study of serotype 4 IPD cases (n=827) reported in Spain between 2009 and 2024. Whole-genome sequencing was performed to assess clonal lineages and phylogenetic relationships. Clinical and epidemiological data were compared between serotype 4 and all other serotypes causing IPD. Epidemiological and genomic analysis confirmed that the rise started as an abrupt cluster of IPD cases in Seville (Andalusia) in the year 2022 due to the ST15063 within GPSC12 lineage. This outbreak initially caused pneumonia episodes that required hospitalization in young individuals associated with high rates of tobacco smoking, alcohol, and inhaled drugs such as cannabis and cocaine, followed by a general distribution pattern throughout the country in the following years, affecting the elderly population. Experimental studies to evaluate potential underlying mechanisms confirmed that ST15063 serotype 4 strains displayed enhanced infection rates of human lung cells that significantly increased in the presence of cigarette smoke exposure and by influenza H3N2 virus coinfection, but not with H1N1. These findings highlight the need for targeted vaccination strategies not only against pneumococcus but also against respiratory viruses such as influenza, RSV and COVID-19 and demonstrate the importance of molecular surveillance to establish effective interventions in high-risk populations.
]]></description>
</item>
<item rdf:about="https://www.biorxiv.org/content/10.64898/2026.03.02.708985v1?rss=1">
<title>
<![CDATA[
Microfilaremic loiasis is associated with T cell hyporesponsiveness against SARS CoV-2 
]]>
</title>
<link>
https://www.biorxiv.org/content/10.64898/2026.03.02.708985v1?rss=1"
</link>
<dc:creator>Auge-Stock, M.</dc:creator>
<dc:creator>Okwu, D. G.</dc:creator>
<dc:creator>More, A.</dc:creator>
<dc:creator>Doralt, A.</dc:creator>
<dc:creator>Bikangui, R.</dc:creator>
<dc:creator>Boussoukou, I. P. M.</dc:creator>
<dc:creator>Eberhardt, K. A.</dc:creator>
<dc:creator>Sandkuhl, M.</dc:creator>
<dc:creator>Zoleko Manego, R.</dc:creator>
<dc:creator>Mombo Ngoma, G.</dc:creator>
<dc:creator>McCall, M.</dc:creator>
<dc:creator>Breloer, M.</dc:creator>
<dc:creator>Esen, M.</dc:creator>
<dc:creator>Addo, M.</dc:creator>
<dc:creator>Lell, B.</dc:creator>
<dc:creator>Veletzky, L.</dc:creator>
<dc:creator>Adamou, R.</dc:creator>
<dc:creator>Mackroth, M. S.</dc:creator>
<dc:date>2026-03-04</dc:date>
<dc:identifier>doi:10.64898/2026.03.02.708985</dc:identifier>
<dc:title><![CDATA[Microfilaremic loiasis is associated with T cell hyporesponsiveness against SARS CoV-2]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory Press</dc:publisher>
<prism:publicationDate>2026-03-04</prism:publicationDate>
<prism:section></prism:section>
<description><![CDATA[
BackgroundLoiasis is a chronic filarial infection endemic to Central and West Africa. Although long considered benign, increasing evidence links loiasis to substantial morbidity and mortality. The infection is associated with immune modulation, including Th2-skewed responses and elevated regulatory cytokines. Clinically, loiasis is classified as microfilaremic (presence of circulating microfilariae) or amicrofilaremic ("occult") disease, the latter defined by a history of eyeworm migration without detectable microfilaremia. This study investigated how chronic L. loa infection influences antibody and T cell responses to SARS-CoV-2 following natural infection.

MethodsBetween 2022 and 2024 this cross-sectional study was done in Lambarene and surrounding rural areas of Gabon. Study procedures included diagnostics for loiasis and immunological assays. Microfilaremia was confirmed by stained blood smear microscopy, and occult disease was identified using the Rapid Assessment Procedure for Loiasis. SARS-CoV-2-specific IgG responses to spike and nucleocapsid proteins were measured by ELISA, and IFN-{gamma} responses to spike antigen were assessed using an interferon-gamma release assay.

ResultsOverall, 192 participants were categorized as microfilaremic (n=43), occult loiasis (n=59), or without evidence of active loiasis (n=90). IFN-{gamma} responses were reduced in microfilaremic individuals compared with other participants (p= 0.031), whereas IgG responses did not differ. Subsequent analysis across the three groups confirmed that IFN-{gamma} responses were lower in microfilaremic compared with occult participants (p= 0.012).

ConclusionThese findings suggest that microfilaremic loiasis may impair proinflammatory T cell responses to viral antigens, highlighting the need for further research into the broader immunological effects of Loa loa infection in endemic populations.

Authors summaryLoiasis is a parasitic infection caused by the worm Loa loa and is common in parts of Central and West Africa. Although long considered relatively benign, growing evidence indicates that loiasis is associated with substantial morbidity. The immunological consequences of chronic Loa loa infection remain poorly understood. A small number of studies suggest that Loa loa may influence immune regulation, but its broader impact on antiviral immunity is largely unknown.

The COVID-19 pandemic provided a unique opportunity to examine immune responses to a newly emerging virus in a population where loiasis is endemic. We therefore investigated how different forms of Loa loa infection influence immune responses after natural SARS-CoV-2 infection. We compared individuals with circulating microfilariae in their blood (microfilaremic), individuals with occult loiasis (history of eye worm), and individuals without signs of active infection.

We found that microfilaremic individuals had weaker virus-specific IFN-{gamma} T cell responses, while antibody levels were similar across groups. These findings suggest that active loiasis may dampen certain antiviral immune functions. Understanding the underlying mechanisms is important, as such immune modulation could affect responses to vaccines and other infectious diseases in endemic regions.
]]></description>
</item>
<item rdf:about="https://www.biorxiv.org/content/10.64898/2026.03.03.709398v1?rss=1">
<title>
<![CDATA[
Defining the Antigenic Topology and Prospective Binding Breadth of Vaccination-induced SARS-CoV-2 Neutralizing Antibodies 
]]>
</title>
<link>
https://www.biorxiv.org/content/10.64898/2026.03.03.709398v1?rss=1"
</link>
<dc:creator>Jaiswal, D.</dc:creator>
<dc:creator>Altomare, C. G.</dc:creator>
<dc:creator>Adelsberg, D. C.</dc:creator>
<dc:creator>Sapse, I. A.</dc:creator>
<dc:creator>Krammer, F.</dc:creator>
<dc:creator>Simon, V.</dc:creator>
<dc:creator>Ellebedy, A. H.</dc:creator>
<dc:creator>Bajic, G.</dc:creator>
<dc:date>2026-03-04</dc:date>
<dc:identifier>doi:10.64898/2026.03.03.709398</dc:identifier>
<dc:title><![CDATA[Defining the Antigenic Topology and Prospective Binding Breadth of Vaccination-induced SARS-CoV-2 Neutralizing Antibodies]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory Press</dc:publisher>
<prism:publicationDate>2026-03-04</prism:publicationDate>
<prism:section></prism:section>
<description><![CDATA[
Antibodies that neutralize SARS-CoV-2 primarily target the viral spike glycoprotein, yet the breadth of these responses is continually challenged by viral evolution. While extensive structural studies have defined epitopes across the spike protein, how antibodies elicited by the initial mRNA vaccination campaigns perform against subsequently emerging variants remains an important question. Here, we structurally and functionally characterize a panel of early plasmablast-derived human monoclonal antibodies isolated following primary mRNA vaccination, targeting both the receptor-binding domain (RBD) and the N-terminal domain (NTD) of spike. Using cryo-electron microscopy, variant-binding analyses, and viral-fusion inhibition assays, we observe that antibodies directed against immunodominant regions of the RBD and NTD are highly potent but more frequently impacted by variant-associated mutations. In contrast, antibodies engaging a conserved hydrophobic pocket within the NTD exhibit broader reactivity and neutralize through distinct molecular mechanisms. Together, these findings extend prior structural studies of spike-directed antibodies by prospectively assessing the breadth of vaccine-elicited antibodies against later variants and identifying structural features associated with differential escape sensitivity. These results contribute to a growing understanding of how early vaccine-induced antibody repertoires relate to subsequent viral evolution.

One sentence summaryAntibody epitopes on SARS-CoV-2 spike determine prospective breadth and vulnerability to viral evolution.
]]></description>
</item>
<item rdf:about="https://www.biorxiv.org/content/10.64898/2026.03.04.709525v1?rss=1">
<title>
<![CDATA[
Fluorinated RNA origami enables serum-stable nanodevices for sensing and targeting 
]]>
</title>
<link>
https://www.biorxiv.org/content/10.64898/2026.03.04.709525v1?rss=1"
</link>
<dc:creator>Kristoffersen, E. L.</dc:creator>
<dc:creator>Zwergius, N. H.</dc:creator>
<dc:creator>Sampedro Vallina, N.</dc:creator>
<dc:creator>Stange, A. D.</dc:creator>
<dc:creator>Desdorf, L. M.</dc:creator>
<dc:creator>Thomsen, S.</dc:creator>
<dc:creator>Birkedal, V.</dc:creator>
<dc:creator>Glück, N.</dc:creator>
<dc:creator>Civit, L.</dc:creator>
<dc:creator>Geary, C.</dc:creator>
<dc:creator>Kjems, J.</dc:creator>
<dc:creator>Valero, J.</dc:creator>
<dc:creator>Andersen, E. S.</dc:creator>
<dc:date>2026-03-04</dc:date>
<dc:identifier>doi:10.64898/2026.03.04.709525</dc:identifier>
<dc:title><![CDATA[Fluorinated RNA origami enables serum-stable nanodevices for sensing and targeting]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory Press</dc:publisher>
<prism:publicationDate>2026-03-04</prism:publicationDate>
<prism:section></prism:section>
<description><![CDATA[
Chemically modified RNAs with increased stability and reduced immunogenicity have transformed RNA therapeutics. Rational RNA design methods, including RNA origami, seek to further extend RNA medicine and biotechnology by encoding advanced functions such as signalling, targeting, and controlled release within the RNA polymer. However, current design methods lack the ability to integrate chemical modification or predict how it shapes the structure of large RNA assemblies inhibiting its use in RNA therapeutics. Here we demonstrate that 2-fluoro pyrimidine RNA (FY-RNA) origami structures can be co-transcriptionally folded to generate serum-stable nanodevices. Cryogenic electron microscopy reveals that FY-RNA can alter folding pathways and perturb tertiary motifs, while molecular dynamics simulations show how 2-fluoro modification affects hydrogen bonding, sugar pucker, and helix-helix interactions. Despite these structural perturbations, fluorogenic aptamers embedded within RNA origami retain partial activity and enable logic-based molecular sensing in human serum. Finally, we use an FY-RNA scaffold to determine the structure of an FY-RNA anti-Spike aptamer bound to the Spike protein at 3.4 [A] resolution, uncovering fluorine-specific structural motifs and protein interactions. Together, our results establish design principles for nuclease-resistant RNA architectures and position FY-RNA as a versatile polymer for constructing medical nanodevices and environmental sensors. More broadly, this work provides a framework for systematically exploring the folding landscape of chemically modified RNAs, expanding the chemical and functional diversity accessible to nucleic acid nanotechnology and RNA medicine.
]]></description>
</item>
<item rdf:about="https://www.biorxiv.org/content/10.64898/2026.03.03.709384v1?rss=1">
<title>
<![CDATA[
Exposure route drives SARS-CoV-2 infection patterns in non-human primates 
]]>
</title>
<link>
https://www.biorxiv.org/content/10.64898/2026.03.03.709384v1?rss=1"
</link>
<dc:creator>Snedden, C. E.</dc:creator>
<dc:creator>Morris, D.</dc:creator>
<dc:creator>Friedrich, T.</dc:creator>
<dc:creator>Lloyd-Smith, J. O.</dc:creator>
<dc:date>2026-03-04</dc:date>
<dc:identifier>doi:10.64898/2026.03.03.709384</dc:identifier>
<dc:title><![CDATA[Exposure route drives SARS-CoV-2 infection patterns in non-human primates]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory Press</dc:publisher>
<prism:publicationDate>2026-03-04</prism:publicationDate>
<prism:section></prism:section>
<description><![CDATA[
Public health policy and clinical interventions against infectious diseases rely on understanding the factors that govern the initiation and progression of infections inside hosts. Animal infection experiments are essential tools to study these complex, multi-scale processes under controlled conditions, and they have shown that the dose and route of exposure can influence within-host disease dynamics. However, observed differences are difficult to quantify and to disentangle from confounding factors because small sample sizes limit the statistical power and scientific scope of individual studies. Here, by compiling and analyzing the largest published database of non-human primate challenge experiments (107 studies; 721 animals; 22,183 observations), we quantify how exposure conditions and demographic factors shape within-host SARS-CoV-2 infection kinetics in the respiratory and gastrointestinal tracts. We show that exposure route has stronger effects on kinetics than dose, age, sex, or species, with directly exposed tissues exhibiting distinct spatiotemporal kinetics from non-exposed tissues. We estimate 50% infectious doses for different tissues and show that they vary greatly (from <101.2 up to >107.4 pfu) depending on the exposure route. We find that dose effects on kinetics are also route-and tissue-specific, primarily influencing nasally-inoculated animals. Our results suggest that exposure route drives infection kinetics more strongly than dose in a critical model system for translational medicine, and they demonstrate the untapped potential for meta-analysis to extract additional insights from costly animal experiments.
]]></description>
</item>
<item rdf:about="https://www.biorxiv.org/content/10.64898/2026.03.02.709177v1?rss=1">
<title>
<![CDATA[
A new mRNA antigen vaccine induces potent B and T cell responses and in vivo protection against SARS-CoV-2 
]]>
</title>
<link>
https://www.biorxiv.org/content/10.64898/2026.03.02.709177v1?rss=1"
</link>
<dc:creator>Wen, J.</dc:creator>
<dc:creator>Moon, J.</dc:creator>
<dc:creator>Tucciarone, L.</dc:creator>
<dc:creator>Bu, T.-H.</dc:creator>
<dc:creator>Sun, A. Y.</dc:creator>
<dc:creator>Miller, R.</dc:creator>
<dc:creator>Timis, J.</dc:creator>
<dc:creator>Wu, L.</dc:creator>
<dc:creator>Smith, D. M.</dc:creator>
<dc:creator>Shresta, S.</dc:creator>
<dc:creator>Gaulton, K. J.</dc:creator>
<dc:creator>Rana, T. M.</dc:creator>
<dc:date>2026-03-03</dc:date>
<dc:identifier>doi:10.64898/2026.03.02.709177</dc:identifier>
<dc:title><![CDATA[A new mRNA antigen vaccine induces potent B and T cell responses and in vivo protection against SARS-CoV-2]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory Press</dc:publisher>
<prism:publicationDate>2026-03-03</prism:publicationDate>
<prism:section></prism:section>
<description><![CDATA[
The SARS-CoV-2 mRNA vaccine provides effective protection against viral infection and severe disease by inducing efficient adaptive immunity. However, vaccine efficacy is decreased against emerging variants, and immune memory is relatively short-lived. Here, we added new T cell epitopes to the RBD (receptor-binding domain) mRNA vaccine and identified a SARS-CoV-2 membrane epitope that significantly improved vaccine-induced immunity and protection in vivo. That new vaccine, designated G1-C, induced 8.2-fold higher levels of RBD-specific antibodies than did RBD and enhanced spike-specific T cell and B cell responses. Remarkably, the G1-C modulated hematopoietic stem cell (HSC) differentiation and increased levels of B and NK cells by regulating multiple signaling pathways in bone marrow potentially via Fos, Klf4, and Klf6 transcription factors. Altogether, these findings identify a new vaccine candidate to control viral infection by affecting the lymphoid-myeloid lineage bias and suggest the potential role of T cell epitopes in vaccine design and development.
]]></description>
</item>
<item rdf:about="https://www.biorxiv.org/content/10.64898/2026.02.27.708159v1?rss=1">
<title>
<![CDATA[
Antigenic landscape of a highly mutated SARS-CoV-2 Spike in ongoing viral evolution 
]]>
</title>
<link>
https://www.biorxiv.org/content/10.64898/2026.02.27.708159v1?rss=1"
</link>
<dc:creator>Turelli, P.</dc:creator>
<dc:creator>Eray, E.</dc:creator>
<dc:creator>Raclot, C.</dc:creator>
<dc:creator>Trono, D.</dc:creator>
<dc:creator>Antanasijevic, A.</dc:creator>
<dc:date>2026-02-27</dc:date>
<dc:identifier>doi:10.64898/2026.02.27.708159</dc:identifier>
<dc:title><![CDATA[Antigenic landscape of a highly mutated SARS-CoV-2 Spike in ongoing viral evolution]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory Press</dc:publisher>
<prism:publicationDate>2026-02-27</prism:publicationDate>
<prism:section></prism:section>
<description><![CDATA[
The ongoing emergence of SARS-CoV-2 variants in an increasingly immune-experienced population is largely enabled by the plasticity of the Spike protein, which lies at the frontline of host immune pressure. Here, we investigated how extensive remodeling of the N-terminal domain (NTD) in Spike influences its antigenic properties. Using BA.2.87.1, a variant heavily mutated in this domain, we found that even large deletions do not substantially disrupt overall Spike structure or pseudovirus infectivity. However, our structural and binding analyses revealed that the NTD exhibits increased flexibility and that interaction with a heme-metabolite, contributing to assembly of an immunodominant epitope, is lost. These conformational effectscoupled with mutations, compromised the ability of human convalescent antibodies to engage this domain, contributing to their reduced neutralizing capacity. Consequently, BA.2.87.1-like variants may escape recognition by the pre-existing NTD-targeting antibodies, potentially reducing protection. Together, our results highlight the intrinsic adaptability of the Spike beyond the receptor-binding domain, with important implications for immune escape during viral evolution.

TeaserStructural flexibility of the Spike and immune escape of a SARS-CoV-2 variant with public health implications.
]]></description>
</item>
<item rdf:about="https://www.biorxiv.org/content/10.64898/2026.02.26.708234v1?rss=1">
<title>
<![CDATA[
Identifying severe COVID-19 risk variants modulating enhancer reporter activity in lung cells 
]]>
</title>
<link>
https://www.biorxiv.org/content/10.64898/2026.02.26.708234v1?rss=1"
</link>
<dc:creator>Weykopf, G.</dc:creator>
<dc:creator>Bickmore, W. A.</dc:creator>
<dc:creator>Biddie, S. C.</dc:creator>
<dc:creator>Friman, E. T.</dc:creator>
<dc:date>2026-02-26</dc:date>
<dc:identifier>doi:10.64898/2026.02.26.708234</dc:identifier>
<dc:title><![CDATA[Identifying severe COVID-19 risk variants modulating enhancer reporter activity in lung cells]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory Press</dc:publisher>
<prism:publicationDate>2026-02-26</prism:publicationDate>
<prism:section></prism:section>
<description><![CDATA[
Common genetic variants contribute to risk for complex human diseases. However, despite thousands of associations, variants modulating disease risk and their functional impact remain largely unknown. This includes SARS-CoV-2 infection, where outcomes range from asymptomatic to fatal. Most host risk variants associated with COVID-19 disease, identified through genome wide association studies, are located in the non-coding genome and may function by altering gene expression in disease-relevant cells and tissues. To address this at scale, we tested >4800 severe COVID-19-associated variants to determine the impact of individual variants and variant combinations on regulatory activity using Self-Transcribing Active Regulatory Region sequencing, a massively-parallel reporter assay, in a lung epithelial cell line (A549). We identify 166 variants within active sequences, of which 29 modulate activity allele-specifically. Evaluating variant combinations, we observe both additive and non-additive effects on regulatory activity. We employ state-of-the-art deep learning models to interpret allele-specific variant effects on regulatory activity and endogenous genomic features. Our work provides a set of prioritised severe COVID-19-associated variants that modulate regulatory activity in lung epithelial cells, candidate transcription factors, and candidate target genes with potential to be disease modifying.
]]></description>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.02.23.26346887v1?rss=1">
<title>
<![CDATA[
Bayesian generative modeling for heterogeneous wastewater data applied to COVID-19 forecasting 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.02.23.26346887v1?rss=1"
</link>
<dc:creator>Johnson, K. E.</dc:creator>
<dc:creator>Vega Yon, G.</dc:creator>
<dc:creator>Brand, S. P. C.</dc:creator>
<dc:creator>Bernal Zelaya, C.</dc:creator>
<dc:creator>Bayer, D.</dc:creator>
<dc:creator>Volkov, I.</dc:creator>
<dc:creator>Susswein, Z.</dc:creator>
<dc:creator>Magee, A.</dc:creator>
<dc:creator>Gostic, K. M.</dc:creator>
<dc:creator>English, K. M.</dc:creator>
<dc:creator>Ghinai, I.</dc:creator>
<dc:creator>Hamlet, A.</dc:creator>
<dc:creator>Olesen, S. W.</dc:creator>
<dc:creator>Pulliam, J.</dc:creator>
<dc:creator>Abbott, S.</dc:creator>
<dc:creator>Morris, D. H.</dc:creator>
<dc:date>2026-02-24</dc:date>
<dc:identifier>doi:10.64898/2026.02.23.26346887</dc:identifier>
<dc:title><![CDATA[Bayesian generative modeling for heterogeneous wastewater data applied to COVID-19 forecasting]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory Press</dc:publisher>
<prism:publicationDate>2026-02-24</prism:publicationDate>
<prism:section></prism:section>
<description><![CDATA[
Infectious disease forecasts can inform public health decision-making. Wastewater monitoring is a relatively new epidemiological data source with multiple potential applications, including forecasting. Incorporating wastewater data into epidemiological forecasting models is challenging, and relatively few studies have assessed whether this improves forecast performance. We present and evaluate a semi-mechanistic wastewater-informed forecasting model. The model forecasts COVID-19 hospital admissions at the state and territorial levels in the United States, based on incident hospital admissions data and, optionally, SARS-CoV-2 wastewater concentration data from multiple wastewater sampling sites. From February through April 2024, we produced real-time wastewater-informed COVID-19 forecasts using development versions of the model and submitted them to the United States COVID-19 Forecast Hub ("the Hub"). We then published an open-source R package, wwinference, that implements the model with or without wastewater as an input. Using proper scoring rules and measures of model calibration, we assess both our real-time submissions to the Hub and retrospective hypothetical forecasts from wwinference made with and without wastewater data. While the models performed similarly with and without the wastewater signal included, there was substantial heterogeneity for individual locations and dates where wastewater data meaningfully improved or degraded the models forecast performance. Compared to other models submitted to the Hub during the period spanned by our submissions, the real-time wastewater-informed version of our model ranked fourth of 10 models, with the hospital admissions-only version of our model ranking second out of 10 models. Across the 2023-2024 winter epidemic wave, retrospective forecasts from wwinference would have performed similarly with and without the wastewater signal included: fifth and fourth out of 10 models, respectively. To better understand the drivers of differential forecast performance with and without wastewater, we performed an exploratory analysis investigating the relationship between characteristics of the input data and improved and reduced performance in our model. Based on that analysis, we identify and discuss key areas for further model development. To our knowledge, this is the first work that conducts an evaluation of real-time and retrospective infectious disease forecasts across the United States both with and without wastewater data and compared to other forecasting models.

Author SummaryWastewater-based epidemiology, in combination with clinical surveillance, has the potential to improve situational awareness and inform outbreak responses. We developed a model that uses data on the pathogen concentration in wastewater from one or more wastewater treatment plants in combination with hospital admissions to produce short-term forecasts of hospital admissions. We produced and submitted forecasts of 28-day ahead COVID-19 hospital admissions from this model to the U.S. COVID-19 Forecast Hub during the spring of 2024 and found that it performed well in comparison to other models during that limited time period. To assess the added value of incorporating wastewater data into the model and to investigate how it would have performed had we submitted it during the entire 2023-2024 winter epidemic wave, we performed a retrospective analysis in which we produced forecasts from the model with and without including wastewater data, using data that would have been available in real-time as of each forecast date. Both versions of the model would have been median overall performers had they been submitted to the Hub throughout the season. When comparing the models performance with and without wastewater data included, we found that overall forecast performance was very similar, with wastewater data slightly reducing overall average forecast performance. Within this result, there was significant heterogeneity, with clear instances of wastewater data improving and detracting from forecast performance. We used trends in the observed data to generate hypotheses as to the drivers of improved and reduced relative forecast performance within our model. We conclude by suggesting future work to improve the model and more broadly the application of wastewater-based epidemiology to forecasting.
]]></description>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.02.21.26345052v1?rss=1">
<title>
<![CDATA[
Reclaiming health: a qualitative, explorative study of long covid recovery journeys involving mind-body approaches. 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.02.21.26345052v1?rss=1"
</link>
<dc:creator>Deurman, C.</dc:creator>
<dc:creator>Brinkman, V.</dc:creator>
<dc:creator>Slagboom, M.</dc:creator>
<dc:creator>Bussemaker, J.</dc:creator>
<dc:creator>Vos, H. M. M.</dc:creator>
<dc:date>2026-02-23</dc:date>
<dc:identifier>doi:10.64898/2026.02.21.26345052</dc:identifier>
<dc:title><![CDATA[Reclaiming health: a qualitative, explorative study of long covid recovery journeys involving mind-body approaches.]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory Press</dc:publisher>
<prism:publicationDate>2026-02-23</prism:publicationDate>
<prism:section></prism:section>
<description><![CDATA[
ObjectiveThis study explored the recovery experiences of individuals who report having (largely) recovered from long covid and who attributed their improvement to mind-body approaches.

Design, setting and participantsWe conducted an explorative qualitative study using purposive recruitment through social media and snowball sampling. Eighteen adult women (aged 37-62 years), who self-identified as having had long covid and having substantially recovered through mind-body approaches participated in semi-structured interviews. Data were analysed using Saunders practical thematic analysis.

ResultsDespite variation in personal narratives, a common trajectory emerged: participants moved away from a biomedical explanatory model towards one centred on nervous system dysregulation. This shift, sometimes following initial scepticism, was often described as a turning point, sparking hope and motivation to engage in self-directed strategies. Recovery was not linear but an iterative process, involving cycles of practice, reflection (especially when progress stagnated) and adaptation of mind-body techniques. Over time, participants gained insights into contributing factors and, in many cases, made intentional life changes to support ongoing recovery. These patterns echo findings from previous research on mind-body approaches in chronic pain and chronic fatigue, and align with neuroscientific perspectives on symptom generation.

Most participants navigated this process without formal clinical support, relying instead on online communities and actively avoiding sources of (biomedical) information that conflicted with their new understanding.

ConclusionsWhile causal inferences cannot be drawn from qualitative data, this study highlights potential mechanisms that may underpin recovery for people with long covid using mind-body approaches. Further research is needed to develop structured interventions, and to evaluate their efficacy and safety.

Future research should also explore how prevailing narratives within healthcare and society influence treatment engagement and recovery trajectories.

STRENGTHS AND LIMITATIONS OF THIS STUDYO_LIThis is the first study exploring experiences of recovery from long covid using mind-body approaches.
C_LIO_LIIn-depth, real-world accounts capture the lived-experiences over time and allow in-depth exploration if the recovery process, while the semi-structured design facilitates the emergence of themes rarely captured in clinical research.
C_LIO_LIGeneralisability is limited due to self-identified long covid status, lack of formal diagnostic verification, absence of strict definitions of  mind-body approaches and  recovery, and a relatively homogenous sample (mostly highly educated women).
C_LI
]]></description>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.02.15.26346122v1?rss=1">
<title>
<![CDATA[
Randomized incentives to increase participation in COVID testing in rural Kenya 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.02.15.26346122v1?rss=1"
</link>
<dc:creator>Chieng, B.</dc:creator>
<dc:creator>Crider, Y.</dc:creator>
<dc:creator>Aitken, C.</dc:creator>
<dc:creator>Araka, S. B.</dc:creator>
<dc:creator>Kihoro, R. W.</dc:creator>
<dc:creator>Kanyi, H.</dc:creator>
<dc:creator>Powers, J. E.</dc:creator>
<dc:creator>Tan, B.</dc:creator>
<dc:creator>Paulos, A. P.</dc:creator>
<dc:creator>Gomes, A. S.</dc:creator>
<dc:creator>Nekesa, C.</dc:creator>
<dc:creator>Nekesa, C.</dc:creator>
<dc:creator>Bwire, B.</dc:creator>
<dc:creator>Allela, D. O.</dc:creator>
<dc:creator>Kiiru, J. N.</dc:creator>
<dc:creator>Kremer, M.</dc:creator>
<dc:creator>Njenga, S.</dc:creator>
<dc:creator>Pickering, A.</dc:creator>
<dc:date>2026-02-22</dc:date>
<dc:identifier>doi:10.64898/2026.02.15.26346122</dc:identifier>
<dc:title><![CDATA[Randomized incentives to increase participation in COVID testing in rural Kenya]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory Press</dc:publisher>
<prism:publicationDate>2026-02-22</prism:publicationDate>
<prism:section></prism:section>
<description><![CDATA[
Low participation in public health testing can lead to biased estimates of disease prevalence and inefficient allocation of public health resources. We evaluated the impact of monetary incentives and revisits on participation in door-to-door COVID testing in rural western Kenya. We conducted a cross-sectional study of all residents in 12 villages in rural western Kenya. We offered an incentive of KSh 200 (1.85 USD), KSh 350 (3.23 USD), or KSh 700 (6.47 USD), randomized at the household level, for each household member >3 months old who participated in COVID testing. Among 7,049 individuals, 5,659 individuals consented to testing. Overall, after revisits, 78.2% consented in the KSh 200 group, 80.6% in the KSh 350 group, and 81.9% in the KSh 700 group. Among individuals offered KSh 200, revisiting increased the consent rate from 68.1% to 78.2%, or 7.3 percentage points higher than the first visit consent rate in the KSh 700 group. Participation was very high (96.9%) among available individuals, but 17.2% of individuals were never available. Offering KSh 200 minimized the cost per consenting individual in our sample, even with revisits, compared to higher amounts. However, individuals in the KSh 700 group were slightly more likely to test positive, which suggests these individuals are missed at lower incentive amounts. Overall 0.3% (95% CI: 0.2, 0.5) tested positive for current infection by qPCR on nasal swabs, and 8.6% (7.7, 9.6) tested positive for SARS-CoV-2-specific antibodies by ELISA on dried blood spots. Accounting for nonresponse bias suggests this COVID population burden may be an underestimate. Our findings suggest incentives can increase participation in household door-to-door public health surveillance testing and may improve disease prevalence estimates by reducing nonresponse bias. However, high incentives may not be cost effective when low incentives motivate very high levels of participation.

Significance StatementAchieving high levels of participation in testing can inform public health strategies for reducing the spread of infectious diseases. Cash incentives are one tool for increasing participation, but there is little evidence on the effectiveness of this approach in low-resource settings. We find that cash incentives increase participation in free COVID-19 testing in rural Kenya and may reduce nonresponse bias.
]]></description>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.02.16.26346134v1?rss=1">
<title>
<![CDATA[
Occupational and Environmental Challenges and Effects of COVID-19 Testing Implementation Experienced by HIV Viral Load Laboratory Staff within a Public Health Sector Laboratory in South Africa 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.02.16.26346134v1?rss=1"
</link>
<dc:creator>Sarang, S.</dc:creator>
<dc:creator>Matingo-Mutava, E.</dc:creator>
<dc:creator>Cassim, N.</dc:creator>
<dc:date>2026-02-22</dc:date>
<dc:identifier>doi:10.64898/2026.02.16.26346134</dc:identifier>
<dc:title><![CDATA[Occupational and Environmental Challenges and Effects of COVID-19 Testing Implementation Experienced by HIV Viral Load Laboratory Staff within a Public Health Sector Laboratory in South Africa]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory Press</dc:publisher>
<prism:publicationDate>2026-02-22</prism:publicationDate>
<prism:section></prism:section>
<description><![CDATA[
BackgroundThe COVID-19 pandemic required South African public sector HIV viral load (VL) laboratories to scale up Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) testing while maintaining essential HIV services. This placed additional pressure on diagnostic services. This dual mandate introduced significant occupational and environmental challenges (OEC) for staff that remain underexplored.

ObjectiveThis study aimed to investigate the OEC and effects that staff experienced during the implementation of COVID-19 testing at public sector VL laboratories in South Africa.

MethodsA quantitative, cross-sectional study utilised a census approach among technical and support staff. Data were collected via a structured REDCap questionnaire using 5-point Likert scales. Pre- and post-implementation challenges were assessed across four domains: workload, environmental conditions (space, ventilation, waste), communication, and PPE availability. Statistical analyses included the Wilcoxon Signed-Rank and Spearmans correlation tests.

ResultsPerceived occupational challenges increased significantly across all domains post-implementation. Staff workload saw the highest rise (mean score 3.02 to 3.53). Adverse health effects were pervasive; 80.2% of staff reported burnout/fatigue, and 76.5% reported increased anxiety/stress. A strong positive correlation was observed between post-COVID-19 challenges and adverse mental and physical health outcomes (rho = 0.449, p < 0.001). Furthermore, 35.8% of staff considered resigning due to increased job demands.

ConclusionIntegrating COVID-19 testing exacerbated systemic weaknesses, causing measurable psychological injury and threatening workforce retention. Findings suggest that the diagnostic workforce requires formal crisis surge staffing models and institutionalised mental health support to safeguard personnel and maintain essential services during future health emergencies.
]]></description>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.02.20.26346719v1?rss=1">
<title>
<![CDATA[
Low Dose Naltrexone Prescribing Practices for Children and Adolescents with Long COVID 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.02.20.26346719v1?rss=1"
</link>
<dc:creator>Villatoro, C.</dc:creator>
<dc:creator>Yonts, A. B.</dc:creator>
<dc:creator>Barter, T.</dc:creator>
<dc:creator>Mohandas, S.</dc:creator>
<dc:creator>Malone, L. A.</dc:creator>
<dc:date>2026-02-22</dc:date>
<dc:identifier>doi:10.64898/2026.02.20.26346719</dc:identifier>
<dc:title><![CDATA[Low Dose Naltrexone Prescribing Practices for Children and Adolescents with Long COVID]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory Press</dc:publisher>
<prism:publicationDate>2026-02-22</prism:publicationDate>
<prism:section></prism:section>
<description><![CDATA[
BackgroundPediatric long COVID is associated with substantial symptom burden, yet evidence-based pharmacologic treatments remain limited. Low-dose naltrexone (LDN) has been proposed as a potential symptomatic therapy, but data in pediatric populations is lacking.

MethodsWe conducted a retrospective analysis of pediatric and young adult patients ([&le;]25 years) with a clinical diagnosis of long COVID who were prescribed LDN between July 2020 and July 2025 at three multidisciplinary pediatric long COVID programs in the United States. Deidentified clinical data were extracted from medical records. Outcomes included symptom prevalence, dosing practices, treatment continuation or discontinuation, adverse effects, and available patient-reported quality-of-life measures (PedsQL and PROMIS(R)).

FindingsThe study included 62 patients (mean age, 15.6 years [range, 8-23]; 53.2% male and 46.8% female). Fatigue was nearly universal (98.4%), followed by headaches (87.1%), brain fog (74.2%), dizziness/lightheadedness (67.7%), anxiety (66.1%), and post-exertional malaise (56.5%). LDN-treated patients demonstrated a higher prevalence of neurocognitive and autonomic symptoms, compared to general clinic cohorts. Most patients (71.0%) reported no adverse effects; the most common were vivid dreams (9.7%) and insomnia (9.7%). At follow-up, 66.1% of patients remained on LDN. Medication discontinuation was attributed to perceived lack of benefit (43.8%) or side effects (25.0%). Baseline quality-of-life measures at initiation showed marked impairment: PedsQL Physical Health (M=38.0, SD=20.9) and Multidimensional Fatigue (M=35.7, SD=15.8) scores were low. PROMIS scores indicated reduced physical functioning (M=36.8, SD=8.7) and cognitive functioning (M=40.8, SD=7.6), with elevated fatigue (M=68.0, SD=10.4) and pain interference (M=58.6, SD=8.2) relative to population norms. The study was not designed to assess efficacy.

InterpretationLDN was primarily prescribed to patients with prominent fatigue, neurocognitive symptoms, and autonomic dysfunction, and was generally well tolerated. These findings provide descriptive evidence of real-world prescribing practices and support the need for clinical trials to systematically evaluate LDNs efficacy in pediatric long COVID.
]]></description>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.02.19.26346601v1?rss=1">
<title>
<![CDATA[
Assessing the impact of the COVID-19 pandemic on routine childhood vaccination uptake in the Netherlands 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.02.19.26346601v1?rss=1"
</link>
<dc:creator>Pijpers, J.</dc:creator>
<dc:creator>Haverkate, M.</dc:creator>
<dc:creator>van Gaalen, R.</dc:creator>
<dc:creator>Hahne, S.</dc:creator>
<dc:creator>de Melker, H.</dc:creator>
<dc:creator>van den Hof, S.</dc:creator>
<dc:date>2026-02-20</dc:date>
<dc:identifier>doi:10.64898/2026.02.19.26346601</dc:identifier>
<dc:title><![CDATA[Assessing the impact of the COVID-19 pandemic on routine childhood vaccination uptake in the Netherlands]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory Press</dc:publisher>
<prism:publicationDate>2026-02-20</prism:publicationDate>
<prism:section></prism:section>
<description><![CDATA[
BackgroundInitial reports from the Netherlands indicate a decline in routine childhood vaccination uptake during and after the COVID-19 pandemic, with emerging evidence of reduced parental vaccine confidence. This study aimed to evaluate the long-term impact of the COVID-19 pandemic on routine childhood vaccination uptake.

MethodsWe conducted a retrospective nationwide cohort study including all children born in the Netherlands in 2016-2024. First-dose DTaP-IPV vaccination status by age six months was obtained from the national immunisation register. National trends in vaccination uptake across pre-pandemic, pandemic, and post-pandemic periods were assessed using interrupted time series analyses. To further assess the independent effect of the pandemic, a matched-sibling analysis compared vaccination uptake within families before, during and after the pandemic.

ResultsInterrupted time series analyses showed significant immediate decreases in vaccination uptake both at the start and end of the pandemic, accompanied by a continuing downward trend during the pandemic (OR 0.984, 95%CI 0.982-0.985) that further declined after its end (OR 0.995, 95%CI 0.994-0.997). In the matched-sibling analysis children eligible during and after the pandemic had lower odds of being vaccinated (pandemic: OR 0.66, 95%CI 0.55-0.80; post-pandemic: OR 0.20, 95%CI 0.17-0.25) compared to their pre-pandemic siblings. Also, later birth order was associated with lower odds compared to first-born siblings (second-born: OR 0.42, 95%CI 0.37-0.48).

ConclusionsBoth analyses indicate a negative impact of the COVID-19 pandemic on parental vaccination decisions, which may reflect lingering pandemic effects or new post-pandemic factors, highlighting the need for further research into the drivers of vaccination uptake changes in the post-pandemic era.
]]></description>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.02.18.26346561v1?rss=1">
<title>
<![CDATA[
Potential public health and economic impact of the next-generation COVID-19 vaccine mRNA-1283 in the Netherlands 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.02.18.26346561v1?rss=1"
</link>
<dc:creator>van der Pol, S.</dc:creator>
<dc:creator>Beck, E.</dc:creator>
<dc:creator>Westra, T.</dc:creator>
<dc:creator>Postma, M.</dc:creator>
<dc:creator>Boersma, C.</dc:creator>
<dc:date>2026-02-19</dc:date>
<dc:identifier>doi:10.64898/2026.02.18.26346561</dc:identifier>
<dc:title><![CDATA[Potential public health and economic impact of the next-generation COVID-19 vaccine mRNA-1283 in the Netherlands]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory Press</dc:publisher>
<prism:publicationDate>2026-02-19</prism:publicationDate>
<prism:section></prism:section>
<description><![CDATA[
COVID-19 remains a substantial public health challenge in the Netherlands. Next-generation COVID-19 vaccine, mRNA-1283, is approved in the European Union, with potential for higher relative vaccine efficacy compared with originally-licensed COVID-19 vaccines. Its potential public health and economic impact, in adults [&ge;]60 years and high-risk 18-59 years, was modelled versus no vaccination and originally-licensed mRNA-1273 and BNT162b2, adapting a published static Markov model with 1-year time horizon. COVID-19 burden reflected two full post-pandemic seasons. Vaccine efficacy versus mRNA-1273 was based on pivotal phase 3 NextCOVE trial data; efficacy versus BNT162b2 was derived from an indirect treatment comparison. The economically justifiable price (EJP) of mRNA-1283 versus no vaccination, and price premiums over existing vaccines, were determined at a willingness-to-pay threshold of {euro}50,000/quality-adjusted life-year (QALY) gained. Without COVID-19 vaccination, an estimated 460,000 infections, 23,800 hospitalizations and 5,300 deaths would occur. With current coverage, mRNA-1283 was estimated to prevent 68,000 infections, 5,400 hospitalizations, and 1,200 deaths, saving 9,667 QALYs and over {euro}66.5 million in treatment costs. The EJP was {euro}238 versus no vaccination. Compared with mRNA-1273 and BNT162b2, mRNA-1283 was estimated to prevent additional burden (e.g., 1,309 and 1,679 hospitalizations, respectively), and was cost-effective at an incremental EJP of {euro}62 versus mRNA-1273, and {euro}80 versus BNT162b2. The results support continued COVID-19 vaccination to mitigate the ongoing health and societal burden of SARS-CoV-2 in the Netherlands. The comparative analyses indicate that mRNA-1283 may be associated with substantial health benefits over originally-licensed mRNA vaccines; consequently, its use may further improve health outcomes and economic efficiency within COVID-19 vaccination programs.
]]></description>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.02.18.26346542v1?rss=1">
<title>
<![CDATA[
Early Fc-effector antibody signatures impact COVID-19 disease trajectory 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.02.18.26346542v1?rss=1"
</link>
<dc:creator>Escalera, A.</dc:creator>
<dc:creator>Gonzalez-Reiche, A. S.</dc:creator>
<dc:creator>Aslam, S.</dc:creator>
<dc:creator>Bernal, E.</dc:creator>
<dc:creator>Alter, G.</dc:creator>
<dc:creator>Rojo-Fernandez, A.</dc:creator>
<dc:creator>Rombauts, A.</dc:creator>
<dc:creator>Abelenda-Alonso, G.</dc:creator>
<dc:creator>Amper, M. A.</dc:creator>
<dc:creator>Nair, V. D.</dc:creator>
<dc:creator>van Bakel, H.</dc:creator>
<dc:creator>Carratala, J.</dc:creator>
<dc:creator>Garcia-Sastre, A.</dc:creator>
<dc:creator>Aydillo, T.</dc:creator>
<dc:date>2026-02-19</dc:date>
<dc:identifier>doi:10.64898/2026.02.18.26346542</dc:identifier>
<dc:title><![CDATA[Early Fc-effector antibody signatures impact COVID-19 disease trajectory]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory Press</dc:publisher>
<prism:publicationDate>2026-02-19</prism:publicationDate>
<prism:section></prism:section>
<description><![CDATA[
Why do some individuals develop mild COVID-19 while others progress to severe disease remains a central challenge in SARS-CoV-2 immunology. In this study, we leveraged the BACO Cohort - a unique historical cohort of immunologically naive, hospitalized COVID-19 patients from the first pandemic wave - to investigate early immune determinants of clinical disease trajectories. Integrating bulk RNA-seq, Olink proteomics, and systems serology, we identified two fundamentally distinct immune trajectories according to disease phenotypes. Severe patients exhibited upregulation of proinflammatory genes and monocyte-associated transcripts, alongside downregulation of genes related to T cell responses and immune signaling. Notably, an upregulation of inhibitory Fc-receptor-associated gene was also found in severe cases. In contrast, mild cases showed coordinated lymphoid activation and limited inflammation. Building on these findings, we performed a functional profiling of Fc-effector activity in the polyclonal serum of the patients and found that monocyte-mediated phagocytosis was a common feature of mild disease. Interestingly, this response was mainly driven by rapid induction of S1-specific antibodies. Conversely, severe patients tended to generate higher levels of S2-biased antibodies early after infection with poor Fc-effector functionality. Together, these findings demonstrate that early S1-directed, Fc-competent humoral immunity is a key determinant of favorable COVID-19 outcomes, while delayed functional maturation and early S2 bias characterized severe disease in the BACO cohort.
]]></description>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.02.16.26346431v1?rss=1">
<title>
<![CDATA[
COVID-19 Symptom burden, chronic disease, mental health, and executive function: Multi-Country evidence from four African countries" 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.02.16.26346431v1?rss=1"
</link>
<dc:creator>Malete, L.</dc:creator>
<dc:creator>Ezeamama, A.</dc:creator>
<dc:creator>Ricketts, C.</dc:creator>
<dc:creator>Joachim, D.</dc:creator>
<dc:creator>Naghibolhosseini, M.</dc:creator>
<dc:creator>Zayernouri, M.</dc:creator>
<dc:creator>Ocansey, R.</dc:creator>
<dc:creator>Muomah, R. C.</dc:creator>
<dc:creator>Tladi, D. M.</dc:creator>
<dc:creator>Ndabi, J. S.</dc:creator>
<dc:date>2026-02-18</dc:date>
<dc:identifier>doi:10.64898/2026.02.16.26346431</dc:identifier>
<dc:title><![CDATA[COVID-19 Symptom burden, chronic disease, mental health, and executive function: Multi-Country evidence from four African countries"]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory Press</dc:publisher>
<prism:publicationDate>2026-02-18</prism:publicationDate>
<prism:section></prism:section>
<description><![CDATA[
BackgroundEvidence from high-income countries suggests that COVID-19 may adversely affect cognitive functioning, yet population-based data from African countries remain scarce. Understanding how COVID-19 symptom burden, chronic disease, and mental health intersect to shape cognitive outcomes is critical in low-resource settings disproportionately affected by structural and health system constraints.

MethodsCross-sectional data were collected from 3,058 adults (M_age = 27.2 years) in Botswana, Ghana, Nigeria, and Tanzania between April 2020 and November 2022 using the Sonde Health platform. Participants self-reported sociodemographic characteristics, COVID-19 symptoms, chronic disease diagnoses, mental health symptoms, physical activity, and sedentary behavior. Executive function was assessed using the Stroop Color-Word interference score. Multivariable linear regression models estimated adjusted mean differences in executive function associated with COVID-19 symptom burden and chronic disease, controlling for sociodemographic, health, mental health, and behavioral factors. Effect modification by country was evaluated using interaction terms (p < 0.10).

ResultsExecutive function declined with increasing COVID-19 symptom burden, with Stroop scores decreasing from 0.14 among participants reporting no symptoms to 0.07 among those reporting three or more symptoms (p < 0.001). Being symptom-free was associated with better executive function in Ghana (adjusted mean difference = 0.06; 95% CI: 0.00, 0.11) and Nigeria (adjusted mean difference = 0.07; 95% CI: 0.02, 0.12), but not in Botswana or Tanzania. Lower chronic disease burden was associated with better executive function in Nigeria (adjusted mean difference = 0.16; 95% CI: 0.06, 0.26). Higher educational attainment was consistently associated with better executive function across countries.

ConclusionsCOVID-19 symptom burden and chronic disease were associated with poorer executive function across the four African countries studied, with substantial cross-country variation. Education emerged as a consistent protective factor. These findings highlight the importance of integrated, context-sensitive approaches that address both physical and mental health to support cognitive well-being during and beyond public health crises.
]]></description>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.02.17.26346448v1?rss=1">
<title>
<![CDATA[
Revised estimates of the types and durations of long Covid symptoms based on claims records from 245 Million US patients 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.02.17.26346448v1?rss=1"
</link>
<dc:creator>Nilforoshan, H.</dc:creator>
<dc:creator>Reisler, J.</dc:creator>
<dc:creator>Jahanparast, E.</dc:creator>
<dc:creator>Moor, M.</dc:creator>
<dc:creator>Goodman, S.</dc:creator>
<dc:creator>Wager, S.</dc:creator>
<dc:creator>Leskovec, J.</dc:creator>
<dc:date>2026-02-18</dc:date>
<dc:identifier>doi:10.64898/2026.02.17.26346448</dc:identifier>
<dc:title><![CDATA[Revised estimates of the types and durations of long Covid symptoms based on claims records from 245 Million US patients]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory Press</dc:publisher>
<prism:publicationDate>2026-02-18</prism:publicationDate>
<prism:section></prism:section>
<description><![CDATA[
COVID-19 has been shown to cause a range of harmful long-term effects on nearly every organ system1-3. These findings are based on retrospective studies comparing COVID-19 patients to patients with similar medical histories and demographics but no COVID-19 diagnosis4-16. However, concerns have emerged that these comparisons may be biased if COVID-19 patients had unrelated health conditions or other factors not recorded in their medical records17-21. Here, using a massive dataset of 14.4 billion health insurance claims from 244.7 million U.S. patients, we find that the large majority of long-term effects attributed to COVID-19 by methods used in conventional studies are likely due to bias from selective testing. This bias arises because individuals with non-COVID health conditions producing long-term symptoms were more likely to seek care and be tested for COVID-19. As a result, their non-COVID symptoms are attributed to COVID-19. We develop a study design that reduces this bias by only considering individuals who have taken a COVID-19 PCR test, and then comparing similar patients whose first test came back positive vs. negative. This way the COVID-19 patients and control group are more similar and non-COVID factors play less of a role. We examine 614 clinical outcomes over a 2-year followup period and reveal an order of magnitude smaller--but still clinically significant--number of long-term effects attributed to COVID-19 that persist for up to one year after infection. We confirm that the long-term effects of COVID-19 span many organ systems, including respiratory, cardiovascular, musculoskeletal, and integumentary systems, but are significantly narrower in scope and duration than previously believed. Although some symptoms exist more than one year after COVID-19 infection, they occur at similar rates in individuals who tested negative and are therefore not attributable to COVID-19 infection. Our findings pinpoint the specific long-term effects of COVID-19 and show how large-scale data can be used to enable careful evaluation and design of population health studies.
]]></description>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.02.15.26346356v1?rss=1">
<title>
<![CDATA[
Adherence to Public Health Recommendations, Restrictions, and Requirements among Priority Populations at Risk for COVID-19 Mortality and Infection in Australia 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.02.15.26346356v1?rss=1"
</link>
<dc:creator>Narayanasamy, S.</dc:creator>
<dc:creator>Altermatt, A.</dc:creator>
<dc:creator>Wilkinson, A. L.</dc:creator>
<dc:creator>Heath, K.</dc:creator>
<dc:creator>Gibney, K.</dc:creator>
<dc:creator>Hellard, M.</dc:creator>
<dc:creator>Pedrana, A.</dc:creator>
<dc:date>2026-02-17</dc:date>
<dc:identifier>doi:10.64898/2026.02.15.26346356</dc:identifier>
<dc:title><![CDATA[Adherence to Public Health Recommendations, Restrictions, and Requirements among Priority Populations at Risk for COVID-19 Mortality and Infection in Australia]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory Press</dc:publisher>
<prism:publicationDate>2026-02-17</prism:publicationDate>
<prism:section></prism:section>
<description><![CDATA[
ObjectiveTo examine adherence to COVID-19 public health measures among culturally and linguistically diverse (CALD) and low socio-economic status (SES) populations in Victoria using a unique longitudinal cohort.

Study DesignThe Optimise Study was a mixed-methods longitudinal cohort and social networks study (September 2020 - December 2023) assessing the impact of COVID-19 and related public health measures in Victoria, Australia. We used a serial cross-sectional design to analyse adherence to public health recommendations, restrictions, and requirements.

Settings, participantsThe study examines two 28-day periods during the COVID-19 pandemic in Victoria: April 23- May 20, 2021 ( non-lockdown), and September 13-October 10, 2021 ( lockdown). We explored adherence to three categories of COVID-19 public health measures -- Recommendations (non-enforced, longer-term), Restrictions (mandated during lockdown periods), and Requirements (mandated, longer-term) -- among participants who completed questionnaires during these periods. Participants were grouped as: 1) non-CALD high SES (did not meet CALD or low-SES criteria), 2) CALD, or 3) non-CALD low-SES.

Main outcome measuresPrimary outcomes were adherence to Recommendations, Restrictions, and Requirements during the two study periods.

ResultsOf 782 participants recruited, 579 (75%) completed a survey or diary during at least one study period and were included in the analysis. Of these, 275 (47%) were in the  non-CALD high-SES group, 114 (20%) in the CALD group, and 190 (33%) in the  non-CALD low-SES group. Across all groups, risk-reduction behaviours increased during the lockdown. CALD participants showed higher adherence to some Recommendations and Restrictions compared to the other groups. Overall, 28% left home while awaiting a COVID-19 test result, commonly due to work.

ConclusionsHigh adherence among CALD and  non-CALD low-SES groups suggest structural barriers, rather than behavioural non-compliance, contributed to higher COVID-19 impacts, highlighting the need for tailored support. During future public health emergencies, better supports are needed for individuals working outside of home to remain in isolation while awaiting a test result.

Summary box O_TEXTBOXWhat is already known about this subject? In Australia, priority populations such as culturally and linguistically diverse (CALD) and low socio-economic status (SES) groups experienced higher COVID-19 infection, mortality and a disproportionate impact from public health restrictions.

What does this study add? CALD populations had an overall higher level of adherence to public health behavioural measures during both lockdown and non-lockdown periods compared to non-CALD populations. Over 25% of participants did not comply with stay-at-home requirements while awaiting a COVID-19 test result, largely due to work responsibilities.

How might this impact on clinical practice? Pandemic preparedness efforts should focus on understanding the reasons for non-adherence with isolation requirements and considering tailored support during future pandemics to address the diverse

C_TEXTBOX
]]></description>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.02.13.26346228v1?rss=1">
<title>
<![CDATA[
Electroconvulsive Therapy during the COVID-19 Pandemic: Nationwide Data from Denmark 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.02.13.26346228v1?rss=1"
</link>
<dc:creator>Reinecke-Tellefsen, C. J.</dc:creator>
<dc:creator>Orberg, A.</dc:creator>
<dc:creator>Ostergaard, S. D.</dc:creator>
<dc:date>2026-02-17</dc:date>
<dc:identifier>doi:10.64898/2026.02.13.26346228</dc:identifier>
<dc:title><![CDATA[Electroconvulsive Therapy during the COVID-19 Pandemic: Nationwide Data from Denmark]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory Press</dc:publisher>
<prism:publicationDate>2026-02-17</prism:publicationDate>
<prism:section></prism:section>
<description><![CDATA[
The COVID-19 pandemic had substantial impact on healthcare systems across the globe, including psychiatric services. Use of electroconvulsive therapy (ECT), a lifesaving intervention for severe mental illness, was reported to have declined during the pandemic in several countries, but nationwide data remain scarce. Using nationwide data from the Danish National Patient Register, we examined all ECT treatments administered in Denmark from September 2019 to May 2025. Weekly treatment numbers were visualized across the three national COVID-19 lockdowns to descriptively assess changes in ECT use. A notable reduction in ECT treatments was observed in the weeks preceding and during the first lockdown (March 11 to May 18, 2020). A post-hoc estimation indicated approximately 1,366 "missed" treatments during the initial pandemic phase in 2020. When these were added to the 27,033 treatments delivered in 2020, the adjusted total approximated annual treatment volumes in 2019 and 2022, suggesting a temporary disruption rather than sustained decline. In contrast, ECT activity during the second and third lockdowns appeared largely unaffected. These findings suggest that ECT provision in Denmark was temporarily reduced during the initial phase of the pandemic but remained resilient thereafter. In the case of a future pandemic, safeguarding timely access to ECT--particularly in early phases-- should be prioritized given its critical role in the treatment of severe mental illness.
]]></description>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.02.13.26346301v1?rss=1">
<title>
<![CDATA[
Disruption and recovery of notifiable infectious diseases after COVID-19 in Australia, 2015-2025 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.02.13.26346301v1?rss=1"
</link>
<dc:creator>Farquhar, H. L.</dc:creator>
<dc:date>2026-02-17</dc:date>
<dc:identifier>doi:10.64898/2026.02.13.26346301</dc:identifier>
<dc:title><![CDATA[Disruption and recovery of notifiable infectious diseases after COVID-19 in Australia, 2015-2025]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory Press</dc:publisher>
<prism:publicationDate>2026-02-17</prism:publicationDate>
<prism:section></prism:section>
<description><![CDATA[
BackgroundCOVID-19 non-pharmaceutical interventions (NPIs) disrupted transmission of many infectious diseases worldwide. While disruption patterns are well-documented, systematic analysis of post-pandemic recovery trajectories across diverse pathogens remains limited. We examined disruption and recovery of 47 nationally notifiable diseases in Australia from 2015 to 2025.

MethodsWe analysed NNDSS surveillance data for 47 diseases across six transmission modes, quantifying disruption using observed-to-expected (O/E) ratios against 2015-2019 baselines. We applied difference-in-differences (DiD) to estimate causal NPI effects, Kaplan-Meier survival analysis for time-to-recovery, and bootstrap 95% confidence intervals for cumulative immunity debt.

ResultsDuring 2020-2021, 28 diseases decreased (median O/E 0.51), with border-sensitive and vaccine-preventable diseases most affected. DiD analysis estimated that border closures were associated with significantly greater suppression among import-dependent diseases (coefficient -0.50, 95% CI -0.90 to -0.10, p=0.016). By 2025, recovery was heterogeneous: 17 diseases exceeded baseline levels, 12 returned to expected levels, 15 remained below baseline (9 partially recovered, 6 in sustained suppression), and 3 had insufficient data for trajectory classification. Five diseases showed suppression-then-overshoot trajectories suggestive of immunity debt, though bootstrap 95% confidence intervals confirmed statistically significant cumulative excess for only one (rotavirus); for influenza, high baseline variability precluded statistical confirmation despite a large absolute overshoot.

ConclusionsPost-pandemic disease recovery in Australia is heterogeneous and incomplete. Fifteen of 47 diseases have not returned to baseline levels by 2025, while 17 exhibit overshoot. These findings argue for differentiated surveillance of still-suppressed diseases and targeted catch-up vaccination in pandemic birth cohorts.

Article summaryWe analysed disruption and recovery of 47 nationally notifiable diseases in Australia from 2015 to 2025, finding that 15 diseases remain below pre-pandemic levels three years after NPI relaxation. Border closures caused disproportionate suppression of import-dependent diseases, and recovery trajectories varied by disease characteristics, with immunity debt statistically confirmed for only one of five candidate diseases.
]]></description>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.02.16.26346388v1?rss=1">
<title>
<![CDATA[
Peak alpha frequency is associated with pain severity in Long COVID patients with new-onset chronic pain 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.02.16.26346388v1?rss=1"
</link>
<dc:creator>Silva-Passadouro, B.</dc:creator>
<dc:creator>Khoja, O.</dc:creator>
<dc:creator>Casson, A. J.</dc:creator>
<dc:creator>Delis, I.</dc:creator>
<dc:creator>Brown, C.</dc:creator>
<dc:creator>Sivan, M.</dc:creator>
<dc:date>2026-02-17</dc:date>
<dc:identifier>doi:10.64898/2026.02.16.26346388</dc:identifier>
<dc:title><![CDATA[Peak alpha frequency is associated with pain severity in Long COVID patients with new-onset chronic pain]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory Press</dc:publisher>
<prism:publicationDate>2026-02-17</prism:publicationDate>
<prism:section></prism:section>
<description><![CDATA[
New-onset chronic pain is a common and debilitating symptom of Long COVID (LC) that remains not fully understood in terms of pathophysiology and therapeutic targets. A growing body of evidence in chronic pain syndromes similar to LC demonstrates an association between EEG alpha oscillatory activity and the experience of pain, with clinical studies showing maladaptive changes in oscillatory activity, particularly a slowing of alpha activity. This study aims to investigate the association between EEG alpha oscillatory activity and pain perception in new-onset LC-chronic pain. We recruited 31 individuals (20 females) with a clinical diagnosis of LC reporting new-onset chronic pain and 31 healthy pain-free age-and sex-matched controls. Participants completed questionnaires regarding symptoms and psychological functioning prior to recording eyes-open resting-state EEG. Peak alpha frequency (PAF) and spectral power within the alpha band (8-13 Hz) were extracted from EEG signals. Lower PAF over the posterior scalp region was significantly associated with higher LC-chronic pain severity when controlling for age and depression. This observation was consistent across PAF estimation methods. PAF was significantly increased, particularly in the posterior region, in the moderate pain LC subgroup compared to both severe pain subgroup and controls, while alpha power did not differ between the three groups and was not associated with pain severity. Our findings highlight associations between PAF and pain symptoms in a new post-infection chronic pain syndrome. PAF can thus be explored as a potential biomarker and therapeutic target for EEG-based neuromodulation interventions in LC-chronic pain. These results may have implications for other similar chronic pain syndromes.

SummaryLower resting-state EEG peak alpha frequency in posterior scalp region is associated with higher severity of new-onset Long COVID chronic pain.
]]></description>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.02.13.26346281v1?rss=1">
<title>
<![CDATA[
A Case Report Describing a Persistent SARS-CoV-2 Infection Outcomes and Mutations Associated with B-cell Deficiency 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.02.13.26346281v1?rss=1"
</link>
<dc:creator>Mohamed, R.</dc:creator>
<dc:creator>Shipe, A.</dc:creator>
<dc:creator>Lail, A.</dc:creator>
<dc:creator>Emmen, I. E.</dc:creator>
<dc:creator>Vuyk, W.</dc:creator>
<dc:creator>Minor, N. R.</dc:creator>
<dc:creator>Bradley, T.</dc:creator>
<dc:creator>Gifford, A.</dc:creator>
<dc:creator>Wilson, N. A.</dc:creator>
<dc:creator>O'Connor, D.</dc:creator>
<dc:creator>Garonzik Wang, J.</dc:creator>
<dc:creator>Smith, J.</dc:creator>
<dc:date>2026-02-17</dc:date>
<dc:identifier>doi:10.64898/2026.02.13.26346281</dc:identifier>
<dc:title><![CDATA[A Case Report Describing a Persistent SARS-CoV-2 Infection Outcomes and Mutations Associated with B-cell Deficiency]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory Press</dc:publisher>
<prism:publicationDate>2026-02-17</prism:publicationDate>
<prism:section></prism:section>
<description><![CDATA[
BackgroundImmunocompromised (IC) individuals are at increased risk for persistent SARS-CoV-2 infections and can develop new viral mutations and lineages not seen in the community. In this case report, a persistent SARS-CoV-2 infection (330 days) in an IC patient is examined for viral mutations and mutations associated with cryptic lineages.

Case PresentationThe patient was followed in a longitudinal study examining persistent SARS-CoV-2 in IC patients. The patient provided stool and nasal swab samples biweekly until 28 days post-enrollment, then monthly, and then quarterly after 12 month post enrollment until the participant was no longer positive for SARS-CoV-2. Staff performed RT-qPCR and viral sequencing on the samples. Viral mutations from the XBK lineage were already present in the initial sample. By the end of the infection period, there were 40 fixed consensus changes from XBK of which two mutations were typical for cryptic lineages. Mutations increased steadily over time, with most mutations fixed by day 253, including the cryptic typical mutations.

ConclusionThis case demonstrates the potential for persistent SARS-CoV-2 infections to develop mutations and lineages in IC patients and highlights the need for continued SARS-CoV-2 monitoring and treatment in this vulnerable population.
]]></description>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.02.12.26346177v1?rss=1">
<title>
<![CDATA[
COVID-19 hospitalizations in the Netherlands, 2023-2024: disease burden and vaccine effectiveness 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.02.12.26346177v1?rss=1"
</link>
<dc:creator>de Gier, B.</dc:creator>
<dc:creator>Smagge, B.</dc:creator>
<dc:creator>van Roon, A.</dc:creator>
<dc:creator>Veldhuijzen, I.</dc:creator>
<dc:creator>de Boer, P.</dc:creator>
<dc:creator>Knol, M.</dc:creator>
<dc:creator>Hahne, S.</dc:creator>
<dc:creator>de Melker, H.</dc:creator>
<dc:date>2026-02-16</dc:date>
<dc:identifier>doi:10.64898/2026.02.12.26346177</dc:identifier>
<dc:title><![CDATA[COVID-19 hospitalizations in the Netherlands, 2023-2024: disease burden and vaccine effectiveness]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory Press</dc:publisher>
<prism:publicationDate>2026-02-16</prism:publicationDate>
<prism:section></prism:section>
<description><![CDATA[
Since the cessation of real-time monitoring of COVID-19 hospitalizations in early 2024, the burden of and vaccine effectiveness (VE) against severe COVID-19 in the Netherlands was largely unknown. Recently, hospitalization data from 2024 were made available for the purpose of monitoring and evaluating the COVID-19 vaccination campaigns. These data were linked to the population registry, vaccination registry and healthcare use data (for classification into medical risk groups).

We analyzed the number and incidence of COVID-19 hospitalizations in 2023 and 2024 by age and medical risk group. VE against hospitalisation of the autumn booster of 2023 (by time since vaccination, 25 September 2023 to 16 September 2024) and of the autumn booster of 2024 (16 September to 31 December 2024) were estimated by medical risk group among persons aged 60 years and older using Cox proportional hazards models with calendar time as underlying time scale and vaccination status as time-varying exposure. Models were adjusted for age, sex, region and household socio-economic status.

From around age 60 onward, intermediate and high medical risk groups had a markedly higher incidence than younger age groups, increasing with age. Persons in the low medical risk group had a low incidence up to the age of 80. In 2024, incidence was lower than in 2023. For both autumn booster rounds, estimated VE against hospitalisation was moderate at 55-67% in the first 3 months post-vaccination. In the high medical risk group, 2023 VE decreased fast and was no longer significant at 6 months post-vaccination. For both years, estimates of the number of averted hospitalizations and number needed to vaccinate to prevent one hospitalization indicated that significant health benefit can be achieved by vaccinating the intermediate and high medical risk groups aged 60 years and older. Efforts to increase the moderate vaccine uptake among risk groups could potentially prevent a considerable disease- and healthcare burden.

Highlights- In 2023 and 2024, incidence of COVID-19 hospitalization was highest among medical risk groups aged 60 years and older, despite vaccination campaigns.
- Estimated VE against hospitalisation of the 2023 and 2024 autumn booster campaigns was moderate (55-67%) in the first year-quarter post-vaccination among persons aged 60 years and older.
- Estimated VE of the 2023 autumn booster decreased over the year, and faster among persons with a medical risk condition. Data availability precluded estimates of 2024 VE beyond the first 3 months since the start of the campaign.
- Despite lower and waning VE, the estimated number needed to vaccinate to prevent one COVID-19 hospitalization was much lower among intermediate and high medical risk groups compared with the low medical risk group.
]]></description>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.02.13.26346245v1?rss=1">
<title>
<![CDATA[
Sickness presenteeism due to respiratory infection in the English workforce: prevalence estimates and demographic factors from the Winter COVID-19 Infection Study (WCIS) 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.02.13.26346245v1?rss=1"
</link>
<dc:creator>Burdon, M. G.</dc:creator>
<dc:creator>Denson, S.</dc:creator>
<dc:creator>Tang, M.</dc:creator>
<dc:creator>Mellor, J.</dc:creator>
<dc:creator>Ward, T.</dc:creator>
<dc:date>2026-02-16</dc:date>
<dc:identifier>doi:10.64898/2026.02.13.26346245</dc:identifier>
<dc:title><![CDATA[Sickness presenteeism due to respiratory infection in the English workforce: prevalence estimates and demographic factors from the Winter COVID-19 Infection Study (WCIS)]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory Press</dc:publisher>
<prism:publicationDate>2026-02-16</prism:publicationDate>
<prism:section></prism:section>
<description><![CDATA[
BackgroundWorking while sick (presenteeism) with an infectious disease contributes to the spread of infections and is detrimental to productivity. Respiratory illnesses are a common cause of sickness in the working population and understanding the prevalence of presenteeism linked to respiratory illness is therefore important.

MethodsWinter Covid Infection Study (WCIS) panel members in work aged 18-64 were surveyed in February - March 2024 and asked about presenteeism in the previous 28 days. Multilevel regression and poststratification was used to estimate the prevalence and length of presenteeism and its effect on productivity in the English workforce, as approximated using the WCIS survey sample calibrated to census proportions. Differences by demographic groups and work sector were also analysed.

ResultsAround one in six working adults in England worked while sick with a respiratory infection during the study period, and one in ten attended a non-home workplace. Overall, around one day per adult was spent working while sick with a respiratory infection, approximately half of which was non-home working. Respondents felt they were able to work at around three-quarters of their usual capacity while sick. Presenteeism was more common among respondents who were younger, White, worked in a hybrid pattern, lived in larger households, had Long COVID-19, or worked in teaching and education.

ConclusionWorking while sick with a respiratory infection is relatively common, including among those who primarily work away from the home.

Key messagesAround one in six working-age adults in employment worked while sick with a respiratory infection during the study period (Feb-Mar 2024). - The likelihood of working while sick with a respiratory infection varied by demographic group and work sector. - On average, survey respondents said they could work at around three quarters their normal effectiveness while sick with a respiratory infection.
]]></description>
</item>
<item rdf:about="https://www.biorxiv.org/content/10.64898/2026.02.13.705786v1?rss=1">
<title>
<![CDATA[
It is not just about the science - the impact of undergraduate research projects and COVID-19 on graduate attributes and employability. 
]]>
</title>
<link>
https://www.biorxiv.org/content/10.64898/2026.02.13.705786v1?rss=1"
</link>
<dc:creator>Kyriazi, M.</dc:creator>
<dc:creator>Jung, J. F.</dc:creator>
<dc:creator>Wilkinson, S.</dc:creator>
<dc:creator>Brown, A.</dc:creator>
<dc:creator>Panti, K.</dc:creator>
<dc:creator>Armstrong, V. L.</dc:creator>
<dc:date>2026-02-16</dc:date>
<dc:identifier>doi:10.64898/2026.02.13.705786</dc:identifier>
<dc:title><![CDATA[It is not just about the science - the impact of undergraduate research projects and COVID-19 on graduate attributes and employability.]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory Press</dc:publisher>
<prism:publicationDate>2026-02-16</prism:publicationDate>
<prism:section></prism:section>
<description><![CDATA[
Over the past two decades, Higher Education Institutions have increasingly prioritised transferrable skills to enhance graduate employability. Graduate Attributes (GAs) now act as key indicators of student competencies for both learners and employers. Final-year research projects, typically high in credit value, represent capstone experiences that promote subject expertise and GA development through research, written work, and oral presentations.

This study analyses pre- and post-project survey data from RQF Level 6 biomedical and biomolecular science students at a Russell Group University over four years (2019-2023). Most projects were laboratory-based, though the 2020-2021 cohort completed theirs remotely due to COVID-19.

Students reflected on expectations and experiences of GA development, subject knowledge, and employability. Initial responses revealed anxiety and uncertainty, particularly among the 2020-2021 cohort, but most anticipated gains in skills and employability. Post-project feedback confirmed this, identifying critical thinking, confidence, resilience, collaboration, and future focus as key outcomes. Digital capability was notably strengthened, especially during remote delivery.

The findings emphasise the importance of a shared understanding of GAs in bioscience education and the value of embedding structured reflection and preparatory support to help students recognise and articulate their evolving skills.
]]></description>
</item>
<item rdf:about="https://www.medrxiv.org/content/10.64898/2026.02.12.26346136v1?rss=1">
<title>
<![CDATA[
Risk of new-onset obstructive sleep apnea up to 4.5 years after COVID-19 in the urban population. 
]]>
</title>
<link>
https://www.medrxiv.org/content/10.64898/2026.02.12.26346136v1?rss=1"
</link>
<dc:creator>Changela, S.</dc:creator>
<dc:creator>Katz, R.</dc:creator>
<dc:creator>Shah, J.</dc:creator>
<dc:creator>Henry, S. S.</dc:creator>
<dc:creator>Duong, T. Q.</dc:creator>
<dc:date>2026-02-15</dc:date>
<dc:identifier>doi:10.64898/2026.02.12.26346136</dc:identifier>
<dc:title><![CDATA[Risk of new-onset obstructive sleep apnea up to 4.5 years after COVID-19 in the urban population.]]></dc:title>
<dc:publisher>Cold Spring Harbor Laboratory Press</dc:publisher>
<prism:publicationDate>2026-02-15</prism:publicationDate>
<prism:section></prism:section>
<description><![CDATA[
RationaleObstructive sleep apnea (OSA) is linked to cardiovascular, metabolic, and cognitive morbidity. Although COVID-19 has been associated with long-term respiratory and neurological sequelae, its role in precipitating new-onset OSA remains unclear.

ObjectivesTo evaluate whether SARS-CoV-2 infection increases risk of developing OSA up to 4.5 years post-infection and how risk varies by hospitalization status, demographics, comorbidities, and vaccination status.

MethodsThis retrospective cohort study used electronic health records from the Montefiore Health System in the Bronx. Adults tested for SARS-CoV-2 between March 1, 2020, and August 17, 2024, were classified as hospitalized COVID+, non-hospitalized COVID+, or COVID-. Patients with prior OSA or inadequate follow-up were excluded. Inverse probability weighting adjusted for demographic, clinical, socioeconomic, and vaccination covariates. New-onset OSA was assessed using weighted Cox proportional hazards models. Secondary outcomes including hypertension, myocardial infarction, heart failure, stroke, arrhythmia, pulmonary hypertension, type 2 diabetes, and obesity were evaluated with Poisson regression. Sensitivity analysis used a pre-pandemic control cohort.

ResultsAmong 910,393 eligible patients, hospitalized [HR 1.41 (95% CI 1.14-1.73)] and non-hospitalized [HR 1.33 (95% CI 1.22-1.46)] COVID+ patients had higher adjusted risk of new-onset OSA versus COVID- controls. Similar findings were observed using historical controls (n=621046). After OSA onset, hospitalized COVID+ patients had higher risks of heart failure and pulmonary hypertension, while non-hospitalized COVID+ patients had higher risk of obesity vs COVID- patients.

ConclusionsSARS-CoV-2 infection is independently associated with increased risk of new-onset OSA. These findings support targeted screening in post-COVID populations.
]]></description>
</item>
</rdf:RDF>
